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ABSTRACT 
Cancer, a malignant disease, is one of the leading causes of mortality and morbidity among 
humans. However, selective targeting of cancerous tissue remains challenging. The enhanced 
permeability and retention effect (EPR-effect), a naturally occurring phenomenon in solid 
cancerous tissue, is a suitable treatment pathway to selectively target cancerous tissues, whereas 
healthy tissue remains untouched, and therefore side effects are reduced. This effect is observed 
for large and heavy molecular structures. Ruthenium has shown to possess anti-cancer activity, 
and is able to form macromolecular assemblies that could potentially exploit the EPR-effect 
and selectively accumulate on the tumor site to fight the disease locally. The goal of this thesis 
is to prepare macromolecular and multi-nuclear arene ruthenium metalla-assemblies to target 
the EPR-effect. 
 
 
Le cancer, une maladie maligne, est l’une des principales causes de mortalité et de morbidité 
chez l’homme. Cependant, le ciblage sélectif des tissus cancéreux reste un défi. L'effet de 
perméabilité et de rétention accrue (effet EPR) est un phénomène naturel dans les tissus 
cancéreux solides qui est observé pour les structures moléculaires grandes et lourdes. 
Il constitue donc une voie de traitement appropriée pour cibler de manière sélective les tissus 
cancéreux, laissant intacts les tissus sains et réduisant les effets secondaires.  Le ruthénium 
possède une activité anticancéreuse et est capable de former des assemblages 
macromoléculaires susceptibles d'exploiter l'effet EPR et de s'accumuler de manière sélective 
sur le site de la tumeur pour lutter localement contre la maladie. Le but de cette thèse est de 
préparer des métalla-assemblages 
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1. INTRODUCTION 
Cancers are among the leading causes for mortality worldwide. It describes a group of diseases 
that are able to affect any part of the body and spread and invade into healthy tissues or organs. 
Other terms for cancers are malignant tumors. Any abnormal proliferation of cells is referred 
to as tumor which may be distinguished between malignant and benign. Benign tumors remain 
in their original location. They do not spread nor invade to other body parts and can be removed 
by surgery. However, malignant tumors are able to spread beyond their usual boundaries and 
throughout the whole body via the circulatory and lymphatic systems. Only malignant tumors 
are referred to as cancers. With their ability to metastasize, they are often resistant to local 
treatments like surgery which makes them dangerous and life-threatening.1,2 
 
Approximately 14.1 million new cancer cases and 8.2 million cancer related deaths were 
reported in 2012 and these numbers are expected to rise by around 70% over the next twenty 
years. In 2012, 32.6 million cancer patients over the age of 15 were estimated who had had a 
cancer diagnosed in the previous five years. In 2015, 8.8 million cancer related deaths were 
reported, which makes a sixth of all deaths globally.1 In 2018, the number of death rose to 9.6 
million.3 Therefore, there is an urgent need for cancer research to cure cancer. 
 
To date there are more than a hundred different types of cancers known. They can alternate 
significantly in their behavior and their respond to treatments. All tumors are classified 
according to their origin. Most cancers can be categorized into three main groups: carcinomas, 
sarcomas and leukaemias/lymphomas. Carcinomas, which are malignancies of epithelial cells, 
represent with approximately 90% the largest group of human cancers. Sarcomas are with 
around 2% rare in humans. They represent solid tumors of connective tissues, such as muscles, 
bones, cartilages and fibrous tissues. Leukaemias and lymphomas stand for 8% of human 
cancers. They originate from blood-forming cells or from cells of the immune system, 
respectively.2 In 2018 the most common cancers were: lung (18.3%), colorectal (9.0%), 
stomach (8.2%), liver (8.1%) and breast (6.5%).1 For an effective cancer treatment a correct 
diagnosis is necessary because every type of cancer requires a specific treatment. Some cancers 
have high cure rates if detected at an early stage. Otherwise the primary goal is to prolong life 
of patients and to improve their quality of life.1 
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1.1. CANCER DEVELOPMENT AND PROGRESSION 
Cancers arise from one single mutated cell that is transformed to a tumor cell in a process 
containing multiple steps involving mutation and selection for those cells with capacity for 
proliferation, survival, invasion and metastasis.2,4 Characteristic for cancer cells are their 
abnormal rapid growth and proliferation, owning to the excessive angiogenesis, which supports 
nutrition and oxygen uptake. They divide uncontrolled and invade into healthy tissues and 
organs and eventually they spread throughout the whole body. Figure 1 shows the 
oversimplified illustration of cancer progression. Before cancer cells are formed, a hyperplasia 
is observed, where the number of cells in certain organs increase abnormally. Those cells may 
or may not become cancers.5 The formation of carcinoma in situ is also called stage 0 disease. 
It describes a group of abnormal cells that are only found in one place and do not spread. Also 
these cells may or may not become cancers.6 In case of cancer development, angiogenesis will 
lead to cell growth and cell proliferation and the carcinoma in situ will turn into an invasive 
carcinoma, that spreads beyond its place of origin and grows into its surroundings.7 Cancer cell 
migration, intravasation of cancer cells into the circulatory system, dissemination of a cancer 
cell to a distant organ and extravasation of those cells out of the blood stream lead to the 
development of metastasis.8,9 Dormant tumor cell is the term for cancer cells that lack of the 
ability for proliferation until the conditions are favorable for successful proliferation and only 
then macro-metastases are formed.10,11  
 
Figure 1: Cancer progression.12 
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Reasons for cancer cells to develop can be diverse and are a result of the interaction between 
genetics and external carcinogens. External carcinogens may be of physical nature such as UV 
light and radiation, or of chemical nature like tobacco smoke, drinking water/food contaminants 
and air pollution or of biological nature such as infections from viruses, bacteria and parasites. 
Some carcinogens act by damaging DNA and inducing mutations. These carcinogens are 
known as inducing agents, since the induction of mutations in genes is assumed to be the initial 
event leading to cancer development. Compounds that contribute to tumor cell proliferation 
rather than inducing mutations are referred to as tumor promoters. Examples for molecular 
tumor promoters are phorbol esters and their derivatives which are able to stimulate tumor cell 
proliferation, phenobarbital and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) are shown in 
figure 2.13–15  
 
Figure 2: Structures of tumor promoters tetradecanoyl phorbol-13-acetate (TPA), phenobarbital, 2,3,7,8-tetrachlorodibenzo-
p-dioxin (TCDD).13,15 
However, the development of cancer cannot be affiliated to one single cause, but many factors 
are playing a part. The risk of cancer can be reduced by regular physical activity and avoiding 
tobacco, alcohol and unhealthy food with low fruit and vegetable intake.1 Cancer cell 
development is connected to signal transduction between biomolecules within a cell. Not only 
cancer cells, but also healthy cells communicate via those signals, in order to know whether 
they have to grow, divide, survive, or undergo apoptosis. All cellular processes within a body 
are controlled and managed by signal transduction in signaling pathways. They control and 
coordinate cell growth of all eukaryotic cells with the supply of nutrients in their environment. 
Signaling pathways are complex networks, where signals are transducted between many 
biomolecules to regulate cellular processes, such as cell survival and cell migration. Figure 3 
shows a very simplified illustration of such a complex network within a cell, where proteins 
and biomolecules and their upstream and downstream targets are interlinked. Such signaling 
pathways are composed of numerous components which interact with each other. Mutations in 
components of those complex signaling networks, caused for example by tumor inducing agents 
might have severe consequences, as wrong signals are sent and received. This might cause 
activation or inhibition of undesired components in the signaling pathway, leading to undesired 
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cell responses. Such undesired cell responses might lead to the survival, migration and 
proliferation of undesired cells. Mutations of signaling pathways that control cellular processes, 
such as PI3K (phosphoinositide 3-kinase), Ras (Rat sarcoma) and their downstream factors are 
observed in many human cancers.12,16,17 In figure 3 a cell is depicted with several signaling 
pathways and the genes that are known to be functionally altered in solid cancers are highlighted 
in red. Deregulated processes involve growth factor pathways: EGFR (epidermal growth factor 
receptors), TGF (transforming growth factor), IGF (insuline-like growth factor) and further 
signaling pathways: Wnt pathways (wingless/integrated)18, Hedgehog pathway, Akt/mTOR 
(mammalian target of rapamycin)19, Jak/Stat pathway (Janus-family tyrosine kinase/signal 
transducer and activator of transcription), MAPK pathway (mitogen-activated protein kinase), 
PI3K pathway (phosphoinositide 3-kinase), ERK pathway (extracellular signaling-regulated 
kinase), NF-kB (nuclear factor-kappa B) and IL pathway (interleukin). All listed pathways can 
be regarded as targets for cancer research.  
 
Figure 3: Signal transduction in solid cancer cells. Genes that are known to be functionally altered are highlighted in red.20 
Once cancer cells have developed they do not respond appropriately to the signals arising 
from those networks, which may lead to over-proliferation and migration of those cells. If 
propagation of these cells is not kept under control, this might result in death.1,2 
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1.2. CANCER THERAPIES 
Every cancer type needs a dedicated treatment. The type of treatment depends on the type of 
cancer and on its state of development. Mostly, there will be a combination of different 
treatment types.21 The different types of treatments are:  
- Surgery, where the tumor can be fully or partly removed by excise.22,23 There are methods of 
surgery that do not involve cuts: cryosurgery24, lasers25, hyperthermia26 and photodynamic 
therapy (PDT).27 
- Radiation therapy with high doses of radiation to destroy cancer cells.28 
- Immunotherapy, since cancers are not recognized as a threat by the immune system certain 
immunotherapies boost the immune system, others label the cancer cells so the immune system 
is able to find and destroy them.29  
- Targeted therapy, where biomolecules and proteins that are responsible or involved in cancer 
development, growth and proliferation of cancer cells are targeted to inhibit their function using 
small molecule drugs or monoclonal antibodies.30,31  
- Hormone therapy is a type of targeted therapy, which is used to treat tumors that need 
hormones to grow. Two types of hormone therapy are applied: one type prevents the body from 
making them, and the other type prevents the hormones from acting on the cells.32 
- Stem cell transplant can be administered to fight certain types of cancers, like multiple 
myeloma and some types of leukaemia. The treatment works via the graft-versus-tumor effect, 
which occurs when white blood cells from the donor (graft) attack cancer cells in the patients' 
body (tumor).33 
- Precision medicine, where the treatment for each patient is specific depending on their tumors' 
genetic changes. Same cancer types can act and develop differently depending on the patients' 
genetics. Furthermore, patients can respond differently to the same treatment. Therefore, a 
biopsy is needed for the further cancer treatment evaluation and application.34 
- Chemotherapy, where cells that grow and divide quickly are attacked by chemical drugs to 
inhibit their growth. Numerous and severe side effects are often observed, because not only 
cancer cells are attacked, but also healthy cells that grow and divide quickly. Chemotherapy is 
generally used in combination with other treatments and applied to different kind of cancers.35  
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1.3. THE MODERN ERA OF CHEMOTHERAPY 
Origins of cancer treatments are found in ancient documents such as the Ebers papyrus, the 
Edwin Smith papyrus and in the Ramayana, to only name very few examples.36 Nevertheless, 
most treatments were ineffective until the 19th century. At the starting point cancer treatment 
was dominated by removal by surgery or radiology. However, due to formation of metastases 
in some cancer types, surgery or radiology were not always suitable and hence, small molecule 
drugs came into the focus of researchers. 
 
The beginning of the modern era of chemotherapy was in the 1940s with the discovery of 
nitrogen mustard and antifolate drugs (figure 4).37 In 1942, Goodman and Gilman proposed that 
nitrogen mustard might destroy lymphoid tumor, according to examinations of soldiers dying 
of exposure to sulfur mustard gas during the first World War, as the victims had profound 
lymphoid hypoplasia and myelosuppression.38 Shortly after the Second World War, in 1950 
Sydney Farber examined the effects of folic acid and its synthetic analogues on patients with 
leukaemia. Antifolates were able to suppress proliferation of malignant cells, and therefore 
became the first compounds to successfully induce remission in children with acute 
lymphoblastic leukaemia (ALL).37 Furthermore, in 1958, Hertz and Li discovered that 
methotrexate, an antifolate analogue, was the first compound to cure a solid cancer.39  
 
Figure 4: The history of chemotherapy.37 
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In the following years, other interesting properties, activities and the mode of action of 
antifolates were investigated by other researchers.40–43 Modern chemotherapy began with the 
development of purine analogues such as 6-mercaptopurine (6-MP) and the discovery of Vinca 
alkaloids which were able to inhibit the growth of tumor cells and to block tumor cell 
proliferation (figure 5). Most interestingly in this era, POMP (purinethol, oncovin, methotrexate 
and prednisone) was realized, which is a combination of methotrexate, vincristine (Vinca 
alkaloid), 6-MP and prednisone, which was able to induce long-term remission in children with 
ALL.44–48 
 
Figure 5: Beginning of the modern era of chemotherapy. 
Systematic drug screening began at the National Cancer Institute (NCI) in 1955. Each year 
15'000 new drugs and natural products were screened.49 The years from 1960 - 1970 can be 
regarded as the golden era of chemotherapy with the discovery of cisplatin, a cell division 
inhibitor in Escherichia coli, in 1965 by Rosenberg.50 Subsequently a derivative of cisplatin 
named carboplatin was developed with a broad antitumor activity and less nephrotoxicity.51 
Meanwhile, other organometallics were developed and their behavior is later discussed in this 
thesis. Around the same time, nitrosoureas were found to alkylate and crosslink DNA at the O6 
position of guanine, which was effective against malignant gliomas.52 This finding was 
interesting, since cisplatin crosslinks DNA at the N7 position of guanine (scheme 2.53 This 
demonstrated that totally different compounds can undergo a similar mode of action. In figure 
6 the structure of guanine is depicted with the respective positions. 
 
Figure 6: Structure of nucleobase guanine with the respective positions. 
Despite the success of anticancer drug development, researchers repeatedly encountered 
problems due to the acute and long-term toxicities of chemotherapies, which affected every 
organs of the body. These drawbacks were accepted as the price for controlling a fatal disease.37 
In the 1980s, the development of cancer research stagnated due to long-term trials resulting in 
minor gains against tumors. Additionally, mouse models only poorly predicted the outcome of 
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clinical trials. Thus, screening of numerous drug analogues, random chemicals and natural 
products did not show the expected results against tumors and the costs exploded. Therefore, 
the NCI started to use human tumor xenografts in mice, covering a broad range of tumor types 
with 60 cell lines.37 However, success did not come, since large screening did not lead to the 
identification of any novel anticancer agent. Despite the unsuccessfulness of new anticancer 
drug development, there were significant improvements in screening methodology, suggesting 
a need to change strategies.  
 
Investigations on molecular and biological mechanisms of cell biology and cancers have led 
to the identification of new signaling networks that regulate and control cellular processes, like 
proliferation and survival. Many mutations and alterations were found in the signaling networks 
of cancer cells. Here began the era of targeted therapy. Researchers began the attempt to repair 
those mutations by targeting affected biomolecules and proteins within cells.54 Research in the 
area of targeted therapy in connection with cell biology grew rapidly resulting in the 
identification of a large number of target molecules, which transformed cancer cell 
development from a low-budget, government-supported research to a multi-billion dollar 
industry.37 Numerous inhibitors of specific targets were identified due to new technology and 
thousands of potential drugs were designed by means of combinatorial chemistry. Their 
properties concerning specificity and bioavailability were then optimized using computer 
simulations.55 New standards for drug administration were established in respect to drug 
compatibility, metabolic stability, well-absorption after oral administration and favorable 
toxicity profiles at biologically effective doses.37 The development of imatinib mesylate was a 
significant milestone in the research of targeted cancer therapy. Imatinib mesylate is an inhibitor 
of the kinase BCR-ABL, a fusion gene responsible for the development of chronic myeloid 
leukaemia (CML).56 Moreover, it inhibits the KIT tyrosine kinase and platelet derived growth 
factor receptor-β (PDGFRβ) tyrosine kinase which is effective against gastrointestinal stromal 
tumors and other neoplasms.57 Gefitinib, an inhibitor of the epidermal growth factor receptor 
(EGFR) was able to cause remissions in 10-15% of patients with non-small cell lung cancer 
(NSCLC).58 The structure of imatinib and gefitinib are shown in figure 7. 
  
Figure 7: Targeted cancer drugs imatinib and gefitinib. 
N
N
N
H
O
N
H
N
N
N
O
N O
O N
N
HN
F
Cl
gefitinibimatinib
INTRODUCTION 
 
 9  
Despite successes, there were also disappointments in targeted therapy research, and it still 
remains a challenge to create the perfect anti-cancer drug due to many reasons. Animal models 
can only poorly simulate the effects of a drug in humans because of their more rapid 
metabolism, greater tolerance to side effects and differences in protein binding. Even with the 
use of human xenografts in mice, the results are not totally reliable for humans. In addition, 
cancers are heterogeneous diseases and differ in molecular diversity in same organs or among 
different individuals.59 Furthermore, sub-clones present in human cancers can develop 
resistance or respond differently to drugs. Resistant cancer cells are able to survive treatment 
which might lead to a relapse of the disease.60 Resistance mechanisms might involve mutations 
or amplification of the target enzyme, overexpression of drug transporters or mutations in cell 
death pathways. Combination therapy is therefore essential to overcome this problem since 
clinical trials have demonstrated great synergy between targeted molecules and traditional 
chemotherapy.37 Thus, it is crucial to continue investigations in all areas of cancer research. 
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2. ENHANCED PERMEABILITY AND RETENTION EFFECT 
The previous chapter dealt with methods of cancer treatment, and herein, a different approach 
to cure the disease is presented. As mentioned previously, to fight this disease it is necessary to 
know its behavior and to learn about the events that take place therein.  
 
Most solid tumors show unique characteristics which are not observed in healthy tissues and 
organs, such as increased production of a number of vascular permeability mediators, defective 
vascular architecture, impaired lymphatic drainage and impaired recovery system and extensive 
angiogenesis which lead to hypervasculature. All these features comprise the enhanced 
permeability and retention effect (EPR-effect) which is a natural phenomenon that is observed 
in most if not all solid tumors and most importantly also in metastatic tumors.61–63 
 
Angiogenesis plays an important role in many physiological and vital processes such as 
embryonic development, female reproductive cycle, wound healing and organ and tissue 
regeneration. But it can also support the development of unwanted tumors and hypervasculature 
can be observed even when tumor nodules are smaller than 0.2 mm.64,65 The connection 
between angiogenesis and tumor proliferation and the formation of metastases was 
demonstrated by Folkman in 1971.66 The elevated blood flow in tumors also supports 
angiogenesis.67 The excessive production of vascular mediators causes an excessive 
extravasation of macromolecules from the blood vessel into the tumor tissue, providing 
nutrients and oxygen for a rapid tumor growth. This excessive uptake of macromolecules is a 
useful feature, which could be exploited for drug delivery. Additionally, tumor blood vessels 
do not have a fixed, compact structure like in healthy tissues. The endothelial cells are 
disorganized and irregularly shaped with large gaps between each other, which makes them 
leaky and permeable.68 The size of those gaps can be from 100 nm to 2 µm, whereas in normal 
tissue the gaps are < 6 nm (continuous endothelial cells in striated muscles), 10 up to 100 nm 
in diameter (fenestrated endothelial cells in renal medula, endocrine glands, renal glomerulus, 
choroid plexus in the brain, intestinal villus) or even larger (discontinuous endothelial cells in 
sinusoid vessels, liver, spleen, bone marrow, extraneous particles from the blood) depending 
on the tissue type.65,68–70 Due to this fenestration they lack of the normal barrier function, 
therefore small and large substances are able to enter into tissues. High molecular weight 
compounds such as nanoparticles, macro molecular drugs, polymeric drugs and lipid particles 
enter into tumor tissue rather than into normal tissue, so there is a selectivity. In other words, 
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an enhanced permeability in tumors, which is useful for drug delivery. The lymphatic drainage 
which is responsible for the elimination of foreign substances is found to be damaged in tumors, 
therefore those substances remain in the tissue for a prolonged time (retention). Currently only 
a small number of drugs are effective against metastatic cancers, thus the EPR-effect offers a 
great advantage in nanomedicine therapy.  
2.1. DISCOVERY OF THE EPR-EFFECT 
The EPR-effect was first described in 1986 by Maeda and is believed to be a promising 
element for cancer-selective drug delivery.61,62 Maedas' research around 1978 focused on 
developing an anticancer drug to target metastatic tumors and particularly the lymphatic system. 
Amongst other things he worked with the anticancer protein neocarzinostatin (NCS). NCS is 
an antitumor antibiotic that is obtained from Streptomyces carzinostaticus var. F-41 and was 
first isolated in 1965.71 NCS was a widely used anticancer agent, but most interestingly for 
Maeda, it showed a predominant accumulation in regional lymph nodes. This discovery was 
highly important, due to the fact that the lymphatic system was often the route by which cancer 
cells metastasize and metastases are the main reason why many treatments failed. Therefore, 
targeting the lymphatic system more effectively could bring significant advances in cancer 
research. However, NCS showed an extremely short half-life with t1/2 = 1.8 min in vivo and in 
vitro, therefore in its native form, it was not very effective. In 1979, Maeda reported on the 
synthesis of its protein conjugate SMANCS (styrene maleic acid conjugated NCS), where 
styrene maleic acid forms a synthetic polymer, which is soluble in both, water and organic 
solvents.72 Various tests were performed by different research groups to determine the plasma 
clearance time of a number of polymer conjugates or modified proteins and the results are 
summarized in table 1. The tests with NCS and SMANCS (table 1, entries 1-2) were performed 
by Maeda. 
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entry protein 
type of polymer 
modification 
molecular mass 
(kDa) 
t1/2 test animal 
1. NCS none 12 1.8 min mouse 
2. SMANCS 
poly(styrene-
comaleic acid)-NCS 
16 19 min mouse 
3. ribonuclease none 13.7 5 min mouse 
4. ribonuclease dimer cross-linked 27 18 min mouse 
5. 
soybean trypsin inhibitor 
(SBTI) 
none 20 < 2.0 min rabbit 
6. dextran–SBTI dextran 127 ≃ 20 min rabbit 
7. ovomucoid 
diethylene triamine 
pentaacetic acid 
(DTPA)/NH2/51Cr 
29 5 min mouse 
8. 
Cu2+, Zn2+ superoxide 
dismutase (SOD) 
none 30 4 min rat 
9. SOD–SMA SMA conjugate 40 > 300 min rat 
10. bilirubin oxidase none 50 < 10 min rat 
11. PEG –bilirubin oxidase PEG 70 5.0 min rat 
12. serum albumin, mouse none 68 3-4 days mouse 
13. serum albumin, mouse evans blue dye - 2 h mouse 
14. 
formaldehyde- 
conjugated human serum 
albumin 
formaldehyde/125I - 25 min rat 
15. L-asparaginase none 65 × (2-8) 1.5-3.4 h rat 
16. L-asparaginase–PEG PEG2-linked - 56 h mouse 
17. immunoglobin G, mouse DTPA 150 60 h rat 
18. α2-macroglobulin, human iodination/125I 180 × 4 140 h mouse 
19. 
α2-macroglobulin–
plasmin complex 
iodination/125I 180 × 2 2.5 min mouse 
Table 1: Plasma clearance time of various proteins and their polymer conjugates or modified proteins.73 
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As shown in the list, in most cases the plasma clearance time increases in the presence of a 
polymer conjugate. Generally, the obtained data indicate that a molecular weight of around or 
above 50 kDa, neutral or negative electric charge and biocompatibility are important parameters 
for a prolonged plasma half-time. However, some proteins, such as albumin, can have a shorter 
t1/2 value after chemical modification or denaturation. 
 
In order to increase the half-life t1/2 of NCS, Maeda synthesized poly(styrene-co-maleic acid 
anhydride (SMA), a copolymer to modify NCS to increase its lipophilicity and stability. It 
seemed ideal due to the anhydride groups, that would react with the amino groups of NCS and 
the styrene groups which would add a hydrophobicity to the compound. Smaller or larger sized 
SMA were used and the conjugate was just as effective to bind plasma albumin. As shown in 
table 1, t1/2 was increased by a factor of ten (table 1, entries 1-2; figures 8 and 9).73 
 
  
Figure 8: a) Structure of SMA; b) reaction with NCS to produce the conjugate SMANCS. 73 
This compound was the very first polymer-conjugated macromolecular anticancer agent, 
furthermore it was the first macromolecular anticancer drug possessing anti-metastatic 
activities and was used against different solid tumors in humans.73 Moreover, SMANCS' further 
interesting property was its effect against the multidrug resistance of tumor cells.74 Even though 
SMANCS is a relatively small protein with 16 kDa, it can bind non-covalently to albumin in 
vivo and behaves therefore like a large protein of about 80 kDa.75 Figure 9 illustrates that NCS 
traces are found in the blood plasma after 240 minutes, whereas SMANCS showed improve 
stability in the same time range. 
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Figure 9: Plasma concentration of NCS and SMANCS in human after intravenous injection. The concentration was measured 
by radioimmunoassay for NCS and immunological assay for SMANCS.73 
Generally, macromolecules with a molecular weight of 50 kDa are retained in the blood stream 
and do not leak out of the vascular endothelial compartment into normal tissue. However, 
macromolecules behave differently in inflammatory tissue and more importantly in tumor 
tissues. Tests have shown that SMANCS and other macromolecules preferentially accumulate 
in solid tumors and granulomas than in normal organs or tissues. Most interestingly in tumors, 
these substances are unlikely recovered by the lymphatic system, as it is the case in healthy 
tissue, as a result these macromolecules are retained in the tumor tissue more effectively. This 
natural behavior, named the EPR-effect, takes place in solid tumors and can be exploited to our 
benefit.73 
 
In 1986, Maeda investigated on the accumulation of proteins with different weight (Mw 12'000 
to 160'000) on tumors in mice. He used 51Cr-labelled proteins and dye-complexed serum 
albumin to visualize protein accumulation in tumors.63 
Figure 10 illustrates the selectivity of the EPR-effect. Albumin, a serum protein with an 
approximate molecular weight of 68 kDa and Evans blue, an azo dye with a high affinity for 
albumin, were administered on tumors. In figure 10a a homogenous uptake is depicted, whereas 
in 10b the heterogeneity of a tumor causes uptake only at the tumor periphery. It is nicely shown 
that only the tumor tissue is colored and the healthy tissue remains untouched. Human tumors 
are highly heterogeneous. They possess widely different structures and their size can vary from 
less than 1 mm to over 10 cm. Different stages of tumors show different vascular densities. 
Furthermore, different etiologies of tumors increase the heterogeneity between tumors.76 
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Figure 10: Selective treatment with EPR-effect. (a) A S180 tumor on the skin of a mouse. Relatively homogenous uptake of 
Evans blue/albumin is shown, but normal skin in the background contains no blue color. (b) Heterogeneity of EPR-effect is 
shown. Only the tumor periphery took up Evans blue/albumin.74  
The development of the perfectly selective low-molecular weight drug able to prevent tumor 
cell growth without causing side effects was challenging to realize in practice. Therefore, tumor 
targeting and synthetic macromolecular therapeutics using drug delivery systems and nano-
sized vectors made a crucial contribution to cancer therapy in recent times.77 This offers a wide 
range of methods: biodegradable polymers containing entrapped drugs can be placed in the 
body and can be used for localized and therefore more selective and targeted drug delivery. In 
this manner, a controlled release of a drug over a period of months is possible as well.77 
2.2. MECHANISM OF THE EPR-EFFECT 
The key mechanism for the EPR-effect was found to be retention of high-molecular weight 
substances in the tumor environment, whereas low-molecular weight substances were returned 
to the blood circulatory system by diffusion.29 Retention is caused by the impaired lymphatic 
drainage. An intact lymphatic drainage ensures that ectopic substances are removed from the 
tissues. However, in a damaged lymphatic drainage, only low-molecular weight substances are 
removed and high-molecular weight substances remain in the tissue. After administration of 
such high-molecular weight compounds it was shown that their concentration are 10 - 200 times 
higher in tumors than in normal tissues.65  
 
A promising drug in general has to fulfill certain requirements. The candidate has to be water 
soluble, stable over time as well as biologically stable, biocompatible, inert and non-toxic and 
must show no interactions with blood components or blood vessels. Further, it has to be 
cytotoxic against certain cells and it must demonstrate no antigenicity, limited clearance by the 
reticuloendothelial system and no cell lysis. Moreover, it needs to be long-circulating in the 
blood system. The perfect drug to exploit the EPR-effect acquires a certain size (> 6 nm but 
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variable depending on tissue type) to pass the membrane and to avoid excretion by the renal 
clearance threshold. Thereby, passive targeting can be converted into the EPR-effect.77 
However, researchers disagree about the perfect size. 
 
To investigate the molecular weight dependence Jain and coworkers examined in 1995 
compounds between 25 and 160 kDa in a mice transplanted human colon adenocarcinoma using 
intravital fluorescence microscopy technique.78 The permeability increased by a factor of two 
in the range of 25 to 160 kDa molecular weight. This confirmed that tumor vessels are less 
permselective than healthy vessels, which is caused by the large pores in the vessel wall arising 
from the large gaps (~1 µm)65 between the single endothelial cells. The transport of 
macromolecular size compounds appears by diffusion through these porous structures. 
Experiments on tumors with liposomes performed by the same group suggest that the cutoff 
size of the pores lies between 400 and 600 nm in diameter.78 Yet, tumor microvascular 
permeability depends on tumor size and growth rate, but in general it is always higher than in 
normal tissues. In the year 2000 Maeda stated that the EPR-effect was observed at a molecular 
weight of 60 kDa, whereas later he stated that accumulation was observed already at a weight 
of 40 kDa.61,62,79,80  In 2006, Haag und Kratz observed an EPR-effect at a molecular weight of 
20 kDa, but they also stated that the renal clearance occurs at a molecular weight of 30 - 50 
kDa.81 In 2014, Kobayashi estimated a needed size of over 6 nm in diameter, which is 
approximately the pore size of a glomerulus of the kidney, to avoid excretion thus for the drugs 
to be effective, a prolonged retention being mandatory.82 Caliceti stated in 2003 that renal 
clearance can be avoided from a molecular weight of 70 kDa, but molecules that exceed this 
size can be eliminated from the body by other pathways such as liver uptake, proteolytic 
digestion and clearance by the immune system.83 Expressed in nm, it means that the threshold 
for rapid renal clearance is 5.5 nm and molecules larger than 8 nm in hydrodynamic diameter 
(HD) are excreted via hepatobiliary clearance (figure 11).84 According to Choi and co-workers, 
molecules can undergo the EPR-effect when they possess an hydrodynamic diameter comprised 
between 10 nm and 200 nm.84 
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Figure 11: Biomedical imaging (top row) and naturally occurring materials (bottom row). ICG = indocyanine green. 84 
But one thing is certain: As molecular size increases, systematic clearance decreases. The 
surface charge of a drug should be weakly negative to near neutral to avoid any interactions 
with endogenous substances. Positively charged molecules will be filtered more efficiently by 
the kidney than negatively charged compounds.82 However, a positive charge shows also 
advantages as for some drugs interaction with endogenous substances is mandatory to be 
effective. For example, some biomolecules like DNA have a negative overall charge.85 
Therefore positively charged compounds are able to bind DNA. Mitochondria as well has an 
overall negative charge and other biomolecules like proteins have a partly negative charge, 
which gives them the ability to attract positively charged molecules.86 Furthermore, charged 
compounds have a better water solubility, which is also essential for administration.  
 
In figure 12 a simplified illustration of the EPR-effect is depicted. In the upper part the healthy 
tissue is shown where the endothelial cells (red) and the normal cells (yellow) are compact. 
This prevents macromolecules from entering the tissue. Only small molecular-weight 
molecules like nitric oxide (NO), prostacyclin (PGI2), endothelium derived hyperpolarizing 
factor (EDHF) or vasoconstrictive factors such as thromboxane (TXA2) and endothelin-1 (ET-
1) are able to enter, which are removed after a while by the lymphatic drainage.87 The lower 
part of figure 12 shows damaged cancerous tissue with large gaps between the single cell units. 
As a consequence, macromolecules are able to enter into this tissue and due to the poor 
lymphatic drainage those macromolecules are not removed from the tissue. Macromolecular 
anti-cancer drugs could fight the tumors locally. 
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Figure 12: Illustration of a blood - top: healthy tissue - bottom: tumor tissue.88 
Many macromolecular drugs including liposomes, polymers, micelles, nanoparticles and 
conjugates containing an active small molecular drug which is linked to biologically relevant 
enzymes or proteins were developed and have passed clinical and preclinical trials. Active 
components were taken and modified to obtain large conjugates with elevated stability and 
pharmacokinetic properties. Some examples of the active components are shown in figure 13 
below.  
  
Figure 13: Anti-cancerous active components used to make large conjugates. 
The structures shown in figure 13 possess anti-cancerous activity and all of them are also 
administered as single agents or as a component in combination therapy without their 
conjugates. Generally, their mode of action lies in inhibiting cell division. But as cell division 
belongs to the most important cellular processes in our body, its inhibition also brings numerous 
side effects. A way to reduce the number of side effects is the formulation of large conjugates 
which are able to exploit the EPR-effect and therefore fight cancer more selectively by doing 
less harm to healthy cells. Furthermore, conjugates can increase the water solubility of those 
drugs and therefore the effectiveness of the drug is increased as well. Polymer conjugation alters 
the bio-distribution of low molecular weight drugs enabling tumor-specific targeting.77 Some 
of the polymer-anti-tumor-conjugates are listed in table 2: 
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entry drug 
active 
component 
conjugate mode of action 
1 DaunoXome® 
daunorubicin 
(anthracycline) 
daunorubicin citrate 
liposome 
prevention of DNA 
replication, inhibition of 
protein synthesis, conjugate 
decreases side effects 89 
2 Abraxane® 
paclitaxel 
(taxanes) 
paclitaxel bound to 
albumin 
blocks mitosis and one stade 
of cell divison.90 
3 DepoCyt® cytarabine 
cytarabine encapsulated 
in multivesicular lipid 
particles for sustained 
release (DepoFoam) 
antimetabolite that are 
similar to normal substances 
in the cell. When they are 
incorporated into the 
cellular metabolism the cells 
are unable to divide.91 
4 Doxil® 
doxorubicin 
(anthracycline) 
PEGylated liposomal 
doxorubicin 
hydrochloride 
prevention of DNA 
replication, inhibition of 
protein synthesis, conjugate 
improves drug penetration 
into tumors and decreases 
drug clearance 92 
5 Myocet® 
doxorubicin 
(Anthracycline) 
doxorubicin 
hydrochloride packed in 
liposomes 
prevention of DNA 
replication, inhibition of 
protein synthesis, conjugate 
decreases side effects 93 
6 Genexol-PM® paclitaxel 
paclitaxel-loaded 
polymeric micelle 
antineoplastic activity, 
interferes with mitosis, 
conjugate increases water-
solubility 94 
7 Oncaspar® -Pegaspargase L-asparginase 
PEG conjugated with 
L-asparginase 
L-aspargine depletion blocks 
protein synthesis and cell 
proliferation. 
77,95 
8 
Oncaspar® 
-Calaspargase 
Pegol 
L-asparginase 
E. coli-derived 
L-asparginase II 
conjugated with 
succinimidyl carbonate 
monoethylene glycol 
antineoplastic activity, L-
aspargine depletion blocks 
protein synthesis and cell 
proliferation. 77,95 
Table 2: Macromolecular anti-cancer drugs that passed clinical trials or preclinical trials.88 
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Conjugates in table 2 were designed to follow the passive tumor targeting by the EPR-effect. 
In the case of DaunoXome®, Abraxane®, DepoCyt®, Doxil®, Myocet®, Genexol-PM® a 
small molecule active component was taken and modified to increase the size and efficiency 
and to decrease the toxicity and number of side effects. In the case of Oncaspar® the active 
component is the already large enzyme L-asparaginase which causes an L-asparagine depletion 
that prevents protein synthesis and cell proliferation. The drug was further modified by 
PEGylation which has proven to be useful for a variety of reasons:77,96 
- increases protein solubility and stability and reduces protein immunogenicity. 
- prevents the rapid clearance of small proteins. 
- known to be non-toxic and non-immunogenic, therefore more attractive than other water-
soluble polymers. 
- increases plasma residence of the drug. 
- can increase the therapeutic index, so the dose can be elevated without being toxic. 
- its high degree of hydration provides a water shell which supports protein masking. 
All these features of PEG can be used to create a conjugate which could be a potential anti-
cancer candidate.  
 
As previously discussed, there are great diversities among tumors and the grade of EPR-effect 
observed can differ tremendously. Some tumors show a strong EPR-effect whereas others only 
a poor, which can be demonstrated by arterial angiography using an X-ray lipid contrast agent.62 
Vascular permeability and the grade of EPR-effect may depend on tumor type and may increase 
with tumor size and growth rate and it might be higher in the periphery than in the central 
regions of tumors.78 Therefore, there is no uniform treatment of solid cancers exploiting the 
EPR-effect, which ensures sufficient drug delivery to all tumor regions.97 The over production 
of vascular mediators such as bradykinin, nitric oxide (NO), vascular endothelial growth factor 
(VEGF) and carbon monoxide (CO) can further enhance the permeability of tumors and can be 
used for the augmentation of EPR based tumor targeting, achieving more tumor accumulation 
of macromolecular drugs.65 NO production is inevitable for tumor growth to maintain the supply 
of nutrients and oxygen. In the presence of a NO-scavengers the extravasation was significantly 
inhibited. CO is involved in many biological functions including vascular regulation, anti-
apoptosis, anti-inflammation and angiogenesis. CO was found to increase vascular 
permeability, blood flow and augment the EPR-effect. Usage of CO donors can increase the 
grade of EPR-effect.65 Another strategy to augment the EPR-effect is the elevation of systolic 
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blood pressure via slow angiotensin II infusion.79 Infusion of angiotensin II, a peptide hormone, 
leads to a tremendous increase of the blood flow in tumor tissue without increasing blood flow 
in normal tissue.98 
 
However according to recent statements the EPR-effect might not be valid in humans but only 
in rodents. Models that are used to investigate the EPR-effect might not be accurate enough, as 
the murine tumor differs from that of the human in regards to the rate of development, the size 
relative to host, metabolic rates and host lifespan.99 Nevertheless, further tests have to be done 
to confirm this assumption. 
 
Other promising candidates for exploiting the EPR-effect are large organometallic assemblies, 
such as platinum containing substances which are already known to possess anti-cancer activity 
and are also administered on patients suffering from cancer.100,101 In this project we are aiming 
to create large organometallic assemblies containing ruthenium. Ruthenium-based anti-cancer 
drugs are very attractive as they have shown to cause less side effects than platinum-containing 
anti-cancer drugs.102 The size of the assembly can be increased by the usage of different ligands 
or by functionalizing the building blocks. 
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3. RUTHENIUM AND THE PLATINUM FAMILY 
Karl Karlovitch Klaus may be regarded as a pioneer of the chemistry of the platinum metals. 
He discovered a new platinum metal in 1844 at the University of Kazan, Russia and he named 
it ruthenium, after Ruthenia, the latinized name for Russia, in honor of his motherland.103 
 
Platinum was recovered and extracted from the Ural placer deposits in Russia and the 
insoluble residues, containing the other platinoids rhodium, iridium and osmium, were collected 
but not further used. During this time platinum was of great interest in Russia, which might be 
the reason Klaus started his research on the platinoids. He developed a method to extract the 
platinum from the residue he was investigating. Klaus studied the platinum metals in his own 
way, using a microscope and by smelling and tasting the preparations and next to platinum he 
found osmium, iridium, palladium and a new 'body' he could not assign. As shown in scheme 
1 he found ways to extract the ruthenium from the residue. It depends on the precipitation of 
double salts of ruthenium and potassium (K2RuCl6, K3RuCl6, K4Ru2OCl10 · H2O etc.) and the 
precipitation of ruthenium from its chloride solution by zinc. Furthermore, he discovered that 
when treating chloride salts of ruthenium with hydrogen sulfide (H2S) a dense sapphire-blue 
formed, which was not observed with any of the other metals. His discovery and his general 
conclusion about the studies on the residue of the Ural platinum deposits were published.104 He 
described in detail all the characteristics, properties and behavior of ruthenium and assigned to 
it the atomic weight of 104.2 u.  
 
 
RUTHENIUM AND THE PLATINUM FAMILY 
 24 
 
Scheme 1: Extraction of ruthenium.103 
Not only was Klaus an excellent experimental worker but his interest and ability in 
investigating theories in depth was as well outstanding. He stated that platinum metals have a 
number of properties in common and can be grouped in pairs (platinum and palladium; iridium 
and rhodium; osmium and ruthenium according to their likeness and can be further arranged in 
two super-imposed groups of three forming triads, composed of the secondary series containing 
ruthenium, rhodium, palladium and the principal series containing osmium, iridium and 
platinum.105 He observed that osmium, iridium and platinum had approximately the same 
weight and that ruthenium, rhodium, palladium had approximately half their weight, which 
implies that they are closely connected by similar properties and morphologies. This 
observation about the similarities and differences within the elements of the triads Ru-Rh-Pd, 
Os-Ir-Pt led to Dimitri Ivanovich Mendeleevs' conclusion that the platinum metals belonged in 
one group (VIII) of his periodic table.103 This discovery can be regarded as an early 
categorization of elements which led to todays' periodic table by Dimitri Ivanovich Mendeleev 
and Lothar Meyer.106 
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3.1. PROPERTIES OF THE PLATINUM METALS 
Figure 14 shows the position of the platinum family elements in the periodic table highlighted 
in red. 
 
 
Figure 14: Elements of the platinum family in the periodic table highlighted in red. 107 
Ru, Rh and Pd which belong to the upper row of the periodic table represent the 'light' elements 
of the platinum family and Os, Ir and Pt which are respectively in the lower row represent their 
'heavy' counterparts. In table 3 the atomic and physical properties of the metals of the platinum 
family is summarized.  
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Table 3: Atomic and physical properties of the platinum group metals.108 
In general, the elements of the platinum family have high melting points, low vapor pressures, 
high temperature coefficients of electrical resistivity and low coefficients of thermal expansion. 
The atomic radius of all six metals are very close, which is explained by the fact that the 'heavy' 
elements possess fully occupied 4 f 14 orbitals, which leads to a more compact electron shell. 
Due to the small energy differences between the electron shells many oxidation states are 
possible which are depicted in table 4. 
Ru - 2  0  + 2 + 3 + 4 + 5 +6 +7 +8 
Rh  - 1 0 + 1 + 2 + 3 + 4 + 5 + 6   
Pd   0  + 2 + 3 + 4     
Os - 2  0 + 1 + 2 + 3 + 4 + 5 + 6 + 7 + 8 
Ir  - 1 0 + 1 + 2 + 3 + 4 + 5 + 6   
Pt   0  + 2  + 4 + 5    
Table 4: Possible oxidation states and principal oxidation states in bold.108 
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Additionally, as transition metals they possess other properties like their catalytic activity due 
to their inconsistent valence structure and their ease to change it, their ability to form 
intermediate compounds with different reagents, color, para-magnetism due to unpaired 
electrons and their strong tendency to form complexes. In the periodic table the elements within 
a group have similar chemical and physical characteristics. However, in the group of platinum 
metals also neighboring elements show similarities.108 Nowadays ruthenium is used in different 
fields, such as catalysis, solar cells and most importantly for our research also in biological 
applications.109–111 
3.2. CISPLATIN AS METAL-BASED ANTI-CANCER AGENT 
Cisplatin belongs to the most known metal-based anti-cancer drugs.53,112 It was first 
synthesized by Peyrone in 1844 and its chemical structure was first elucidated by Werner in 
1893.112 Its activity as a cell division inhibitor was discovered serendipitously by Rosenberg in 
the 1960s.113  
 
Scheme 2 shows the mode of action of cisplatin upon activation. The neutral cisplatin is 
believed to be biologically inactive and it is activated by an aquation reaction which involves 
the exchange of the two chlorides as leaving groups with two water molecules. The activation 
is prevented if there is a high concentration of chlorides. The concentration of chlorides in 
intracellular fluids is approximately one-thirteenth compared to the concentration in 
extracellular fluids, hence under these conditions cisplatin is activated leading to DNA damage. 
Once cisplatin is activated it will bind two sites of DNA. There are two possible ways of 
binding. A DNA adduct is formed when the two binding sites are on the same DNA strand 
(scheme 2) or a DNA cross-link is formed when the two binding sites are on two different 
strands. Cisplatin is able to bind all nucleobases but it has a higher affinity for the N-7 positions 
of adenine and guanine due to the high nucleophilicity of the N-7 positions of purine bases. 
Both DNA adducts and DNA cross-links are able to inhibit DNA replication in mammalian 
cells and as a result cell division is inhibited as well.53 
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Scheme 2: Aquation reaction of cisplatin  and adduct formation at the N-7 position of guanine on two sites of DNA, which 
results in DNA damage, leading to cell death.53,114 
Cisplatin entered phase I clinical trials in 1971 and was approved for the treatment of testicular 
and ovarian cancer in 1978.100 It also shows highly curative effects on many solid malignancies. 
Since its discovery many inorganic chemists have been working on developing new platinum-
based anti-cancer drugs. However, after numerous clinical candidates only two more platinum-
containing anti-cancer drugs were approved worldwide: carboplatin (1993) and oxaliplatin 
(2002), which are both analogues of cisplatin and their structures are shown in figure 15. In all 
three square planar structures of the top row of figure 15 platinum is present as Pt(II). Pt(IV) 
containing structures are octahedral and are prodrugs that require activation via reduction.115 
 
Figure 15: Pt(II) complexes (top) and Pt(IV) complexes (bottom).115 
Platinum-containing drugs show effectiveness in chemotherapeutical cancer treatments but 
there are also limitations. Many common types of cancers cannot be cured, also drug resistance 
was observed and a treatment includes a number of side effects like nerve damage, hair loss, 
nausea, nephrotoxicity, gastrointestinal toxicity and ototoxicity. To overcome these limitations 
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other metal-based drugs were developed and tested on their anti-cancerous activity. Other 
metals, such as gallium, ruthenium and titanium were recognized for their antineoplastic 
potential more than two decades ago, but the development of non-platinum containing drugs 
was not pursued because of the clinical success of cisplatin.101  
3.3. RUTHENIUM AS ANTI-CANCER AGENT 
Ruthenium and iron containing drugs seemed to be good alternatives to platinum considering 
that they are well tolerated in vivo and show fewer and less severe side effects. Ruthenium 
complexes exhibit an excellent cytotoxicity and low general toxicity.116 The fewer side effects 
of ruthenium can be partly explained by the fact that ruthenium and the essential iron are in the 
same group. Therefore, ruthenium has the ability to mimic iron in binding within minutes to 
biological molecules like human serum albumin and transferrin. It is also known that the anti-
cancer activity is significantly higher for apotransferrin-bound complexes compared to the 
albumin-bound or free species.101,117,118 This leads to the assumption that apotransferrin acts as 
a natural carrier of such drugs to the tumor due to numerous transferrin receptors on the surface 
of tumors.118 Ruthenium containing drugs are able to use the iron detoxification paths inside 
the body which also explains why less harm is done to healthy tissue.119 
 
The lower toxicity can also be explained by the fact that ruthenium is accessible in different 
oxidation states. For example, ruthenium (III) complexes are inactive compared to ruthenium 
(II) complexes. In other words, ruthenium can be activated by reduction. The inactive Ru(III) 
enters the reductive environment of cancers, where it is reduced to Ru(II) and thereby activated. 
The low oxygen level and the lower extracellular pH and the presence of cellular reducing 
agents like glutathione provides good conditions for a selective reduction of the drug exploiting 
the Ru(III)/Ru(II) redox potential.101,102 Furthermore, ruthenium drugs are less prone to 
resistance mechanism than platinum drugs.119 Complexes of such kind bind non-covalently to 
DNA by electrostatic or van der Waals forces and the mode of interaction depends on the 
structure of the complex and can involve intercalation, cross-linking and ionic interactions.119 
The majority of the known ruthenium-containing drugs act by causing DNA damages in cancer 
cells.119 Furthermore, ruthenium complexes have mainly an octahedral coordination chemistry, 
which implies a reactivity and mode of function different from the square-planar platinum(II)-
complexes. Additionally, ruthenium is stable when exposed to air and shows relatively slow in 
vivo ligand exchange.102 
RUTHENIUM AND THE PLATINUM FAMILY 
 30 
Figure 16 shows the ruthenium(III)-containing anti-cancer candidates NAMI-A and KP1019 
and the Ru(II)-arene containing RAPTA-C.120,121 NAMI-A and KP1019 are Ru(III) containing 
prodrugs that need to be activated by reduction.122 NAMI-A reduces the formation of metastases 
and inhibits their growth. However, it has only little impact on primary tumors. Furthermore, it 
interferes with the interactions of tumor cells with the extracellular matrix, increases cell 
dependent cell adhesion, inhibits matrix degradation, reduces cell invasiveness and migration 
which results in a less malignant cell phenotype.101 However, clinical trials for NAMI-A were 
terminated due to insufficient effects and elevated side effects.123 
 
Figure 16: Chemical structures of NAMI-A, KP1019 and RAPTA-C. 
RAPTA-C shows great potential for clinical applications. It is proposed that the RAPTA-C 
treatment triggers the mitochondrial apoptotic pathway. Furthermore, its 1,3,5-triaza-7-
phosphaadmantane (PTA) ligand has shown moderate anti-cancerous activity in various cell 
lines and excellent activity in reducing the number of weight of solid metastases.124 RAPTA-C 
remains the best anti-cancerous compound of the series of Ru(II)-series drugs, nonetheless the 
molecular mechanism and the signaling pathways remains to be elucidated.  
 
KP1019 is currently under clinical investigations. It is suggested that the mechanism of 
KP1019 involves interaction with mitochondria due to rutheniums similarity with iron.101,125 
However, its precise mechanism of action remains poorly understood.126 Mitochondria use and 
accumulate a large amount of iron, and mitochondrial iron is mainly used in three metabolic 
pathways: heme synthesis, iron-sulphur cluster biogenesis and mitochondrial iron storage.127 
Heme is a non-protein, crucial for every organism since it is one of the constituents of 
hemoglobin, chlorophyll, myoglobin and cytochrom.128 There are many different kinds of iron-
sulphur clusters ([2Fe-2S]; [3Fe-4S]; [4Fe-4S] etc.) and depending on the cluster type they 
interact with different proteins being responsible for many biological processes. An excess of 
iron is stored in ferritin, which is a multimeric protein composed of 24 subunits and is able to 
store around 4500 iron atoms. Mitochondrial ferritin serves as additional iron storage.129 In 
cancer, for example in lung carcinoma, approximately 20% of total cellular iron was present in 
mitochondria. Another example are hepatocytes in rats, where in mitochondria the 
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concentration of metabolic iron was twice as much as in the cytosol. However, the role of 
mitochondrial iron in cancer development is only poorly elucidated.127 
 
With the development of compounds like NAMI-A, KP1019 and RAPTA-C ruthenium was 
established as a potential anti-cancer agent. Therefore, in this project we would like to combine 
rutheniums' potential anti-cancer activity with the EPR-effect. As mentioned before, for the 
EPR-effect macromolecules are required which cannot be removed from cancerous tissue 
because of their large size.  
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4. STRATEGIES TO INCREASE THE MOLECULAR WEIGHT OF ARENE 
RUTHENIUM ASSEMBLIES TO EXPLOIT THE EPR-EFFECT 
To date there are no ruthenium-containing compounds known to exploit the EPR-effect. With 
the knowledge about the anti-cancer activity of ruthenium complexes and their ability to form 
supramolecular structures the development of ruthenium containing anti-cancer drugs to exploit 
the EPR-effect presents an interesting field of research. In this chapter the preparation of diverse 
ruthenium complexes is discussed starting from small mono-nuclear compounds to large multi-
nuclear compounds. The goal of this project is to develop a suitable arene ruthenium based anti-
cancer agent with the ability to exploit the EPR-effect. 
 
In figure 16 three examples of ruthenium containing drugs are shown which have been in 
clinical trials. They carry different ligands and therefore, they differ in weight, size and shape. 
With DMSO and imidazole NAMI-A has rather small ligands, whereas KP1019 with indazoles 
carries clearly larger ligands, which results in larger weight and size. RAPTA-C belongs to the 
piano stool family, where one ligand is a cyclic polyhapto ligand. In the case of RAPTA-C the 
cyclic polyhapto ligand is p-cymene. Furthermore, the cyclic polyhapto ligands or arenes are 
known to stabilize the Ru(II) centers, which is the active form of such complexes. Furthermore, 
the arene provides a hydrophobic surface, allowing cellular diffusion through the lipophilic 
plasma membrane.130 For these reasons, arene-ruthenium complexes as anti-cancer drugs have 
been extensively investigated in recent years.  
 
Arenes are defined as hydrocarbons with a conjugated monocyclic molecular structure 
according to IUPAC.131 They are strong electron donors and are able to form strong bonds with 
d-metals. d-Elements possess an incomplete d shell and an empty last p-shell and therefore they 
accept and share electrons from ligands to increase their stability.132 Since arenes are strong 
electron donors they present an interesting group of ligands for organometallic chemistry. A 
depletion of π-electron density is observed in arenes when bound to a transition metal, which 
supports the theory that strong bonds are formed between an arene and a d-metal.133 
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Figure 17: Dewar-Chatt-Duncanson model π-bonding and π*-antibonding for a π-accepting alkene  ligand with a  transition 
metal.132 
Figure 17 illustrates how π-electron donors, in this case an olefin, form a σ-bond by donating 
electrons in a coaxial manner from the filled p-orbitals of the ligand to the empty d-orbitals of 
the metals. Furthermore, there is a lateral π-type backbonding from a filled d-orbital to a vacant 
antibonding orbital of the alkene ligand forming a π-bond.132 The π-bond point in the opposite 
direction to the σ-bond. This partly compensates the σ-bond and allows the metal to return part 
of the excess of electron density and therefore it is able to exist in a low or negative oxidation 
state.132 Using this molecular orbital theory the stabilisation of Ru(II) centers using arenes can 
be explained. 
 
As already mentioned, ruthenium can possess an octahedral geometry. For the metal to form 
the desired assembly, some of the coordination sites at the metal center must be occupied. In 
this manner the accessibility of the coordination sites can be controlled. This can be done with 
the use of η5 or η6 ligands. In this thesis η6 ligands are discussed. The use of such aromatic 
ligands brings advantages as three of the six coordination sites are occupied by the aromatic 
ligands, hence there is a better control in the synthesis of the desired assemblies. Furthermore, 
the strongly bonded aromatic ligand can be further modified to enhance the size, mass and 
solubility or to add new properties to the assemblies.134 
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4.1. MONONUCLEAR PIANO STOOL COMPLEXES 
Half-sandwich compounds possess a piano stool geometry, meaning the metal center is 
coordinated to an arene or a cyclopentadienyl ligand on one site. The general structure of such 
a compound as well as the structure of [(η6-benzene)Ru(II)(metronidazole)Cl2] is comparable 
to the geometry of a piano stool as illustrated in figure 18. 
 
Figure 18: General structure of piano stool complexes and  [(η6-benzene)Ru(II)(metronidazole)Cl2] synthesized by Dale and 
co-workers in 1992.122,135 
The first biologically inspired compound of this kind was prepared by Dale and co-workers. 
He used metronidazole (1-β-hydroxyethyl-2-methyl-5-nitro-imidazole), a known anti-cancer 
drug to coordinate to a Ru(II) benzene dichloride fragment. [(η6-
benzene)Ru(II)(metronidazole)Cl2] has shown to have a better activity than metronidazole 
alone.122 
 
Figure 19: Structures of [(η6-benzene)Ru(II)(L-alanine)Cl], [(η6-benzene)Ru(II)(L-alanine methyl ester)Cl2], [(η6-
benzene)Ru(II)(L-alanine)(ethylguanine] and [(η6-benzene)Ru(II)(ethylguanine)Cl2]show how different ligands can be used 
to prepare a variety of piano stool complexes.136 
Later, Sheldrick and co-workers reported the synthesis of [(η6-arene)Ru(II)(LL)Clx] half-
sandwich compounds (figure 19), where the amino acids L-alanine, guanine and their 
derivatives are used as ligands. These examples show how different ligands can be used to 
prepare a variety of piano stool complexes. 
 
Figure 20: Half-sandwich complexes using different arenes and ethylenediamine [(η6-arene)Ru(II)(en)Cl].137 
Sadler and co-workers prepared half-sandwich complexes using different arenes as illustrated 
in figure 20 and ethylenediamine (en) to establish structure-activity relationships.137 In this 
manner it is possible as well to prepare a variety of complexes. In table 5 the impact of the 
different arenes in respect to their IC50 values are depicted: 
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arene-Ru drug IC50 [µM] 
benzene 17 
p-cymene 10 
biphenyl 5 
tetrahydroanthracene 0.5 
dihydroanthracen 2 
Table 5: Arene-ruthenium complexes with respective IC50 values in human ovarian A2780 cancer cells after 24 h drug 
exposure.137 
Dyson and co-workers prepared a series of half-sandwich complexes using modified arene 
ligands and PTA (1,3,5-triaza-7-phosphaadamantane) to develop a structure-activity 
relationship (figure 21). These structures were considered to be the prototypes of the Ru(II) 
anti-cancer drug RAPTA-C. 
 
Figure 21: [(η6-arene)Ru(II)(PTA)Cl2] half-sandwhich complexes with different arenes. 138 
Half-sandwich piano stools are mono-nuclear complexes with only one metal center. 
However, complexes can also be formed with multiple metal centers. The following chapter 
deals with multi-nuclearity and its link to supramolecular chemistry. Furthermore, it describes 
how the choice of the ligand and its denticity is crucial for the final shape and size of the desired 
assembly.  
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4.2. CONCEPTS OF MULTI-NUCLEAR ASSEMBLIES 
Maverick and co-workers were the first to report the synthesis of a copper based M2L2-type 
rectangular structure in 1984.139 Shortly after in 1986, they reported on the synthesis of a second 
macrocycle.140 He used a Cu(II) metal center and β-diketones as ligands. Both macrocylces are 
shown in figure 22.  
 
Figure 22: First macrocylces synthesized by Maverick. 
A few years later, Fujita reported the preparation of a polynuclear Pd(II) complex, 
[(en)Pd(4,4'-bpy)]4(NO3)8, where the cis position of the square-planar Pd atoms were occupied 
by ethylenediamine ligands and the remaining coordination sites linked to each other by 
bridging 4,4'-bipyridine spacer ligands (figure 23).141  
  
Figure 23: Polynuclear Pd(II) complex synthesized by Fujita, in 1990.141 
Hereafter, many other groups have also developed similar supramolecular structures.142–148 In 
2001 Stang and co-workers developed a strategy to generate supramolecular rectangles from so 
called 'molecular clips'. Molecular clips are dinuclear building blocks with two 90 ° angles as 
shown in scheme 3. In order to form a rectangle, he combined two molecular clips by 
introducing a bidentate bridging ligand to connect the platinum metal centers with each other. 
Stang recognized that it was necessary for the molecular clip to possess a rigid backbone, to 
avoid formation of complex mixtures.142 
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Scheme 3: a) Simplified illustration of molecular clip (left) and resulting rectangle (right) b) molecular clip 1,8-bis(trans-
Pt(PEt3)2-(NO3))anthracene (left) and resulting rectangle cyclobis[1,8-bis(trans-Pt(PEt3)2)anthracene)(4,4'-dipyridyl] (right) 
by Stang and co-workers.142  
Stang further increased the size of this rectangle shown in figure 24 by exchanging the 4,4'-
bypyridine with larger bidentate ligands. He interlinked 1,2-di(pyridin-4-yl)ethene and 1,4-
bis(pyridin-4-ylethynyl)benzene between the two molecular clips. 
 
Figure 24: Rectangles by Stang with 1,2-di(pyridin-4-yl)ethene (left) and 1,4-bis(pyridin-4-ylethynyl)benzene (right) between 
two molecular clips.142 
When comparing the rectangle containing 4,4'-bypyridine (scheme 3b) and 1,4-bis(pyridin-4-
ylethynyl)benzene (figure 24, right) as ligands, we can see that the size increased. It seems 
obvious that the choice of an even larger ligand results in the formation of an even larger 
rectangle. In these examples each bidentate bridging ligand possesses two donor groups to 
undergo coordination to the metal center. In the cases shown herein, the nitrogen heteroatom 
acts as donor group via its lone pair.132 Now it seems possible to use ligands of a higher denticity 
to make different kinds of supramolecular structures. This strategy will be discussed in the 
following section based on ruthenium containing assemblies. 
  
Pt
Pt
ONO2
ONO2
PEt3
PEt3
PEt3
PEt3
Pt
Pt
N
N
PEt3
PEt3
PEt3
PEt3
N
N
Pt
Pt
PEt3
PEt3
PEt3
PEt3
a)
b)
Pt
Pt
N
N
PEt3
PEt3
PEt3
PEt3
Pt
Pt
PEt3
PEt3
PEt3
PEt3
N
N
Pt
Pt
N
N
PEt3
PEt3
PEt3
PEt3
Pt
Pt
PEt3
PEt3
PEt3
PEt3
N
N
4+ 4+
STRATEGIES TO INCREASE THE MOLECULAR WEIGHT OF ARENE RUTHENIUM ASSEMBLIES 
 
 39  
4.3. ARENE-RUTHENIUM BASED MULTINUCLEAR ASSEMBLIES 
As discussed before arene-ruthenium complexes possess interesting anti-cancer properties and 
some examples of mononuclear compounds were shown. In 1997, Süss-Fink and co-workers 
used a similar approach to synthesize tetra-nuclear rectangles containing ruthenium.142,149 
 
Scheme 4: Molecular clip [Ru2(µ-η4-C2O4)(Cl)2((η6-p-cymene)2] (left) and the resulting rectangle [Ru4(µ- η4-C2O4)2(µ2-η4: 
η4-bipy) 2-(η6-p-cymene) 4]4. 
The molecular clip (scheme 4, left) is a dinuclear arene-ruthenium complex, where the two 
metal centers are linked by a spacer ligand. In this manner the molecular clip possesses a rigid 
structure in order to avoid formations of polymers or other complex structures in the following 
step. Likewise to Stang (schemes 3 and figure 24) it is possible to connect two rigid molecular 
clips by introducing bridging ligands. The spacer ligand used in scheme 4 to connect the two 
metal centers is oxalate, which is a chelating bidentate ligand. However, in this case, since one 
ligand is coordinating to two different Ru centers it is called a bis-bidentate ligand. Keppler and 
co-workers have shown that anti-cancer activity is as well observed in dinuclear ruthenium 
complexes. Furthermore, they have also demonstrated that the anti-cancer activity is further 
increased the longer the distance between the two metal centers is.150,151 A method to further 
augment the distance between the metal centers is the use of a different spacer ligand. 
 
Figure 25: Dinuclear arene ruthenium precursor and metalla-clips with respective spacer length. Precursor: [Ru2(p-
cymene)2(µ-Cl)2Cl2] and clips: [Ru2(p-cymene)2(µ-C2O4)Cl2], [Ru2(p-cymene)2(µ-dhbq)Cl2] and [Ru2(p-cymene)2(µ- 
dhnq)Cl2] (from left to right).134,152 
In figure 25 dinuclear ruthenium species are illustrated and the influence of the spacer ligands 
on the size of the molecular clips is shown. [Ru2(p-cymene)2(µ-Cl)2Cl2], the first molecule 
shown in figure 25, is the ruthenium precursor which is prepared from RuCl3 · nH2O and α-
phellandrene in EtOH. It is used for the preparation of dinuclear metalla-clips by introducing 
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the spacer ligands. The precursor possesses two chlorine atoms which act as bridging ligands 
to connect the two ruthenium metal centers. The length from one ruthenium to the other 
ruthenium amounts 3.7 Å. By introducing oxalate as a spacer ligand the size increases to 5.5 Å. 
In the last two examples of figure 25 dihydroxybenzoquinone (dhbq) and 
dihydroxynaphtoquinone (dhnq) were used as spacer ligands and the distances were increased 
to 7.9 Å and 8.4 Å respectively. All spacer ligands illustrated in figure 25 are bis-bidentate 
ligands. It is shown that spacer ligands need certain properties to be suitable for the formation 
of such clips. In the example of oxalic acid and dhbq, there are two hydroxy groups within the 
ligand and in their α-position there are carbonyl functions. In the example of dhnq there are as 
well two hydroxy groups and in their β-position there are carbonyl functions. The deprotonated 
hydroxy groups form a bond to the metal centers and the carbonyl functions further coordinate 
with their lone pairs to the metal centers. In this manner a bis-bidentate chelating mode is 
possible. 
 
Once, the molecular clip is synthesized, two of them can be combined by introducing another 
ligand, so called panel ligands. In schemes 3 and 4 and figure 24 rectangles are formed using 
bidentate linkers, which act as bridging ligands. In all cases two linkers were required to connect 
two clips to form a rectangle and therefore a tetra-nuclear metalla-assembly. 
 
Figure 26: Tetra-nuclear ruthenium rectangles with respective length of panel ligands: [Ru4(p-cymene)2(µ-prz)2(µ-dhnq)2]4+, 
[Ru4(p-cymene)2(µ-bpy)2(µ-dhnq)2]4+ and [Ru4(p-cymene)2(µ-bpe)2(µ-dhnq)2]4+.152,153 
The linkers used for the formation of the rectangles shown in figure 26 are the bidentate 
pyrazine, 4,4'-bipyridine and (E)-1,2-di(pyridine-4-yl)ethene. Like before the distance between 
the ruthenium metal centers can be increased using diverse panel ligands. Depending on the 
choice of the connector the final assembly can possess a different structure as illustrated in 
figure 27.  
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Figure 27: Preparation of different kinds of assemblies with the right choice of ligands. Tetra-nuclear rectangle (left), hexa-
nuclear prism (center) and octa-nuclear prism (right). 
Polypyridyl derivatives are suitable panel ligands for the preparation of cage-like structures. 
They possess several position to coordinate to a metal center. In figure 28 some examples of 
tridentate polypyridyl derivatives are shown.  
 
Figure 28: Tri-dentate polypyridyl panel ligands to form hexa-nuclear ruthenium prisms.154–157 
2,4,6-tri(pyridin-4-yl)-1,3,5-triazine is prepared from isonicotinonitrile and NaOH.155 Three 
pyridyl moieties are directly attached to the triazine ring in the center at 2, 4 and 6 position. In 
this thesis 2,4,6-tri(pyridin-4-yl)-1,3,5-triazine will be referred to as 4-tpt. 1,3,5-Tris((E)-2-
(pyridin-4-yl)vinyl)benzene is prepared from 1,3,5-tribromobenzene and 4-vinylpyridine in a 
Heck reaction and will be referred to as tris-pvb.156 In this case the pyridyl moiety is connected 
to the aromatic ring in the center via an olefin. 1,3,5-Tris(pyridin-4-ylethynyl)benzene is 
prepared from 1,3,5-triethynylbenzene and bromobenzene in a Sonogashira cross-coupling 
reaction to form a triple bond between the three pyridyl moieties and the aromatic ring in the 
center.157 A triple bond is shorter than a double bond, however, since a triple bond possesses a 
linear structure, the overall size is increased. Using these ligands, it is possible to synthesize 
hexa-nuclear prism-like structures, as shown in figure 29. 
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Figure 29: Structure of a hexa-nuclear prism using a tri-dentate panel ligand. 
In figure 30 some other structural motifs of polypyridyl derivatives are shown. In particular, 
tetra-dentate ligands that are able to coordinate four ruthenium centers. 
 
Figure 30: Tetra-dentate polypyridyl panel ligands to form octa-nuclear ruthenium assemblies.158,159 
1,2,4,5-Tetrakis((E)-2-(pyridin-4-yl)vinyl)benzene is prepared in a Wittig-Horner reaction 
starting from 4-pyridinecarboxaldehyde and 1,2,4,5-tetrakis(bromomethyl)benzene which is 
converted to the respective phosphonate.158 1,2,4,5-tetrakis(pyridin-4-ylethynyl)benzene is 
synthesized in a Sonogashira cross-coupling reaction starting from 1,2,4,5-tetraiodobenzene 
and 4-ethynylpyridine.159 The length of the ligand was increased by replacing the double bond 
with a triple bond, due to its linear structure. The last example shown in figure 30 is a 
polypyridyl porphyrin derivative and in this theses it is referred to as tpp. It is prepared from 
isonicotinaldehyde and 1H-pyrrole.160,161 The molecular weight was increased significantly for 
the porphyrin derivative compared to the other two tetra-pyridyl ligands. As mentioned in 
chapter 2, not only the size but also the molecular weight matters for the EPR-effect. Using 
these tetradentate ligands the formation of octa-nuclear assemblies is possible. 
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Figure 31: Structure of octa-nuclear cube using a tetra-dentate panel ligand. 
Figure 31 shows an octa-nuclear cube using 1,2,4,5-tetrakis((E)-2-(pyridin-4-
yl)vinyl)benzene as panel ligand, which has the ability to coordinate four ruthenium metal 
centers. 
4.4. AIM OF THIS THESIS 
The aim of this project is to synthesize macromolecular multi-nuclear arene-ruthenium 
metalla-assemblies with anti-cancer activity to target cancer cells via the EPR-effect. This study 
should provide access to novel arene-ruthenium assemblies with an increased mass and size to 
exploit the discrepancy between cancerous and healthy tissues. Moreover, encapsulation of 
anti-cancerogenic guest molecules into the metalla-assembly will be tested. The biological 
activity of the herein synthesized complexes will be examined by the group of Prof. Paul Dyson 
at the EPFL in Lausanne, Switzerland. 
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5. SYNTHETIC STRATEGY 
The synthesis of arene-ruthenium assemblies starts with the preparation of a ruthenium 
precursor which is obtained from RuCl3 · n H2O and a cyclic diene. Two of the four chlorine 
atoms of the precursor act as bridging ligands to connect the two ruthenium metal centers and 
the cyclic diene becomes the arene that coordinates to the metal center with a hapticity of 6. In 
the second step of the synthetic pathway, the spacer ligand is introduced. In scheme 5 the spacer 
ligand is illustrated as an orange square and its corners represent heteroatoms that are able to 
undergo coordination with the metal center. Spacer ligands are for example bis-bidentate 
ligands with the ability to bind two metal centers. In the last step the panel ligand, which is 
depicted as blue triangles is inserted. It is able to coordinate several clips to form a hexa-nuclear 
prism. 
  
Scheme 5: Simplified synthesis of an hexa-nuclear arene-ruthenium prism. Orange bar: spacer ligand; blue triangle: 
tridentate panel ligand. 
In this project, we mainly focused our attention on the preparation of spacer ligands, in view 
to increase the size and molecular weight of the metalla-assemblies. 
5.1. MODIFICATION OF SPACER LIGANDS 
5.1.1. Oxalamides 
Oxalamides are structurally similar to oxalate, which have already presented to be suitable 
spacer ligands as shown in figure 25. Like oxalate, they possess four heteroatoms on two 
neighboring carbons, which allows coordination to two metal centers by creating a chelating 
complex (molecular clip). The advantage of oxalamides as compared to oxalate is their facility 
to be functionalized. In both cases the spacer ligands must be doubly deprotonated in order to 
be able to undergo coordination with the metal centers. The oxalate possesses no substituents 
other than the carboxylic acid functions on both carbons. Therefore, there is no possibility to 
further modify this ligand. Oxalamides on the other hand, are easily functionalized, owning to 
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the presence of the nitrogen atoms. Therefore, there is room for a substituent on the nitrogen 
atom. Once the ligand is deprotonated, the negative charge is delocalized between the 
heteroatoms, which will result in a coordination between the ligand and the metal center to form 
a stable chelate complex. Oxalamides have already been used for the formation of molecular 
clips.162 Figure 32 illustrates two molecular clips that were synthesized previously, [(η6-p-
cymene)2Ru2(µ4-N1,N2-bis(2-hydroxyethyl)oxalamide)Cl2] (1) and [(η6-p-cymene)2Ru2(µ4-
N1,N2-bis(2-(2-hydroxyethoxy)ethyl)oxalamide)Cl2] (2). Oxalamides are bis-(bidentate 
ligands) and they are symmetrical ligands. 
 
Figure 32: Molecular clips synthesized by our group using oxalamides as spacer ligands.162 
Scheme 6 depicts the synthesis of four oxalamides (3 - 6), which are easily prepared in a one-
step reaction starting from oxalyl chloride and the commercially available amine.163 The ligands 
N1,N2-dihexyloxalamide (3) and N1,N2-dioctyloxalamide (4) were synthesized in excellent 
yields, whereas N1,N2-didecyloxalamide (5) and N1,N2-ditetradecyloxalamide (6) were isolated 
in lower yields. It was shown that the yields decreased with longer alkyl chains. This can be 
explained by the presence of the long alkyl chains that reduce solubility. To resolve this issue, 
hydrophilic functions were added to the structure. 
 
Scheme 6: Oxalamides ligands 3 - 6.163 
5.1.2. Pegylated Oxalamides 
As mentioned on page 21, PEG chains possess many features that are interesting in biological 
applications. PEG chains are known to be non-toxic and non-immunogenic, therefore the 
therapeutic index can be increased. Furthermore, they increase the overall solubility and 
stability of the compound, prevent rapid clearance of small molecules and can increase the 
plasma residence of certain drugs.77,96,164,165 Therefore, in the second series of ligands, PEG 
chains are introduced, similar to those shown in figure 32. 
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As presented in scheme 7, the synthetic pathway started with the commercially available 2-
(2-(2-chloroethoxy)ethoxy)ethan-1-ol (PEG 1). First, the chloride is converted into the azide, 
and then reduced in a Staudinger reaction into the corresponding amine. This pegylated amine 
(PEG 2) then allowed to react with oxalyl chloride to obtain the desired ligand N1,N2-bis(2-(2-
(2-hydroxyethoxy)ethoxy)ethyl)oxalamide (7). Separation of this ligand from NEt3·HCl was 
challenging, however, in earlier reports of similar compounds, the presence of NEt3·HCl was 
also observed in the final product.162 The yield is rather poor with 14%, which might be 
explained by the possible formation of polymers. 
  
Scheme 7: Synthesis of pegylated ligands N1,N2-bis(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)oxalamide (7).166 
5.1.3. Diazene Dicarboxylates and Hydrazine Dicarboxylates 
The synthesis of a diazene carboxylate derivative as spacer ligand for the formation of a 
molecular clip has been reported.162 Diethyldiazene-1,2-dicarboxylate was used as spacer 
ligand to form the molecular clip [(η6-p-cymene)2Ru2(µ4-diethyl diazene-1,2-
dicarboxylate)Cl2] (8) (figure 33).  
 
Figure 33:Molecular clip 8 formed from diazene carboxylate or hydrazine dicarboxylates as spacer ligand.162 
Diazene dicarboxylates are synthesized in a two-step reaction starting from hydrazine and the 
commercially available chloroformate to form the hydrazine dicarboxylates (9 and 10). Then, 
they are oxidized to the desired diazene dicarboxylate ligands 11 and 12 with NBS. A shorter 
analog of such ligands is used to form clip 8, however the ligands 9 and 10 might also be 
interesting for the formation of molecular clips. Therefore, they were considered as potential 
spacer ligands as well (scheme 8). 
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Scheme 8: Hydrazine dicarboxylates (9, 10) and diazene dicarboxylates (11, 12) as spacer ligands.167 
5.1.4. Diazenes Diacyls and Hydrazines Diacyls 
The next type of ligands is very similar to those shown in scheme 8. However, in this case, 
the dicarboxylate functions next to the hydrazine and diazene function are replaced by carbonyl 
functions in order to obtain molecular clips such as 13 (figure 34). 
 
Figure 34: Molecular clips obtained from diazene diacyls or hydrazine diacyls. 
Scheme 9 shows the synthesis of the ligands starting from hydrazine. Two synthetic pathways 
are depicted. The top pathway involves an anhydride and the bottom pathway involves an acid 
chloride. Both pathways provide the same hydrazine derivatives 14 and 15 in excellent yields, 
which might be potential ligands. In the second step, the hydrazine derivatives are oxidized 
using Pb(OAc)4 to form the respective diazene compounds 16 and 17. Diazenes 16 and 17 are 
structurally similar to 12, of which the diethyl analog has already demonstrated to be a suitable 
ligand for the formation of clip 8.162 
 
Scheme 9: Diazene diacyls or hydrazine diacyls as spacer ligands.168–171 
5.1.5. Dihydroxybenzoquinones 
2,5-Dihydroxybenzoquinones (dhbq) are another type of spacer ligands to form clip-like 
complexes. They possess two hydroxy groups in a para position and two carbonyl functions as 
well in a para position to each other. Therefore, they are able to coordinate two metal centers 
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to form a chelating complex. Accordingly, functionalized dhbq derivatives can be exploited to 
increase the size of molecular clips. As illustrated in figure 35, several dinuclear ruthenium 
complexes [(η6-p-cymene)2Ru2(µ4-R-dhbq-R')Cl2] (18) have already been synthesized and 
reported.172 
 
Figure 35: Molecular clips containing a variety of dhbq derivatives as spacer ligands.172 
5.1.5.1. Preparation of dhbq Ligands via Cross-Coupling Reactions 
An approach to obtain modified dhbq ligands is via a Suzuki cross-coupling reaction. As 
illustrated in scheme 10, 3-bromo-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione (20) and 2,5-
dibromo-3,6-dimethoxycyclohexa-2,5-diene-1,4-dione (21) are two suitable candidates for a 
Suzuki cross-coupling reaction in view to increase the size and weight of molecular clips. 
Furthermore, 20 and 21 are prepared in a straightforward two step reaction from dhbq via 2,5-
dimethoxycyclohexa-2,5-diene-1,4-dione (19). The Suzuki cross-coupling is performed once 
or twice on these molecules. Such cross-coupling reactions on 20 and 21 have already been 
reported.173 Then after deprotection, the dhbq derivatives are obtained and ready to react with 
the arene ruthenium complexes. 
 
Scheme 10: Synthesis of 3-bromo-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione (20) and 2,5-dibromo-3,6-
dimethoxycyclohexa-2,5-diene-1,4-dione (21).174 
Figure 36 depicts the general structure of the dhbq derivatives and ligands after 
functionalization of intermediates 20 or 21. The basic scaffold is shown in blue and will remain 
the same during the reaction sequences shown in this chapter. The R1 substituent represents the 
aryl moiety from the Suzuki cross-coupling reaction. If the dibromobenzoquinone 21 is used 
for the Suzuki cross-coupling, R2 is identical to R1 whereas, if the monobromobenzoquinone 
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20 is used R2 represents a hydrogen atom. R3 represents a methyl group for the protected 
hydroxy groups and hydrogen atom for the free hydroxy groups. This general structure is valid 
for the following sequence and the substituents are not outlined again in the figures. 
 
Figure 36: General structure of dhbq derivatives and dhbq ligands after Suzuki cross-coupling. 
PEG is known to possess numerous beneficial properties from the biological and medicinal 
point of view, therefore the preparation of PEG containing ligands are of special interest in this 
project. Furthermore, by increasing the size, solubility is often an issue, however, PEG chains 
can counteract this effect. 
 
Scheme 11 illustrates the retrosynthesis of the functionalized dhbq 22. The proposed 
retrosynthesis of 22 involves a four steps reaction sequence. As depicted, the desired dhbq 
ligand was modified at its 3 and 6 positions and its dhbq-coordination sites are maintained, 
which are crucial for the formation of the clip. Two different methods for the synthesis of 22 
are shown in scheme 11. Route A suggests 4-bromobenzamide (26) as starting material, 
whereas in route B 4-bromobenzoyl chloride (27) is used as starting material. In both cases a 
PEG chain is added to form the amide bond, while in route A, the PEG acts as electrophile and 
in route B the PEG acts as nucleophile to obtain intermediate 25. In the second step the boronic 
ester (24) is prepared via Miyaura borylation.  In the following step the Suzuki cross-coupling 
is performed between the boronic ester 24 and monobromo- 20 or dibromobenzoquinone 21 
(scheme 10) to form 23 and in the final step the hydroxy groups are deprotected in order to 
obtain 22. 
 
Scheme 11: Retrosynthesis of dhbq derivative as potential ligand starting from 4-bromobenzamide (26) or 4-bromobenzoyl 
chloride (27), R2 = H; R1. 
Route A of scheme 12 shows the synthetic attempt to prepare ligand 25a,b,c from 26. NaH was 
used as a base to deprotonate amide 26. The commercially available 2-(2-(2-
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chloroethoxy)ethoxy)ethanol (PEG 1) was used as the first electrophile with chlorine as leaving 
group to form amide 25a. However, the desired product was not obtained and only starting 
material was recovered. Therefore, the reactivity of the PEG was increased by replacing the 
chlorine with iodine (PEG 3) in a Finkelstein reaction. Since there was still no conversion 
observed, a tert-butyldimethylsilyl protected (PEG 4) and a methyl protected (PEG 6) 
electrophile were used. However, the preparation of the desired amides 25b and 25c was also 
unsuccessful. The deprotonation of the amide group might have been the problem causing the 
failure of this reaction.  
 
Scheme 12: Route a): Attempts to prepare 4-bromo-N-(PEG)benzamide (25a,b,c) from 4-bromobenzamide (26) using 
commercially available 2-(2-(2-chloroethoxy)ethoxy)ethan-1-ol (PEG 1), and the prepared 2-(2-(2-iodoethoxy)ethoxy)ethan-
1-ol (PEG 3),175 12-chloro-2,2,3,3-tetramethyl-4,7,10-trioxa-3-siladodecane (PEG 4)176 and 1-chloro-2-(2-(2-
methoxyethoxy)ethoxy)ethane (PEG 6).177 Route b) Synthesis of 25a from 4-bromobenzoyl chloride (27) and 2-(2-(2-
aminoethoxy)ethoxy)ethan-1-ol (PEG 2).166  
As shown in route B of scheme 12 the reaction was repeated with 4-bromobenzoyl chloride 
(27) as starting material and the previously synthesized 2-(2-(2-aminoethoxy)ethoxy)ethan-1-
ol (PEG 2) (scheme 7) was used as nucleophile. The reaction was performed under basic 
conditions in a mixture of acetone and dist. H2O at RT according to a patent178 for a similar 
reaction and amide 25a was obtained in a good yield of 75%. 
 
In the next step the Miyaura borylation was performed using 25a according to another patent 
in 1,4-dioxane at 80 °C in the presence of KOAc and Pd(II)(dppf)Cl2.179 However, the boronic 
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ester 24a was not obtained under these conditions even after extended reaction time and the 
utilization of various bases and different Pd-catalysts (scheme 13). NMR analysis of the 
reactions showed a complex mixture containing the product of proto-demetalation, unreacted 
starting materials and unidentified byproducts. 
 
 
Scheme 13: Attempt to prepare N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-
yl)benzamide (24a). Pd-cat: Pd(II)(dppf)Cl2, Pd(0)(PPh3)4, XPhosPdG2; base: KOAc, NaOAc. 
Since the preparation of the boronic ester 24a was not successful, in the next example 
commercially available boronic esters are used and the Suzuki cross-coupling reaction is carried 
out in the first step with 20 or 21 as shown in scheme 14. In route A the boronic ester (4-
(methoxycarbonyl)phenyl)boronic acid (28) is used to form ester 29. The ester group of 29 
could then be converted to the acid chloride and the nucleophilic attack of PEG 2 would result 
in an amide bond to obtain 23a. The Suzuki cross-coupling reaction was tested in 1,4-dioxane 
using nickel and palladium catalysts in combination with different bases, however compound 
29 was not obtained under these conditions, even after extended reaction times and higher 
temperatures. Route B describes the Suzuki cross-coupling reaction using (4-
hydroxyphenyl)boronic acid (31) to form the phenol 32. The nucleophilic attack of the 
deprotonated phenol 32 on the electrophilic PEGs 1, 3, 4, 6 would result in the formation of 33a 
or 33b,c. The same conditions like for the preparation of 29 were tested, however, also in this 
case the reaction was not successful and intermediate 32 was not obtained. 
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Scheme 14: Suzuki cross-coupling reaction of 20 and 21 with boronic esters (4-(methoxycarbonyl)phenyl)boronic acid (28) 
and (4-hydroxyphenyl)boronic acid (31). Cat: Ni(II)(PPh3)2Cl2, Pd(0)(PPh3)4, Pd(II)(dppf)Cl2, XPhosPdG2; base: K2CO3, 
Na2CO3, CsF; R2 = H; R1. 
NMR analysis of the crude products showed a complex mixture containing the product of 
proto-demetalation, unreacted starting materials and unidentified byproducts. Furthermore, 
NMR analysis of the commercially available starting materials showed several impurities, 
which might have caused the failing of the reaction. 
5.1.5.2. Embelin Derivatives as dhbq Ligands 
Embelin as well, is a derivative of 2,5-dihydroxybenzoquinone (dhbq) with a -C11H23 alkyl 
chain attached at the three position of the six-membered ring (figure 37). Its IUPAC name is 
2,5-dihydroxy-3-undecylcyclohexa-2,5-diene-1,4-dione and as a dhbq derivative it is also a 
potential ligand to form arene-ruthenium metalla-assemblies. Embelin is isolated from the fruit 
of Embelia ribes that grows in India and was used for the treatment of fever, inflammatory and 
gastrointestinal diseases for centuries.180 Embelin derivatives were of special interest for this 
project, as embelin has shown further interesting biological activities like analgesic, anti-
inflammatory, anti-diabetic effects and it also possesses anti-tumor properties.181–185  
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Figure 37: Structure of embelin. 
For this project, we were interested in enlarging the structure of embelin by attaching a longer 
chain and the combined procedures for the synthesis of embelin published by Chen and co-
workers and Filosa and co-workers were used to synthesize a new derivative, as shown in 
scheme 15 below.186,187 The synthetic pathway starts with dhbq, which is converted to 2,5-
dimethoxybenzoquinone under acidic condition and in the presence of MeOH. This 
intermediate is then reduced to 2,5-dimethoxybenzene-1,4-diol (34) using Na2S2O4. In the 
following step the resulting hydroxy groups were converted to methoxy groups using MeI to 
obtain 1,2,4,5-tetramethoxybenzene (35). n-BuLi was used to deprotonate the aromatic proton, 
followed by a lithium-halogen exchange with 1-bromoicosane to form icosane derivative 36. 
This reaction was followed by the oxidation with CAN to form the quinone 3-icosyl-2,5-
dimethoxycyclohexa-2,5-diene-1,4-dione 37. In the last step both methoxy groups were 
converted into free alcohols to obtain the desired ligand (38) in an overall yield of 17%.  
 
Scheme 15: Synthesis of the icosyl derivative of embelin.186,187 
The synthesis of 36, 37 and 38 were the critical steps in this reaction sequence, nevertheless 
all three compounds were successfully prepared. The published yields for the undecan 
analogues to form embelin were 70%, 60% and 80%, respectively, resulting in an overall yield 
of 24%. This implies that a chain of almost twice the size does not interfere significantly in the 
reaction process. 
 
After the successful synthesis of 2,5-dihydroxy-3-icosylcyclohexa-2,5-diene-1,4-dione (38), 
the preparation of other derivatives was attempted using the same procedure. Scheme 15 shows 
that compound 1,2,4,5-tetramethoxybenzene (35) is the key intermediate in this reaction. The 
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reaction with n-BuLi and a suitable electrophile allows the formation of the monosubstituted 
tetramethoxybenzene analouges 38. Subsequent oxidation and deprotection reestablish the 
dihydroxy quinone functionality, required for clip formation. Therefore, several PEG-
molecules were tested as potential electrophiles under the same conditions as illustrated for the 
preparation of 36 in scheme 15. The electrophiles PEG 4 and PEG 6 were previously 
synthesized and used for the attempt to synthesize amides 25b and 25c as shown in route A of 
scheme 12. The bromine PEG 7 was prepared from the respective alcohol PEG 5 using 
molecular bromine and triphenylphosphine. PEG 7 possesses a higher electrophilic character 
than PEG 6 owning to the bromine, which is a better leaving group than chlorine. The reaction 
to attach a PEG chain was performed in dry THF, where n-BuLi was added at - 10 °C and the 
reaction was allowed to warm to RT. However, under these conditions the monosubstituted 
tetramethoxybenzene derivatives 39a,b were not obtained, therefore the reaction was repeated 
and the reaction was heated to 65 °C. The reaction to attach a PEG chain was not successful 
and the attempt to further functionalize 1,2,4,5-tetramethoxybenzene (35) with PEG moieties 
failed. 
 
Scheme 16: Attempt to attach different substituents to key intermediate 35 using various PEG chains: 12-chloro-2,2,3,3-
tetramethyl-4,7,10-trioxa-3-siladodecane (PEG 4), 1-chloro-2-(2-(2-methoxyethoxy)ethoxy)ethane (PEG 6) and 1-bromo-2-
(2-(2-methoxyethoxy)ethane (PEG 7)188 (Route A); alkyl chains: 1-bromotriacontane189 (Route B); and the synthesis of 
2,3,5,6-tetramethoxyterephtalic acid (41)190 (Route C). 
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Since the introduction of the icosyl alkyl chain, using 1-bromoicosane worked under these 
conditions, in the next attempt, 1-bromotriacontane (44) was used as an electrophile to insert a 
triacontyl chain, containing 30 carbons (Route B). Bromine 44 was synthesized from the 
respective alcohol 42, via mesylate intermediate 43. The reaction was performed at RT and at 
65 °C, however, 40 was not obtained. In this case the alkyl chain might be too long, causing 
solubility problems, which resulted in the failure of this reaction. Nevertheless, as shown in 
route C of scheme 16, the introduction of CO2 using dry ice under similar conditions, to 
synthesize 1,2,4,5-tetramethoxyterephtalic acid (41) was successful.190 Since the direct 
attachment of PEG chains was unsuccessful, dicarboxylic acid 41 offers a useful intermediate 
to introduce PEG chains via amide bond formation. 
 
The synthesis of 41 was accomplished according to published methods of Mathison and co-
workers.190 To perform the amide coupling, 2-(2-(2-methoxyethoxy)ethoxy)ethan-1-amine 
(PEG 8) was synthesized from the previously used PEG 6 (scheme 12 and 16), which was first 
converted to the respective azide and then reduced in a Staudinger reduction to the desired 
amine PEG 8, as shown in scheme 17 and several published conditions were tested to 
synthesize 45. In a first attempt, a one pot reaction using thionyl chloride was performed to 
convert the dicarboxylic acid into acid chlorides to increase the reactivity, but the desired 
diamide 45 was not obtained. In a second attempt, the coupling was performed using 
dicyclohexylcarbodiimide (DCC), which is a very popular coupling reagent for the formation 
of amide bonds, but here again, the reaction was not successful. The coupling with DCC was 
repeated under two different conditions (b, c). Conditions d) and e) are normally used for 
esterifications. First, 4-dimethylaminopyridine (DMAP) was added as catalyst and second, 1,4-
dimethylpyridinium p-toluenesulfonate (DPTS) was added as catalyst. However, the coupling 
failed. At last, the amide coupling was performed in the presence of 1-
[bis(dimethylamino)methylene]-1H-1,2,3-triazolo[4,5-b]pyridinium 3-oxid 
hexafluorophosphate (HATU), which is also a known coupling reagent (condition f). However 
also here, the coupling failed and only starting materials were isolated.  
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Scheme 17: Attempt to prepare 2,3,5,6-tetramethoxy-N1,N4-bis(2-(2-(2-methoxyethoxy)ethoxy)ethyl)terephthalamide (45) and 
attempt to synthesize dimethyl 4,4'-((2,3,5,6-tetramethoxyterephthaloyl)bis(azanediyl))dibenzoate (47) from 2,3,5,6-
tetramethoxyterephtalic acid 41 and 2-(2-(2-methoxyethoxy)ethoxy)ethan-1-amine (PEG 8) according to published 
methods.191–196 a) SOCl2, DCM, RT, overnight; b) DCC, CHCl3, 60 °C, overnight; c) DCC, DMAP, CHCl3, 60 °C, overnight; 
d) DCC, DMAP, DCM, RT, overnight; e) DCC, DPTS, DCM, RT, overnight f) HATU, DIPEA, DMF, RT, overnight.  
Since the direct attachment of a PEG chain failed again, in the next attempt methyl 4-
aminobenzoate (46) was added as linker, in order to link dicarboxylic acid 41 with a PEG chain 
as shown in Route B of scheme 17. Also in this case, the amide bond is formed between the 
dicarboxylic acid 41 and the commercially available amide 46 to obtain the intermediate 47. 
The ester group of 47 can then be converted to the acid chloride, which could form another 
amide bond with PEG 8 to obtain 48. However, previously used conditions a) - f) did not lead 
to the formation of the desired product 47, only starting materials were recovered. There is no 
report of syntheses and isolations of similar compounds, which leads to the assumption that this 
synthetic approach is very challenging. 
5.2. PREPARATION OF MOLECULAR CLIPS 
Molecular clips are building blocks of the multi-nuclear prisms, cubes and rectangles, which 
consist of two arene ruthenium metal centers that are bridged by a spacer ligand. The syntheses 
of thirteen potential spacer ligands (3 - 6, 9 - 12, 14 - 17, 38) were illustrated in the previous 
chapter and their ability to form a molecular clip has been tested. Before the preparation of the 
molecular clip, a precursor (49) must be synthesized.  
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5.2.1. Molecular Clip with Oxalamide 3 
 
Scheme 18: Preparation of molecular clip [(η6-p-cymene)2Ru2(µ4-N1,N2-dihexyloxalamide)Cl2] (50). 
In figure 32 two examples of molecular clips prepared by our group, containing oxalamides 
as spacer ligands are shown.162 That reaction was performed in MeOH under reflux and NaOAc 
was used as base. The same condition were tested for the preparation of clip 50 (scheme 18). 
However, the molecular clip was not formed, even after extended reaction time. Therefore, 
different conditions were tested, which are summarized in table 6. 
entry solvent T [°C] t [h] base yield [%] 
1 MeOH 60 15 NaOAc 0 
2 MeOH 60 24 NaOAc 0 
3 MeOH 60 15 NEt3 0 
4 MeOH 60 24 NEt3 0 
5 EtOH 90 15 NaOAc 0 
6 EtOH 80 24 NaOAc 0 
7 EtOH 80 15 NEt3 low 
8 EtOH 80 24 NEt3 low 
9 EtOH 80 15 DIPEA 16 
10 EtOH 80 24 DIPEA 25 
11 EtOH 80 72 DIPEA 27 
Table 6: Tested conditions for the synthesis of molecular clip [(η6-p-cymene)2Ru2(µ4-N1,N2-dihexyloxamide)Cl2] (50). 
NEt3, a stronger base was used, however there was no formation of the desired clip. Next, the 
solvent was changed from MeOH to EtOH (entry 5) and the reaction was performed at 90 °C. 
After 15 h the residue had decomposed and a black precipitate was observed, suggesting that 
the temperature was too high. So the reaction was repeated at 80 °C using first NaOAc and then 
NEt3 as bases. No conversion was observed with NaOAc, but low conversion was observed for 
the reaction with NEt3, but the purification of the crude product was not successful. To achieve 
better conversion, the base was exchanged from NEt3 to DIPEA (entry 9) and the reaction was 
successful. The molecular clip [(h6-p-cymene)2Ru2(µ4-N1,N2-dihexyloxalamide)Cl2] (50) was 
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prepared in EtOH at 80 °C with a low yield of 16%. Reaction time of 24 h yielded in 25% of 
conversion (entry 10) and further extended reaction times have only a small impact on the yield 
as shown in entry 11. The 1H-NMR shows both p-cymene moieties and the hexyl chains with 
diastereomeric protons. Furthermore, the success of this synthesis was confirmed by 13C-NMR 
IR, UV-VIS, ESI-MS and elemental analysis. 
5.2.2. Molecular Clip with Oxalamide 4 
Then N1,N2-dioctyloxalamide (4) was used as bridging ligand and molecular clip [(h6-p-
cymene)2Ru2(µ4-N1,N2-dioctyloxalamide)Cl2] (51) was formed. At 80 °C, only traces of the 
desired clip were observed by 1H-NMR analysis, therefore, the reaction was repeated at a higher 
temperature. At 90 °C the desired molecular clip 51 was obtained with a rather moderate yield 
of 21% (scheme 19). It seems, the longer the aliphatic chains, the higher the required 
temperature to achieve a conversion into the molecular clip. In contrast higher temperatures 
seem to promote decomposition of the molecule, this might be the reason for the low yield. 
 
 
Scheme 19: Synthesis of molecular clip [(η6-p-cymene)2Ru2(µ4-N1,N2-dioctyloxamide)Cl2] (51). 
The 1H-NMR spectra of both clips 50 and 51 look very similar, with only differences in the 
integrals of the aliphatic area. Figure 38 shows the 1H-NMR spectra of molecular clip 51 
recorded in CDCl3. The signals for the aromatic hydrogens of p-cymene are shown as a 
multiplet at around 5.3 ppm and a doublet at 5.0 ppm with an integral of 6 and 2, respectively. 
The singlet at 2.12 ppm and the two doublets at 1.20 ppm and 1.16 ppm with an integral of six 
for each signal belong to the methyl groups and the iPr groups of p-cymene. The two single 
protons of the iPr groups of p-cymene are observed with a multiplicity of seven at 2.68 ppm. 
At around 4.0 ppm and 3.3 ppm two multiplets are shown with an integral of two for each. They 
belong to the CH2 groups in the α-position to the nitrogen atom of the oxalamide moiety. An 
integral of two indicates that the hydrogen atoms are diastereotopic. The shape of the signal at 
about 1.6 ppm with an integral of four implies two overlying multiplets. This signal belongs to 
the CH2 in β-position to the nitrogen. The remaining CH2 groups of the chains arise as a 
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multiplet at around 1.3 ppm with an integral of 20 and the CH3 groups is observed at around 
0.9 ppm. 
     
Figure 38: 1H-NMR spectra of molecular clip 51 (400 MHz, CDCl3, RT). 
In Figure 39 the 13C-NMR of clip 51, recorded in CDCl3 at RT is shown. The signal at 170.1 
ppm belongs to the acyl group of the oxalamide moiety of the spacer ligand. The CH2 group in 
the α-position of the nitrogen is observed at 51.7 ppm and the CH3 group of the chains at 14.3 
ppm. The remaining protons of the CH2 chains are in the aliphatic area. The quaternary carbons 
of p-cymene are seen at 100.7 ppm and 94.4 ppm and the remaining aromatic carbons are 
observed between 82.5 and 79.5 ppm. The methyl groups of the p-cymene moieties are also 
detected at 22.6 and 22.2 ppm in the aliphatic area and all signals were assigned using 2D-NMR 
analysis. 
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Figure 39: 13C-NMR spectra of molecular clip 51 (101 MHz, CDCl3, RT). 
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Figure 40 shows the crystal structure of molecular clip 51 with omitted hydrogen atoms for 
increased clarity. Both p-cymene moieties, both chlorines, as well as the octyl chains point in 
opposite directions. The distance between the two ruthenium metal centers is 5.6 Å, which is 
slightly longer when compared to the oxalate analogue with 5.5 Å. ESI-MS analysis showed 
the same peak ([M - Cl]+) for both molecular clips 50 and 51 at m/z = 761.1 and 817.3, 
respectively and the elemental analysis proved the purity of the compounds. 
 
Figure 40: Molecular structure of clip 51 with omitted hydrogen atoms for clarity. Selected bond lengths/(Å) and angles/(°): 
Ru(1)-Ru(1i) 5.556(2), Ru(1)-O(1) 2.114(5), Ru(1)-N(1) 2.089(4), Ru(1)-Cl(1) 2.400(2), O(1)-C(1) 1.297(1), N(1)-C(1i) 
1.329(7), C(1)-C(1i) 1.459(1); O(1)-Ru(1)-N(1) 76.5(6), O(1)-Ru(1)-Cl(1) 85.6(0), N(1)-Ru(1)-Cl(1) 85.0(9), Ru(1)-N(1)-
C(1i) 114.9(1), O(1)-C(1)-C(1i) 115.3(0), N(1)-C(1i)-C(1) 116.3(5), i = -X; -Y; -Z. 
Comparison of the IR spectra of the ligands 3 and 4 with the IR spectra of the respective clips 
50 and 51 further proves the success of the reaction. The spectra of the ligands show clearly the 
bands representing the N-H stretching of secondary amines at around 3300 cm-1 which have 
disappeared in the spectra of the clips (experimental section).197 
5.2.3. Molecular Clips with Oxalamide 5 and 6 
Molecular clips 50 and 51 were successfully synthesized with the oxalamides 3 and 4. Herein, 
compounds 5 and 6 (scheme 6) are tested for their ability to act as spacer ligands for the 
formation of molecular clips. The same conditions as for the preparation of molecular clips 50 
and 51 were applied (table 7), however only starting materials were isolated. 
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entry solvent T [°C] t [h] base yield [%] 
1 EtOH 80 24 
 
DIPEA 0 
2 EtOH 90 24 
 
DIPEA 0 
3 BuOH 100 24 
 
DIPEA 0 
4 BuOH 110 24 
 
DIPEA 0 
Table 7: Attempt to synthesize molecular clips [(η6-p-cymene)2Ru2(µ4-N1,N2-didecyloxalamide)Cl2 (52) and [(η6-p-
cymene)2Ru2(µ4-N1,N2-ditetradecyloxalmide)Cl2 (53) containing oxalamides 5 or 6. 
The formation of 51 required a higher temperature than 50 due to the longer alkyl chain. In 
these cases, the chains are even longer, therefore, BuOH with a higher boiling point was used 
as solvent and the reaction was performed at 100 °C and 110 °C, however the desired clips 52 
and 53 were not obtained, but decomposition of the starting material was observed at these 
temperatures. 
5.2.4. Molecular Clip with PEGylated Oxalamide 7 
The syntheses of very similar clips, with PEG-monomers or PEG-dimers on each side of the 
oxalamide was realized in our group (figure 32).162 Herein, an attempt to prepare a molecular 
clip from an oxalamide consisting of PEG-trimers on each side (7) was performed according to 
the published method for shorter chains; MeOH at RT, overnight and NaOAc as a base (scheme 
20).162 However, molecular clip 54 was not obtained, even after extended reaction time. Like 
previous examples, several conditions were systematically tested by changing the base, the 
solvent or the temperature. The stronger bases NEt3 and DIPEA were used in order to 
deprotonate the oxalamide functionality. Since it failed, the reaction was carried out in MeOH 
under reflux, retesting all three bases, but the reaction was also unsuccessful. Therefore, MeOH 
was replaced with EtOH and the reaction was repeated at 80 °C and 90 °C. Again no molecular 
clip 54 was obtained. (scheme 20). The PEG chains are very flexible, which might cause 
interactions between the electronegative oxygen-atoms and the electropositive metal center, 
blocking the coordination site for the oxalamide functionality in order to form the clip. 
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Scheme 20: Attempt to synthesize molecular clip [(η6-p-cymene)2Ru2(µ4-N1,N2-bis(2-(2-(2-
hydroxyethoxy)ethoxy)ethyl)oxalamide)Cl2 (54). Base: NaOAc, NEt3, DIPEA; T: RT, 65 °C, 80 °C, 90 °C; t = 15 h, 24 h; 
solvent: MeOH, EtOH. 
5.2.5. Molecular Clips from Diazene Dicarboxylates and Hydrazine Dicarboxylates 
In this section the preparation of another type of molecular clips are shown using different 
spacer ligands. As shown in figure 33 molecular clip 8 is formed using the diethyldiazene-1,2-
dicarboxylate as ligand. Herein we use derivatives of that diazene dicarboxylates 11 and 12 in 
order to form the larger molecular clips 55 and 56 (Route A, scheme 21). The chlorines of the 
precursor 49 are abstracted using AgCF3SO3, to create a coordination site in order to form the 
molecular clip with 11 and 12 as spacer ligands. Another possibility to synthesize the same 
molecular clips 55 and 56 is via the hydrazine dicarboxylates 9 and 10 (Route B). In the latter 
example, inorganic and organic bases are used to deprotonate the ligands.  
 
Scheme 21: Attempt to synthesize molecular clips [(η6-p-cymene)2Ru2(µ4-dihexyl hydrazine-1,2-dicarboxylate)Cl2 (55) and 
[(η6-p-cymene)2Ru2(µ4-dioctyl hydrazine-1,2-dicarboxylate)]Cl2 (56) using diazene dicarboxylates 11 and 12 and hydrazine 
dicarboxylates 9 and 10 as spacer ligands. Base: NaOAc, NEt3, DIPEA; solvent (T): MeOH (RT; 65 °C), EtOH (RT; 80 °C; 
90 °C), DCM (RT; 40 °C), MeCN (RT; 80 °C), MeNO2 (RT, 100 °C). 
To find the optimal conditions for the reaction, the conditions were systematically changed in 
respect of base, solvent and temperature (scheme 21). In Route A, all tested conditions were in 
the presence of AgCF3SO3 in MeOH, EtOH, DCM, MeCN or MeNO2 as solvent. For each 
solvent the reactions were performed at RT and under reflux, additionally also at 80 °C for 
EtOH. However, clips 55 and 56 were not obtained. Route B starts from the hydrazine 
derivatives 9 and 10. Herein, the same conditions as in route A were tested, in combination with 
the inorganic base NaOAc and the organic bases NEt3 and DIPEA. But the reaction was 
unsuccessful and the synthesis of clips 55 and 56 was not observed. No reaction was observed 
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at RT, 40 °C and 65 °C. The formation of a complex mixture was observed for the reactions at 
80 °C and decomposition occurred at higher temperatures.  
5.2.6. Molecular Clips from Diazene and Hydrazines Diacyls 
As discussed previously, molecular clip 8 (figure 33) is synthesized using diethyldiazene-1,2-
dicarboxylate. The atoms involved in the bonding to the metal centers are the centered nitrogen 
atoms and the oxygen atoms of the carbonyl functions. These four atoms are as well present in 
diazene derivatives (16 and 17) and hydrazine derivatives (14 and 15), therefore they are 
potential ligands for the formation of molecular clips (scheme 22). 
 
Scheme 22: Attempts to synthesize molecular clips [(η6-p-cymene)2Ru2(µ4- N'-hexanoylhexanehydrazide)]Cl2 (57) and [(η6-p-
cymene)2Ru2(µ4- N'-octanoyloctanehydrazide)]Cl2 (58) using diazene derivatives 16 and 17  and hydrazine derivatives 14 and 
15 as spacer ligands. Base: NaOAc, NEt3, DIPEA; solvent (T): MeOH (RT; 65 °C), EtOH (RT; 80 °C; 90 °C), DCM (RT; 40 
°C), MeCN (RT; 80 °C), MeNO2 (RT, 100 °C). 
Similarly, route A starts from the diazene derivatives 16 and 17 and the reaction is performed 
in the presence of AgCF3SO3 to abstract the chlorine of precursor 49, while in route B, the 
hydrazine derivatives 14 and 15 are deprotonated using bases NaOAc, NEt3 or DIPEA (scheme 
22). The same conditions were tested, as for the preparation of clips 55 and 56 from spacer 
ligands 11, 12 or 9 and 10 (scheme 21), and again the synthesis of clips 57 and 58 failed. Like 
in the examples before, no reaction was observed at RT or 65 °C, at 80 °C a complex mixture 
of unidentified byproduct was isolated, which were not possible to separate, and decomposition 
occurred at high temperatures.  
5.2.7. Molecular Clips from dihydroxybenzoquinone derivatives 
In this section, the preparation of the molecular clip 59 using the dhbq derivative 38 is shown. 
As mentioned before on page 37, the formation of clips using simple dhbq or its derivatives as 
spacer ligands have already been demonstrated.134  
 
Scheme 23 shows the condition for the synthesis of clip 59 using ligand 38. The synthesis was 
performed according to published methods for the dhbq spacing ligand.198 EtOH was used as 
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solvent in the presence of NaOAc as the base and the reaction was performed at 80 °C and the 
desired clip was successfully synthesized with a good yield (77%).  
 
Scheme 23: Synthesis of molecular clip [(η6-p-cymene)2Ru2(µ4-3-icosyl-dihydroxybenzoquinone]Cl2 (59). 
In figure 41, the 1H-NMR for molecular clip 59 shows at 5.69 ppm a singlet with an integral 
of 1 for the single proton of dhbq, next to two multiplets for the eight aromatic protons of the 
p-cymene moieties at around 5.6 ppm and 5.4 ppm with an integral of four for each signal. The 
single proton of the iPr groups are represented by a septet with an integral of two at 2.90 ppm 
and the methyl groups of the iPr groups as a multiplet with an integral of twelve at around 1.4 
ppm. The remaining methyl groups of the p-cymene moieties are shown as a singlet with six 
protons at 2.91 ppm. The CH2 and CH3 groups corresponding to the icosyl chain are as well 
observed in the aliphatic area as a multiplet with 36 protons at around 1.3 ppm and a triplet with 
three protons at around 0.9 ppm, respectively. 
 
Figure 41: 1H-NMR spectrum of molecular clip 59 (400 MHz, CDCl3, RT). 
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In figure 42 the 13C-NMR of molecular clip 59 is shown and the signal assignment was done 
using 2D-NMR techniques. The signals for the aromatic carbons of the p-cymene are observed 
between 100.6 ppm and 79.1 ppm. The iPr groups of the p-cymene are detected at 31.5 and at 
22.7 ppm, respectively. The remaining methyl groups of the p-cymene moiety arise at 18.7 
ppm. The carbonyl group of the spacer ligand 38 are observed at 184.4 ppm and 181.1 ppm, 
respectively. The CH group of the dhbq ring moiety is observed at 115.5 and the quaternary 
carbon, where the chain is attached is detected at 100.7 ppm. All the CH2 groups of the chain 
are shown in the aliphatic area and the terminal CH3 group of the chain arises at 14.3 ppm. 
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Figure 42: 13C-NMR spectrum of molecular clip 59 (101 MHz, CDCl3, RT). 
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The ESI-MS analysis of clip 59 shows a peak for [M - Cl]+ at m/z = 925.3. The success of the 
reaction and the purity of the compound was further confirmed by elemental analysis. The IR 
spectrum of ligand 38 showed the band representing intramolecular O-H stretching at around 
3300 cm-1 which is not observed anymore in the IR spectrum of the clip 59.197 
5.2.8. Molecular Clips with Precursor 60 
Until this point, molecular clips consisting of p-cymene as arene moiety were discussed. 
Herein a different precursor consisting of another arene moiety is shown. Precursor 60 was 
prepared by Süss-Fink and co-workers in 2004.199 Like in the case of precursor 49 the bridging 
chlorines can be replaced by a spacer ligand to form a molecular clip. 
  
Scheme 24: Attempts to synthesize molecular clips [(η6-phenethyl 4-phenylbutanoate)2Ru2(µ4-dihydroxybenzoquinone)]Cl2 
(61) (route A) and [(η6-phenethyl 4-phenylbutanoate)2Ru2(µ4- N1,N2-dioctyloxalamide)]Cl2.(62) (route B) from precursor 
[Ru2(η6-phenethyl 4-phenylbutanoate)2(µ2-Cl)2Cl2] (60). 199 Solvent (T): MeOH (65 °C), EtOH (80 °C, 90 °C), DCM (40 °C), 
MeCN (80 °C), MeNO2 (100 °C). 
In route A of scheme 24, the commercially available dhbq was used as spacer ligand, in order 
to synthesize molecular clip 61. NaOAc was used as the base, since it has already proven to 
deprotonate dhbq and its derivatives. However, the reaction to insert dhbq was not successful. 
In route B, the previously synthesized N1,N2-dihexyloxalamide (3) is used as spacer ligand in 
the presence of DIPEA as a base, which has demonstrated to be able to deprotonate oxalamides. 
The reaction was tested in several solvents and at different temperatures, but the desired clip 62 
was not obtained. The 1H-NMR showed a complex mixture, nevertheless the expected mass 
was detected in ESI-MS analysis. Nonetheless, it was not possible to isolate the desired clip for 
further tests. The substituent of the arene moiety are large and flexible and are therefore able to 
interfere with the metal centers. This might be the reason for the formation of numerous 
byproducts, which could not be identified. 
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5.3. PREPARATION OF METALLA-ASSEMBLIES 
In this section the final step for the formation of the multi-nuclear assemblies is discussed. As 
explained previously in chapter 4, the connecting ligand, according to its denticity and therefore 
ability to combine a number of molecular clips, is responsible for the formation of such 
structures. Three molecular clips 50, 51 and 59 were successfully synthesized and in this section 
their ability to form a molecular assembly is tested. 
5.3.1. Preparation of Metalla-Prisms from Oxalamide-Clips 
First the tridentate 4-tpt panel ligand is used to prepare a prism. In the first step, AgCF3SO3 is 
used to abstract the chlorines of the clip to obtain the twofold positively charged intermediate. 
Then the panel ligand is added and the assembly is allowed to form by coordination. Scheme 
25 shows the synthesis of prisms 63 and 64 from the clips 50 and 51. Similar prisms have been 
previously prepared by our group in MeOH under reflux.162  
 
Scheme 25: Synthesis of hexa-nuclear molecular prism [(η6-p-cymene)6Ru6(µ4-N1,N2-dihexyloxalamide)3(µ3-4-
tpt)2][CF3SO3]6 (63) and [(η6-p-cymene)6Ru6(µ4-N1,N2-dioctyloxalamide)3(µ3-4-tpt)2][CF3SO3]6 (64). 
Prism 63 was obtained in an excellent yield of 96%, while 64 was obtained with 60% yield, 
which is comparable to similar assemblies.162 Figure 43 shows the 1H-NMR spectra of clip 51 
(top) and prism 64 (bottom). The 1H-NMR spectra of the clip 51 was discussed previously on 
page 57. 
 
The 1H-NMR spectrum of prism 64 (bottom) shows very similar chemical shifts to those in 
the 1H-NMR spectrum of the clip 51 (top) except for the signals associated to 4-tpt arising at 
around 8.5 ppm. Three clips are combined by two panel ligands, increasing rigidity to the 
structure of the prism, this results in broad signals in the 1H-NMR. Despite a slight shift and 
broadening, the signals of clip 51 are clearly seen and the integrals correspond to three clips in 
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relation to the 4-tpt panels. The 4-tpt panels possess 24 protons in total, which are represented 
by a broad multiplet at around 8.5 ppm. The aromatic protons of six p-cymene moieties are 
observed as two multiplets with an integral of 12 each at around 5.5 ppm. The diastereotopic 
protons of the octyl chains and the single proton of the iPr groups are observed as broad 
multiplets at around 4.3 ppm, 3.5 ppm and 2.8 ppm, respectively and with an integral of six for 
each signal. The six CH3 groups of the octyl chains are seen at 0.9 ppm and correspond to 18 
protons. The iPr and methyl groups of the p-cymene moieties and the CH2 groups of the octyl 
chains appear in the aliphatic area, causing overlying signals, nevertheless they are clearly 
visible.  
 
 
 
 
   
Figure 43: 1H-NMR spectra of molecular clip 51 (top) and molecular prism 64 (bottom). Only relevant structural motives of 
prism 64 represented for clarity (400 MHz, CDCl3, RT). 
In figure 44 the 13C-NMR spectra of clip 51 (top) and prism 64 (bottom) are presented. All 
the signals present in the spectrum of the clip are as well observed for the prism. Additionally, 
all four carbons of the panel ligand 4-tpt are observed between 172 ppm and 120 ppm. 
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Figure 44: 13C-NMR spectra of molecular clip 51 (top, 101 MHz, CDCl3, RT) and hexa-nuclear prism 64 (bottom, 151 MHz, 
CDCl3, 45 °C). Only relevant structural motives of prism 64 represented for clarity. 
Figure 45 shows the DOSY (diffusion ordered NMR spectroscopy) spectrum of prism 64. The 
2D-DOSY NMR experiment is a method developed by Morris and Johnson in 1992. This 
method allows molecular components of mixtures to be identified and simultaneously 
characterize the size of aggregates.200 Molecular motion of compounds in solution occur in 
rotational as well as in translational manner. The translational motion is also known as 
Brownian molecular motion and is simply called diffusion or self-diffusion. The diffusion 
coefficient D can be estimated using the Stokes-Einstein equation, when assuming a spherical 
shape for the molecule. 𝐷 =	 𝐾𝑇6𝜋𝜂𝑟 
D: diffusion coefficient [m2·s-1] 
K: Boltzmann constant [1.38064852 × 10-23·m2·kg·s-2·K-1] 
T: absolute temperature [K] 
η: viscosity of solvent [kg·m-1·s-1] 
r: hydrodynamic radius [m] 
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Figure 45: DOSY spectrum of prism 64 (400 MHz, CDCl3, RT). 
The DOSY experiment was recorded in CDCl3, at RT and the spectrum shown in figure 45 
was obtained. The F2 axis of the spectrum shows the chemical shift in ppm and the F1 axis 
shows the diffusion constant of the corresponding site. The signals belonging to prism 64 are 
diffusing at a rate of 2.52 x 10-10 m2·s-1 and the hydrodynamic radius amounts 16.4 x 10-10 m.  
However, the detected signals do not arise perfectly linear, suggesting that there might be more 
than one species present. Further indications for this assumption is seen in the 13C-NMR 
spectrum in figure 44, where too many peaks are observed for the panel ligand 4-tpt. 
Furthermore, the ESI-MS spectrum shows a signal at m/z = 317.3 for [Clip - Cl]+, which means 
that not all chlorines of the clips were successfully abstracted and therefore the presence of 
other species is possible. Nevertheless, the characteristic peaks for [M - 2 CF3SO3]2+ and [M - 
3 CF3SO3]3+ of both prisms 63 and 64 were detected and the elemental analysis showed good 
purity. 
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5.3.2. Preparation of Molecular Prism from dhbq-Clip 
Herein, the previously synthesized molecular clip 59 was used for the formation of the prism. 
Clip 59 includes 38 as spacer ligands, an analog to embelin, a natural product known to possess 
numerous biological activities.181 
 
Scheme 26: Synthesis of molecular prism [(η6-p-cymene)6Ru6(µ4-3-icosyl-dihydroxybenzoquinone)3(µ3-4-tpt)2][CF3SO3]6 
(65). 
Scheme 26 shows the synthesis of the hexa-nuclear prism 65. The synthesis was performed 
under the exact same conditions as the previous prisms, where first the chlorines are abstracted 
using AgCF3SO3 and then the panel ligand 4-tpt is added to allow the formation of the prism in 
MeOH under reflux. 65 was isolated with a good yield 60%.  
 
In figure 46 the 1H NMR spectra of the clip 59 (top) and the respective prism 65 (bottom) are 
presented. The 1H-NMR spectra of 59 was previously discussed, and like before the 1H-NMR 
spectrum of the prism 65 shows very similar shifts to the respective clip 59. In addition, the 
signals of the panel ligands are observed. In the bottom spectrum the shapes of the signals are 
broader and less clear, nevertheless all the characteristic signals for clip 59 are well observed 
with integrals corresponding to a prism. The signals for the panel ligands 4-tpt arise between 
9.0 and 8.5 ppm representing two different protons with an integral of twelve for each signal. 
The aromatic protons of three 59 moieties and the aromatic protons of six p-cymene moieties 
appear in the aromatic region as overlying signals integrating for 27 protons. The methyl groups 
of the p-cymene moieties are observed at around 2.1 ppm, the single proton of the iPr groups 
with an integration of six at around 2.8 ppm is observed as a broad multiplet, while the methyl 
groups are observed around 1.4 ppm. The CH2 groups of the icosyl chains appear between 1.3 
ppm and 1.2 ppm as a large and broad peak. The CH3 group of the icosyl chains is clearly seen 
at 0.8 ppm with an integral of 9. 
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Figure 46: 1H-NMR spectra of molecular clip 59 (top) and metalla-prism 65  (bottom). Only relevant structural motives of 
prism 65 represented for clarity (400 MHz, CDCl3, RT) 
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In figure 47 the 13C-NMR spectra of clip 59 (top) and prism 65 (bottom) are shown. All signals 
observed for the clip are as well present in the prism. In addition, signals corresponding to the 
panel ligands are observed between 170 and 140 ppm for the prism. 
 
 
 
 
Figure 47: 13C-NMR spectra of molecular clip 59 (top) and hexa-nuclear metalla-prism 65 (bottom). Only relevant structural 
motives of prism 65 represented for clarity (101 MHz, CDCl3, RT). 
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Figure 48 shows the DOSY spectrum of prism 65. The diffusion constant shows that all arising 
signals belong to prism 65 apart from the signal at 7.26 ppm belonging to CHCl3. The signals 
belonging to prism 65 are diffusing at a rate of 2.47 × 10-10m2·s-1, which corresponds to a 
hydrodynamic radius of 16.7 x 10-10 m. 
 
Figure 48: DOSY spectra of hexa-nuclear prism 65 (400 MHz, CDCl3, RT). 
All 1D- and 2D-NMR experiments showed the success of the preparation of prism 65. 
Furthermore, the ESI-MS showed the characteristic peaks [M - 2 CF3SO3]2+ and [M - 3 
CF3SO3]3+ and the purity of the compound was further confirmed by elemental analysis. 
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5.3.3. Preparation of Molecular Cubes from Oxalamide-Clips 
Herein, preparation of octa-nuclear molecular cubes is presented. As in the synthesis of hexa-
nuclear prisms, the first step is also the abstraction of the chlorines of the clips 50 and 51 using 
AgCF3SO3. Then the tetra-dentate panel ligand tpp is added to allow the formation of the cube. 
In the first attempt the synthesis was performed in DCM at RT for 15 h, following standard 
procedures.201 However, the cubes were not obtained, only starting materials were isolated even 
after extended reaction times and higher temperature, therefore the reaction was repeated using 
MeOH, EtOH, MeCN or MeNO2 at RT and under reflux for 72 h. As depicted in scheme 27, 
the reaction was successful in MeCN for clips 50 and 51 and the molecular cubes 66 and 67 
were successfully isolated with a yield of 73% and 71%, respectively.  
 
Scheme 27: Synthesis of molecular cubes [(η6-p-cymene)8Ru8(µ4-N1,N2-dihexyloxalamide)4(µ4-tpp)][CF3SO3]8 (66) and [(η6-
p-cymene)8Ru8(µ4-N1,N2-dioctyloxalamide)4(µ4-tpp)2][CF3SO3]8 (67). 
The difficulty of finding the appropriate synthetic conditions was linked to the poor solubility 
of the building blocks. Similarly, recording the NMR spectra was challenging, due to the 
insolubility of cubes 66 and 67. It was not possible to obtain a useful 1H-NMR at RT, therefore 
high temperature experiments were carried out. Figure 49 shows the 1H-NMR spectrum of 
molecular cube 67 recorded in MeNO2-d3 at 65 °C with a field strength of 800 MHz (recorded 
by Dr. Aurélien Bornet at the EPFL in Lausanne). 
 
Despite using a high field strength, the multiplicity of the signals was not clearly 
distinguished: The rigidity of the structure being probably responsible. Nevertheless, the 
significant signals of the tpp, the arene, the diastereotopic protons of the octyl chains and the 
terminal CH3 groups of the chains are clearly detected with their corresponding integrals. All 
remaining protons of the cube appear in the aliphatic region, leading to overlying signals. The 
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tpp panels are observed as multiplets between 9.5 ppm to 8.0 ppm and account for 52 protons. 
The aromatic protons of the p-cymene moieties are detected around 6.0 ppm with an integral of 
32 protons. The diastereotopic protons of the octyl chains are observed around 4.1 ppm and 3.1 
ppm with an integral of eight and the terminal CH3 group of the chain is observed at around 1.0 
ppm with an integral of 24.  
 
 
 
 
Figure 49: 1H-NMR spectra of molecular clip 51 (top, 400 MHz, MeNO2-d3, RT) and molecular cube 67 (bottom, 600 MHz, 
MeNO2-d3, 65 °C). Only relevant structural motives of cube 67 represented for clarity. 
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In figure 50 the 13C-NMR spectra of clip 50 (top) and cube 66 (bottom) is depicted. The signals 
for the oxalamide function, the protons of the aromatic and aliphatic protons of the p-cymene 
and the hexyl chains appear at similar positions in both spectra. In addition, the signals for the 
tpp is also observed.  
 
  
Figure 50: 13C-NMR spectra of molecular clip 50 (top, 101 MHz,  MeNO2-d3, RT) and molecular cube 66 (bottom, 151 MHz, 
MeNO2-d3, 65 °C). Only relevant structural motives of cube 67 represented for clarity. 
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Figure 51 illustrates the DOSY NMR spectrum of cube 67. The experiment shows that the 
signals belonging to cube 67 are diffusing at a rate of 2.3 x 10-10 m2·s-1. The diffusion constant 
can be read from the spectrum and the hydrodynamic radius (17.9 x 10-10 m) can be calculated 
using the Stokes-Einstein equation. 
 
Figure 51: DOSY NMR spectrum of octa-nuclear cube 67 (400 MHz, MeNO2-d3, RT). 
The formation of the cube was further confirmed by ESI-MS analysis. Both cubes 66 and 67 
show the characteristic peaks at [M- 4 CF3SO3]4+ and [M- 3 CF3SO3]3+. The nature of the salts 
was also confirmed by elemental analysis. 
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5.3.4. Preparation of Molecular Cube from dhbq-Clips 
In this section, an attempt to prepare a molecular cube from clip 59 is described. Like in the 
case of the oxalamide-clips 50 and 51 various conditions were tested, however, the preparation 
of the molecular cube 68 from dhbq-clip 59 failed, see 28.  
 
Scheme 28: Attempt to synthesize molecular cube [(η6-p-cymene)8Ru8(µ4-3-icosyl-dihydroxybenzoquinone)8(µ4-
tpp)2][CF3SO3]8 (68). Solvent (T): DCM (RT, 40 °C), MeOH (RT, 65 °C), EtOH (RT, 80 °C, 90 °C), MeCN (80 °C), MeNO2 
(100 °C). 
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5.3.5. Preparation of Molecular Prism with Guest Molecule 
Most assemblies presented in the previous sections possess a cavity, which can be used to 
encapsulate guest molecules. Guest molecules can further increase the weight of the assembly, 
which is beneficial for the EPR-effect. Moreover, small molecules with anti-cancer property 
could be encapsulated and guided to the cancer via the EPR-effect. Synthetically, the procedure 
of encapsulation is straightforward. The guest molecule is added simultaneously during the 
synthesis of the assembly. Non-covalent interactions, including hydrogen-bonding, π-π 
stacking, electrostatic interactions, van der Waals force, and hydrophobicity of the guest 
molecule provide stability to the entire complex.202 
 
Scheme 29 depicts the synthesis of host-guest systems using arene-ruthenium assemblies. In 
the first step, both chlorines are abstracted using AgCF3SO3 in order to be able to form the final 
assembly by coordinating the pyridyl functions of the 4-tpt panel ligand. The guest molecule is 
added simultaneously with the panel ligands and due to various interactions, the guest is 
encapsulated in the cavity. Several guest molecules were successfully encapsulated previously 
in our group using this strategy. All guest molecules possess an aromatic character or 
delocalized electrons, as well as a favorable size which allows them to fit within the cavity of 
the host.203  
 
Scheme 29: Formation of a host-guest system with an arene-ruthenium metalla-assembly using various guests.198 
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Herein, two guest molecules with large functional groups (figure 52) were used as guest 
molecules. The potential guest molecules Guest 1 and Guest 2 are triphenylene derivatives and 
were synthesized by Dr. Franck Camerel from the University of Rennes.  
 
 
Figure 52: Potential guest molecules Guest 1 and Guest 2 synthesized by Dr. Franck Camerel from the University of Rennes. 
The reason a guest molecule is encapsulated, can be explained by its behavior in a certain 
environment. In order for an encapsulation to take place, the choice of solvent is crucial. 
Supposing the solubility of the guest molecule is high in the chosen solvent, there is no necessity 
for it to be encapsulated, since it undergoes stable non-covalent interactions with the 
surrounding solvent molecules and it is therefore not driven into the cavity of a host system. In 
order to be encapsulated the interaction with the solvent molecules must be low or repulsive, 
consequently, there is a driving force compelling the guest into the host. An aromatic guest is 
likely to be found inside the hydrophobic cavity of the assembly. In general, aromatic and 
hydrophobic compounds such as perylene, anthracene, pyrene or coronene showed such host-
guest behavior for ruthenium metalla-assemblies. Methods to verify the success of an 
encapsulation are DOSY, ROESY and fluorescence spectroscopy.203 To find the optimal 
solvent, solubility tests with Guest 1 and Guest 2 were carried out and summarized in table 8.  
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 H2O MeOH EtOH iPrOH BuOH 
Guest 1 – – – – – – – – – – 
Guest 2 – – – – – – – 
 
 pentane hexane petrol ether cyclohexane toluene 
Guest 1 ++ ++ + + ++ 
Guest 2 – – – – – – – – – 
 
 Acetone EtOAc DMF DMSO MeCN 
Guest 1 – ++ – – – – – 
Guest 2 – – – – – – – 
 
 CHCl3 DCM Et2O MeNO2 
Guest 1 ++ ++ + – 
Guest 2 ++ ++ – – – 
Table 8: Solubility of Guest 1 and Guest 2 in various solvents to find optimal condition for encapsulation: 
high = ++; good = +; poor = –; no = – –. (Row 1: polar, protic, hydrophilic; row 2: apolar, aprotic, hydrophobic; row 3: 
polar, aprotic, hydrophilic; row 4: chlorinated (CHCl3, DCM), polar, aprotic, hydrophilic (Et2O) and polar, 
protic,hydrophilic (MeNO2).  
The solubility of a compound is divided in four levels (high solubility, good solubility, low 
solubility and no solubility). In this case, a compound is declared as well soluble if it is dissolved 
at RT and it is described as highly soluble, if it is dissolved at RT without the requirement of 
stirring. A compound is characterized as poorly soluble, if it requires higher temperature to be 
dissolved and no solubility is observed when the compound remains undissolved despite 
stirring and high temperature. For this experiment the guest molecule must show poor solubility 
in a certain solvent. The solvents were categorized depending on their properties. As shown in 
table 8, guest molecule Guest 1 shows poor solubility in acetone, DMF and MeNO2, therefore 
they were tested for the encapsulation. Guest 2 is poorly soluble in MeOH, which was already 
used as solvent for the encapsulation of guest molecules.204 
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Scheme 30: Attempt to encapsulate guest molecules Guest 1 and Guest 2 in the cavity of prisms 71 and 72. 
Hexa-nuclear prisms 71 and 72 were chosen as host molecules for the encapsulation of guest 
molecules Guest 1 and Guest 2 as shown in scheme 30.205,206 The conditions used to test the 
encapsulation of the guest molecules in the prisms 71 and 72 are listed in table 9. In these 
solvents (acetone, DMF, MeNO2, DCM and MeOH) the hosts showed a good solubility.  
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entry guest solvent T [°C] panel ligand observation 
1 Guest 1 acetone 55 4-tpt no reaction 
2 Guest 1 DMF 90 4-tpt no reaction 
3 Guest 1 MeNO2 90 4-tpt decomposition of clip 69 
4 Guest 1 DCM 40 4-tpt no reaction 
5 Guest 1 MeOH 65 4-tpt 
prism formation without 
guest encapsulation 
6 Guest 2 MeOH 65 4-tpt 
prism formation without 
guest encapsulation 
7 Guest 1 MeOH 65 tris-pvb no reaction 
8 Guest 2 MeOH 65 tris-tvb no reaction 
Table 9: Tested conditions for the encapsulation of guest molecules Guest 1 and Guest 2. 
For Guest 1 the reaction was first performed in acetone and DMF (entries 1 - 2), where the 
guest was poorly soluble, however in both cases the prisms were not formed, but only starting 
materials were isolated. In MeNO2, where the guest is as well poorly soluble, decomposition of 
clip 69 was observed (entry 3). This might be due to coordination of the solvent molecules with 
the metal centers of the clip. The reaction was further performed in DCM, where the guest 
showed high solubility, however in this case as well, no reaction was observed (entry 4). Since 
the encapsulation of various guest molecules was successfully performed in MeOH, MeOH was 
also tested to encapsulate Guest 1, however in this case only the empty prism 71 was isolated 
(entry 5).204 The reaction in MeOH was repeated with the second guest molecule, which showed 
poor solubility in MeOH, however no encapsulation was observed (entry 6). To enlarge the size 
of the resulting prism, tris-tvb was used as panel ligands and the encapsulation was tested in 
MeOH (entries 7 - 8) for both guests. However, in both cases the prism formation was not 
observed, only starting materials being isolated. A reason for the failure of this encapsulation 
might be the substituents which results in a rather large size of Guest 1 and Guest 2, preventing 
them from being encapsulated into the host systems. 
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6. BIOLOGICAL ACTIVITIES 
The antiproliferative activities of the DMSO soluble metalla-prisms 28 - 30 were obtained using 
the 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT) assays.207 
Cisplatin and RAPTA-C were used as reference and the results are summarized in table 10. The 
metalla-cubes 66 and 67 were not tested due to insolubility issues. 
 
As shown in table 10, all three prisms possess a much better activity in the ovarian cancer cell 
line (A2780) than the mono-nuclear arene-ruthenium complex RAPTA-C, however they are 
not as active as cisplatin. Amongst the tested compounds, the oxal amide containing prisms 28 
and 29 show the best activities. They are also active in the cisplatin resistant cancer cell line 
(A2780cisR), which indicates that they possess a different mode of action from cisplatin. 
Furthermore, their activities are lower in the non-cancerous human embryonic kidney cell line 
(HEK).  
 
compound A2780 A2780cisR HEK SC 
28 4.5 ± 0.5 5.9 ± 0.3 10.2 ± 0.7 2.3 
29 3.9 ± 0.2 6.1 ± 0.4 10.8 ± 1.0 2.8 
30 10.1 ±0.6 12.4 ± 0.6 10.9 ± 0.8 1.1 
cisplatin 2.0 ± 0.2 18.1 ± 2.1 8.1 ± 1.3 4.0 
RAPTA-C <200 <200 <200 - 
Table 10: IC50-values in µmol for metalla-prisms 28 - 30 in A2780 (ovarian cancer cell line); A2780cisR (cisplatin resistant 
ovarian cancer cell line); HEK (human embryonic kidney cell line); SC (selectivity coefficient [HEK/A2780]). Data obtained 
from the group of Paul Dyson (EPFL). 
The selectivity coefficients (SC = IC50-values on HEK / IC50-values on A2780) of prisms 28 
and 29 are > 1, which means that their cytotoxicity towards cancer cells is higher than towards 
non-cancerous cells, however the values are rather low and therefore the compounds are only 
poorly selective. 
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7. CONCLUSION AND PERSPECTIVES 
The goal of this thesis entitled, "Increasing the Size of Metalla-Assemblies to Target the EPR-
Effect of Tumors and Solid Cancers" was the development of macromolecular and multi-
nuclear arene-ruthenium metalla-assemblies with anti-cancer activity and the ability to exploit 
the EPR-effect of solid cancers. Therefore, dinuclear arene-ruthenium complexes, so called 
molecular clips, were synthesized from the dinuclear arene-ruthenium precursor [Ru2(η6-p-
cymene)2(µ2-Cl)2Cl2] in combination with a spacer ligand. Several clip moieties were connected 
by two multi-dentate panel ligands in order to create supramolecular multi-nuclear assemblies, 
as shown in figure 53. Such an assembly offers four possibilities to increase the overall size and 
weight of assemblies: the arene, the spacer ligand, the panel ligand and the guest molecule.  
 
Figure 53: Typical molecular prism built from arene ruthenium clips and tridentate panels offering the possibility of guest 
encapsulation. 
This project mainly focused on the modification of the spacer ligands. The spacer ligands 
shown in this work possess bis-bidendate chelating properties, in order to combine two 
ruthenium metal centers to form a molecular clip. Four different types of spacer ligands were 
synthesized: oxalamides, hydrazines, diazenes and dihydroxybenzoquinones (figure 54).  
 
 
Figure 54: Synthesized bis-bidentate chelating ligands for clip formation, (from left to right: oxalamides, hydrazine 
derivatives, diazene derivatives, dihydroxybenzoquinone derivatives). 
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The functionalization of oxalamides was straightforward. Oxalyl chloride and a primary 
amine were used as starting materials. Four oxalamides with alkyl chains (N1,N2-
dihexyloxalamide, N1,N2-dioctyloxalamide, N1,N2-didecyloxalamide and N1,N2-
ditetradecyloxalamide) as well as one PEGylated oxalamide derivative (N1,N2-bis(2-(2-(2-
hydroxyethoxy)ethoxy)ethyl)oxalamide) were successfully synthesized.  
For the preparation of hydrazine and diazene derivatives, hydrazine monohydrate was used as 
starting material, which was allowed to react with an acid chloride or a chloroformate to yield 
hydrazine diacyl or hydrazine dicarboxylate, respectively. After oxidation, the diazene 
analogues were obtained. The hexyl and octyl derivatives of hydrazine diacyl, hydrazine 
dicarboxylate, diazene diacyl and diazene dicarboxylate were successfully synthesized. 
 
Another goal of this thesis was the functionalization of dhbq and two methods were tested 
(scheme 31). Methylation and bromination of dhbq yield the mono- and dibromo compounds 
3-bromo-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione and 2,5-dibromo-3,6-
dimethoxycyclohexa-2,5-diene-1,4-dione, which are potential intermediates for further 
functionalization via Suzuki-cross coupling reactions. However, neither the Suzuki-cross 
coupling nor the Miyaura borylation were successful. In the next attempt dhbq was converted 
to 1,2,4,5-tetramethoxybenzene via oxidation followed by methylation. n-BuLi was used to 
deprotonate the aromatic ring at three position in order to react with electrophilic alkyl halides 
or PEG halides.  
 
Scheme 31: Possible methods to functionalize dhbq. 
The derivative of the bioactive natural product embelin, 2,5-dihydroxy-3-icosylcyclohexa-
2,5-diene-1,4-dione, was successfully synthesized. The attempt to attach longer alkyl chains or 
PEGylated chains failed with this method. Therefore, intermediate 1,2,4,5-
tetramethoxybenzene was converted to 2,3,5,6-tetramethoxyterephthalic acid in the presence of 
n-BuLi and CO2, to attach a PEGylated chain via amide bond formation. However, introduction 
of PEGylated chains was also unsuccessful. Nevertheless, 14 spacer ligands were successfully 
synthesized during the Ph.D. thesis. 
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Three new molecular clips were presented in this work (figure 55) that were used to form five 
multi-nuclear assemblies. The spacer ligands N1,N2-dihexyloxalamide, N1,N2-dioctyloxalamide 
and 2,5-dihydroxy-3-icosylcyclohexa-2,5-diene-1,4-dione were successfully used for the 
preparation of the respective molecular clips with a yield of 25%, 21% and 77%, respectively. 
 
Figure 55: Successfully synthesized molecular clips consisting of oxalamides and dhbq derivatives. 
The corresponding hexa-nuclear prism using the tri-dentate panel 4-tpt resulted in the 
formation of three prisms [(η6-p-cymene)6Ru6(µ4-N1,N2-dihexyloxalamide)3(µ3-4-
tpt)2][CF3SO3]6, [(η6-p-cymene)6Ru6(µ4-N1,N2-dioctyloxalamide)3(µ3-4-tpt)2][CF3SO3]6 and 
[(η6-p-cymene)6Ru6(µ4-3-icosyl-dihydroxybenzoquinone)3(µ3-4-tpt)][CF3SO3]6. These prisms 
were isolated in good yields, 96%, 60% and 60%, respectively. The biological activities of the 
metalla-prisms were investigated in the group of Prof. Paul Dyson at the EPFL. The oxal amide 
containing hexa-nuclear prisms show IC50-values in the low micromolar range on ovarian 
cancer cell lines. 
 
Similarly, the three molecular clips were used for the preparation of octa-nuclear cubes using 
the tetra-dentate panel tpp. The reaction was successful with the clips containing oxalamides 
but failed with the clip made from the dhbq derivative. Two octa-nuclear cubes [(η6-p-
cymene)8Ru8(µ4-N1,N2-dihexyloxalamide)4(µ4-tpp)][CF3SO3]8 and [(η6-p-cymene)8Ru8(µ4-
N1,N2-dioctyloxalamide)4(µ4-tpp)2][CF3SO3]8 were prepared with 73% and 71% yield, 
respectively. The weight of these multi-nuclear assemblies ranged from 3.7 kDa to 5.6 kDa 
(figure 56). Synthetic limitations regarding solubility and reactivity were observed when 
increasing the size and apolarity of the compound. Attempts to introduce PEGylated 
functionalities to increase solubility failed, due the low reactivity of the starting materials or 
due to interference of the oxygen rich PEG-groups with the metal moieties. 
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Figure 56: Molecular weights of the successfully synthesized molecular prisms and cubes. 
Limitations regarding size enlargement and solubility were encountered during the thesis. 
Therefore, in the future, modification of the panel ligand can be proposed in order to combine 
a higher number of clips to increase significantly the size and molecular weight. Figure 57 
shows the structure of 1,2,3,4,5,6-hexakis(pyridin-4-ylethynyl)benzene, a hexa-dentate ligand, 
that was used to coordinate Zn-centered porphyrin derivatives.208 This ligand can be used as 
hexa-dentate panel ligand to combine six clips in order to synthesize a dodeca-nuclear 
assembly. A dodeca-nuclear p-cymene-ruthenium assembly consisting of this panel ligand and 
2,5-dihydroxy-3-icosylcyclohexa-2,5-diene-1,4-dione, the largest spacer ligand synthesized in 
this project, and twelve triflate counterions would result in an overall molecular weight of 
around 8.5 kDa. 
 
Figure 57: Possible hexa-dentate panel for the preparation of dodeca-nuclear assemblies.208  
Porphyrin derivatives are ideal panel ligands for the preparation of metalla-assemblies and the 
modification of porphyrins is well described in the literature.161 As presented in a review article 
of Tanaka,209 several porphyrin units can be linked by triple bonds. However, this results in a 
90° angle between adjacent units, which makes an assembly improbable. To overcome this 
problem, two triple bonds can be interlinked between the porphyrin units to obtain flat 
structures, ideal for the preparation of discrete assemblies.209 Figure 58 shows the porphyrin 
derivative synthesized by Osuka and co-workers. In order to serve as a panel ligand, the aryl 
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moiety has to be replaced by pyridyl substituents for coordination. In this manner, multiple 
porphyrin units can be fused and the simplest two singly-linked porphyrin, should already result 
in a dodeca-nuclear ruthenium assembly. 
 
Figure 58: Porphyrin derivative linked by two triple bonds synthesized by Osuka and co-workers.209 
Scheme 32 presents a different approach to synthesize multi-nuclear arene-ruthenium 
assemblies using porphyrin derivatives as panel ligands. The macromolecular structure shown 
in scheme 32 was also synthesized by Osuka and co-worker and demonstrates a method to 
combine up to 128 porphyrin units. However, the geometry of the resulting oligomer is not 
suitable for the assembly using arene-ruthenium molecular clips. He developed a strategy to 
triply fuse the single porphyrin units with each other to obtain a flat macromolecular structure 
and could connect up to 24 porphyrin units in this manner, as confirmed by mass spectroscopy. 
Furthermore, the number of units in such an oligomer can be controlled using Osuka’s 
technique. The coordinating Zn2+ in the center is crucial to increase the solubility of the 
porphyrin oligomer.210–212 
 
Scheme 32: Triply fused porphyrin derivatives to obtain oligomeric structures as described by Osuka.212 
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Replacement of the aryl moieties with pyridyl substituents would offer a potential multi-
dentate ligand with the ability to combine 50 clips. For our purpose, the di-pyridyl and tri-
pyridyl derivatives of porphyrin are used and their preparation was described by Sanders and 
co-workers in 2006.213 Moreover, highly water soluble and smaller spacer ligands could be used 
for clip formation to avoid solubility problems. Two of such 24mer panel ligands in 
combination with 50 molecular clips derived from oxalate and p-cymene with 100 triflate 
counter ions would result in an overall weight of approximately 65 kDa. Using this strategy, 
the resulting metalla-assembly exceeds by far the minimal requirement of 20 kDa, and can 
therefore be ideal to exploit the EPR-effect. Osuka and co-workers were able to fully 
characterize the porphyrin oligomer consisting of four units, without encountering solubility 
issues.212 Therefore, the preparation of a molecular metalla-assembly, consisting of a 24mer 
panel ligand, might be challenging. Nevertheless, a porphyrin panel ligand consisting of seven 
units, in combination with a counter ion and the PEG-containing molecular clip, which was 
prepared and published previously by our group,162 would yield an overall assembly of over 20 
kDa (figure 59). 
 
 
 
Figure 59: Simplified illustration of a multi-nuclear PEG-containing p-cymene ruthenium metalla-assembly connected by 
two 7mer of pyridyl porphyrin derivatives to reach a mass of over 20 kDa in order to exploit the EPR-effect and to counteract 
solubility issues. 
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8. EXPERIMENTAL PART 
Materials and Methods: Commercially available reagents were purchased from Sigma-
Aldrich and Brunschwig and were used as received. All reactions were carried out in abs. 
solvents, which were dried before use according to standard procedures and all reactions were 
performed under an inert atmosphere. Column chromatographic purifications were performed 
on silica gel 60 Å (32 - 63 mesh) under positive pressure of air and with technical grade eluents 
without further purification. Concentration was performed by rotary evaporation at 40 °C under 
reduced pressure and products were dried under high vacuum (~ 1 mbar) at RT.  
Thin layer Chromatography (TLC) plates were obtained from Merck (TLC Silica gel 60 
F254 aluminium sheets, with fluorescence indicator). UV light (254 nm) or a basic aqueous 
KMnO4 - K2CO3 solution were used to visualize the respective compounds. 
Nuclear magnetic resonance (NMR) spectroscopy was performed on a Bruker Avance II 
400 spectrometer at 400 MHz for 1H-NMR and at 101 MHz for 13C-NMR at the University of 
Neuchâtel. 1H- and 13C-NMR of molecular cubes 65 and 66 and 13C-NMR of molecular prisms 
62 and 63 were recorded by Dr. Aurélien Bornet from EPFL in Lausanne and were acquired on 
a Bruker AV3HD 600 MHz spectrometer (14.1 T) equipped with a 5 mm BBO N2 cooled 
cryoprobe at 600 MHZ (1H-NMR) and 151 MHz (13C-NMR). Chemical shifts (δ-values) are 
reported in parts per million (ppm). Spectra were calibrated related to the deuterated 
solvents214,215 residual proton chemical shifts: 7.26 ppm (1H-NMR) and 77.16 (13C-NMR) for 
CDCl3; 2.50 ppm (1H-NMR) and 39.52 (13C-NMR) for (CD3)2SO; 4.33 (1H-NMR) and 62.80 
(13C-NMR) for CD3NO2. 13C-NMR spectra were recorded 1H-decoupled. Multiplets are 
assigned as: s (singlet), d (doublet), t (triplet), q (quartet), sept (septet) and m (multiplet). 
Infrared spectra were recorded with a Thermoscientific Nicolet iS5 spectrometer. Peaks 
were defined as: s (strong), m (medium) and w (weak). 
Electrospray ionization mass spectrometry (ESI-MS) spectra were obtained in positive or 
negative mode with a LCQ Finnigan mass spectrometer recorded at the University of Fribourg 
by Dr. Fredy Nydegger and Dr. Albert Ruggi. 
UV-VIS absorption spectra were recorded with a Perkin–Elmer UV-VIS spectrophotometer.  
Elemental analyses were carried out by the Mikroelementaranalytisches Laboratorium, ETH 
Zürich (Zürich, Switzerland). 
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The ruthenium precursor [Ru2(η6-p-cymene)2(µ2-Cl)2Cl2]216, the spacer ligands 3 - 6163, 9167 
and 11167 and the panel ligands 4-tpt155 and tris-pvb156 were prepared according to published 
methods. 
Ligands that were used for the formation of the final assembly are fully characterized, others 
are characterized by NMR or ESI-MS for identification. All complexes are fully characterized.  
8.1. Synthesis of N1,N2-Dihexyloxalamide (3) 
To a solution of hexylamine (5.0 mL, 37.85 mmol, 4.0 eq) in toluene (10 mL) 
was slowly added a solution of oxalyl chloride (0.8 mL, 9.46 mmol, 1.0 eq) in 
toluene (15 mL) at RT. The mixture was heated to 60 °C to become a clear solution and was 
stirred overnight. The reaction was allowed to cool to RT and the precipitate was filtered and 
washed with cold toluene (3 × 10 mL) and dried to yield the desired amide 3 as a white solid 
(2.38 g, 98%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 7.48 (s, 2H, ΝΗ), 3.30 (q, 3JHH = 6.9 Hz, 
4H, NCH2), 1.58 - 1.51 (m, 4H, CH2), 1.37 - 1.27 (m, 12H, CH2), 0.90 - 0.86 (m, 6H, CH3). 
13C-NMR (CDCl3, 101 MHz): 160.0 (2C, CO), 39.8 (2C, NCH2), 31.5 (2C, CH2), 29.3 (2C, 
CH2), 26.6 (2C, CH2), 22.7 (2C, CH2), 14.1 (2C, CH3). IR (cm-1): 3299 (s), 2956 (m), 2919 
(m), 2854 (m), 1644 (s), 1507 (s), 1474 (s), 1464 (s), 1383 (m), 1291 (w), 1241 (w), 1208 (m), 
1156 (w), 1131 (w), 890 (w), 799 (w), 784 (m), 718 (s), 575 (w), 566 (w), 557 (w), 548 (w), 
539 (w), 538 (m), 531 (w), 509 (w), 501 (w), 493 (w), 485 (w), 475 (w), 467 (w), 458 (w), 449 
(w), 441 (w), 432 (w), 424 (w). ESI-MS+ Calcd for C14H29N2O2 ([M + H]+): m/z 257.2. Found: 
m/z 257.3. UV-VIS (1.0 × 10-4 M, CH2Cl2): λmax 229 nm (ε = 5.6 × 103 M-1cm-1). EA: Calcd for 
C14H28N2O2 (256.4): C, 65.59; H, 11.01; N, 10.93; Found: C, 65.84; H, 11.22; N, 10.97. 
8.2. Synthesis of N1,N2-Dioctyloxalamide (4) 
To a solution of octylamine (1.28 mL, 7.74 mmol, 4.0 eq) in toluene (10 
mL) was slowly added a solution of oxalyl chloride (0.17 mL, 1.93 mmol, 
1.0 eq) in toluene (15 mL) at RT. The mixture was heated to 60 °C and became a clear solution. 
The mixture was stirred at 60 °C for 15 h and then allowed to cool to RT. The white precipitate 
was filtered and washed with hot dist. H2O (3 × 20 mL) and toluene (3 × 20 mL) to yield the 
desired amide 4 as a white solid (555 mg, 92%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 7.56 (s, 
2H, NH), 3.31 - 3.26 (m, 4H, NCH2), 1.58 - 1.51 (m, 4H, CH2), 1.33 - 1.24 (m, 22H, CH2), 0.86 
(t, 3JHH = 6.5 Hz, 6H, CH3). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 160.0 (2C, CO), 39.8 (2C, 
NCH2), 31.9 (2C, CH2), 29.34 (2C, CH2), 29.30 (2C, CH2), 29.27 (2C, CH2), 27.0 (2C, CH2), 
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22.7 (2C, CH2), 14.2 (2C, CH3). IR (cm-1): 3301 (s), 2918 (s), 2849 (m), 1644 (s), 1505 (s), 
1467 (s), 1381 (m), 1266 (w), 1224 (w), 1205 (w), 785 (m), 718 (s), 582 (w), 539 (w), 516 (w), 
502 (w), 462 (w), 447 (w). ESI-MS+ Calcd for C18H37N2O2 ([M + H]+): m/z 313.3. Found: m/z 
313.3. UV-VIS (1.0 × 10-4 M, CH2Cl2): λmax 229 nm (ε = 5.14 × 103 M-1cm1). EA: Calcd for 
C18H36N2O2 (312.5): C 69.18; H 11.61; N 8.96; Found: C 68.89; H 11.53; N 8.84. 
8.3. Synthesis of N1,N2-didecyloxalamide (5) 
Oxalyl chloride (0.11 mL, 1.25 mmol, 1.0 eq) was dissolved in toluene and 
the mixture was cooled to 0 °C and decylamine (1.0 mL, 5.00 mmol, 4.0 eq) 
was added slowly. After the addition, the mixture was heated to 90 °C and stirred overnight and 
then allowed to cool to RT and the resulting solid was filtered and washed with toluene and 
Et2O. The product was dried under high vacuum to yield the desired amide 5 as a white solid 
(295 mg, 64%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 7.45 (s, 2H, NH), 3.30 (q, 3JHH = 6.8 Hz, 
4H, NCH2), 1.58 - 1.51 (m, 4H, CH2), 1.35 - 1.24 (m, 28H, CH2), 0.89 - 0.86 (m, 6H, CH3). 
13C-NMR (101 MHz, CDCl3) δ/ppm: 160.0 (2C, CO), 39.9 (2C, NCH2), 32.0 (2C, CH2), 29.7 
(2C, CH2), 29.6 (2C, CH2), 29.42 (2C, CH2), 29.36 (4C, CH2) 27.0 (2C, CH2), 22.8 (2C, CH2), 
14.2 (2C, CH3). 
8.4. Synthesis of N1,N2-ditetradecyloxalamide (6) 
Oxalyl chloride (0.1 mL, 1.17 mmol, 1.0 eq) was dissolved in toluene (10 
mL) and cooled to 0 °C. Then a solution of tetradecylamine (1.0 g, 4.69 mmol, 
4.0 eq) in toluene (40 mL) was added and the white mixture was heated at 90 °C overnight. The 
solution was allowed to cool to RT to give a white suspension. The mixture was concentrated, 
washed with hot dist. H2O (2 × 50 mL) and redissolved in DCM (50 mL), dried over MgSO4, 
filtered and concentrated to give a white solid. The solid was recrystallized over propylene 
carbonate (15 mL, 240 °C) to obtain the desired amide 6 as a colorless solid (319 mg, 39%). 
1H-NMR (CDCl3, 400 MHz) δ/ppm: 7.43 (s, 2H, NH), 3.30 (q, 4H, 3JHH = 7.0 Hz, NCH2), 1.60 
- 1.61 (m, 12H, CH2), 1.31 - 1.21 (m, 36H, CH2), 0.92 - 0.85 (m, 6H, CH3). 
8.5. Synthesis of N1,N2-bis(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)oxalamide (7) 
 2-(2-(2-aminoethoxy)ethoxy)ethan-1-ol (PEG 2) (138 
mg, 928 µmol, 2.0 eq) was dissolved in dry THF (5 mL) 
and cooled to 0 °C. NEt3 (0.07 mL, 1.02 mmol, 1.1 eq) was added dropwise and the mixture 
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was stirred for 10 min. Oxalyl chloride (0.04 mL, 464 µmol, 1.0 eq) was added slowly and the 
ice bath was removed and the yellow mixture was stirred 16 h. The white solid was filtered off, 
the mixture was concentrated and suspended in THF (20 mL) and the resulting white solid was 
filtered off. The mixture is concentrated and the desired amide 7 is obtained with traces of 
HNEt3Cl salt as yellowish oil (22.9 mg, 14%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 4.48 - 4.45 
(m, 4H, HOCH2), 3.85 - 3.77 (m, 8H, CH2), 3.73 - 3.71 (m, 8H, CH2), 3.68 - 3.65 (m, 4H, 
NCH2). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 160.6 (2C, CO), 69.6 (2C, HOCH2), 31.4 (2C, 
CH2), 28.5 (2C, CH2), 25.4 (2C, CH2), 22.6 (2C, CH2), 14.1 (2C, NCH2). ESI-MS+ Calcd for 
C24H29N2O8 ([M + H]+): m/z 353.2. Found: m/z 353.1. 
8.6. Synthesis of dihexyl hydrazine 1,2-dicarboxylate (9) 
A solution of hydrazine monohydrate (0.5 mL, 6.65 mmol, 1,0 eq) in 
MeOH (5.0 mL) and dist. H2O (5.0 mL) was placed in an ice bath and hexyl 
chloroformate (2.2 mL, 13.7 mmol, 2.0 eq) was added slowly. The mixture was stirred for 2 h 
at 0 °C until a colorless solid was formed. The mixture was extracted with EtOAc (3 x 10 mL) 
and washed with brine (1 x 10 mL), dried over MgSO4, filtered and concentrated. The crude 
product was purified by flash column chromatography (SiO2, pentane/EtOAc 14:1) to yield the 
desired dicarboxylate 9 as a colorless solid (1.55 g, 81%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 
6.86 (s, 2H, NH), 4.09 (t, 4H, 3JHH = 6.8 Hz, OCH2), 1.63 - 1.56 (m, 4H, CH2), 1.34 - 1.22 (m, 
12H, CH2), 0.87 - 0.80 (m, 6H, CH3). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 157.1 (2C, CO), 
66.4 (2C, OCH2), 31.5 (2C, CH2), 28.8 (2C, CH2), 25.4 (2C, CH2), 22.6 (2C, CH2), 14.0 (2C, 
CH3). 
8.7. Synthesis of dioctyl hydrazine 1,2-dicarboxylate (10) 
A solution of hydrazine monohydrate (0.22 mL, 4.60 mmol, 1,0 eq) in 
MeOH (5.0 mL) and dist. H2O (5.0 mL) was placed in an ice bath and octyl 
chloroformate (1.8 mL, 9.20 mmol, 2.0 eq) was added slowly. The mixture was stirred for 2 h 
at 0 °C until a colorless solid was formed. The mixture was extracted with EtOAc (3 x 10 mL) 
and washed with brine (1x 10 mL), dried over MgSO4, filtered and concentrated. The crude 
product was purified by flash column chromatography (SiO2, pentane/EtOAc 14:1) to yield the 
desired dicarboxylate 10 as a colorless solid (1.16 g, 73%). 1H-NMR (CDCl3, 400 MHz) d/ppm: 
6.45 (s, 2H, NH), 4.13 (t, 3JHH = 6.6 Hz, 4H, NCH2), 1.63 (t, 3JHH = 7.2 Hz, 4H, CH2), 1.35 - 
1.26 (m, 20H, CH2), 0.88 (t, 3JHH = 6.2 Hz, 6H, CH3). 13C-NMR (CDCl3, 101 MHz) d/ppm: 
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156.9 (2C, CO), 66.6 (2C, OCH2), 31.9 (2C, CH2), 29.3 (2C, CH2), 19.3 (2C, CH2), 29.0 (2C, 
CH2), 25.9 (2C, CH2), 22.8 (2C, CH2), 14.2 (2C, CH3). 
8.8. Synthesis of dihexyl azodicarboxylate (11) 
The hydrazine derivative 9 (50.0 mg, 192 µmol, 1.0 eq) was dissolved in 
DCM (5 mL) and NBS (34.2 mg, 192 µmol, 1.0 eq) was added at RT and 
the mixture was stirred for 2 h. After TLC showed full conversion of starting materials the 
mixture was diluted by DCM (20 mL) and the organic layer was washed by dist. H2O and brine, 
dried over MgSO4, filtered and concentrated. The crude product was further purified by flash 
column chromatography (SiO2, pentane/EtOAc 14:1) to yield the desired azodicarboxylate 11 
a yellow oil (40.1 mg, 73%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 4.43 (t, 4H, 3JHH = 6.7 Hz, 
OCH2), 1.82 - 1.75 (m, 4H, CH2), 1.44 - 1.38 (m, 4H, CH2), 1.35 - 1.27 (m, 8H, CH2), 0.90 (m, 
6H, CH3). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 160.6 (2C, CO), 69.7 (2C, OCH2), 31.4 (2C, 
CH2), 28.5 (2C, CH2), 25.4 (2C, CH2), 22.6 (2C, CH2), 14.1 (2C, CH3). 
8.9. Synthesis of dioctyl azodicarboxylate (12) 
The hydrazine derivative 10 (1.0 g, 3.50 mmol, 1.0 eq) was dissolved in 
DCM (20 mL) and NBS (623 mg, 3.50 mmol, 1.0 eq) was added at RT and 
the clear solution turned yellow-orange and then red. After 2 h the mixture was diluted with 
DCM, washed with dist. H2O (3 × 40 mL) and brine (1 × 40 mL) and concentrated. The crude 
product was purified by flash column chromatography (SiO2, pentane/EtOAc 5:1 à 5:2) to 
obtain the desired azodicarboxylate 12 as yellow oil (720 mg, 60%). 1H-NMR (CDCl3, 400 
MHz) d/ppm: 4.44 (t, 3JHH = 7.0 Hz, 4H, NCH2), 1.79 (q, 3JHH = 7.1 Hz, 4H, CH2), 1.44 - 1.37 
(m, 4H, CH2), 1.34 - 1.23 (m, 16H, CH2), 0.90 - 0.86 (m, 6H, CH3). 13C-NMR (CDCl3, 101 
MHz) d/ppm: 160.6 (2C, CO), 69.6 (2C, OCH2), 31.9 (2C, CH2), 29.2 (4C, CH2), 28.6 (2C, 
CH2), 25.7 (2C, CH2), 22.8 (2C, CH2), 14.2 (2C, CH3). 
8.10. Synthesis of N'-hexanoylhexanehydrazine (14) 
A solution of hydrazine monohydrate (0.07 mL, 1.14 mmol, 1.0 eq) in dist. 
H2O (5.0 mL), was cooled to 0 °C and hexanoic anhydride (1.08 mL, 4.67 
mmol, 3.3 eq) was added dropwise while stirring. The mixture was stirred for 2 h and the formed 
precipitate was filtered and washed with dist. H2O and Et2O and dried under high vacuum to 
obtain the desired hydrazine derivative 14 as a white solid (232 mg, 89%). 1H-NMR (CDCl3, 
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400 MHz) δ/ppm: 8.97 (s, 2H, NH), 2.26 (t, 3JHH = 7.5 Hz, 4H, OCCH2), 1.68 - 1.63 (m, 4H, 
CH2), 1.34 - 1.29 (m, 8H, CH2), 0.91 - 0.86 (m, 6H, CH2). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 
169.9 (2C, CO), 34.2 (2C, CH2), 31.5 (2C, CH2), 25.2 (2C, CH2), 22.5 (2C, CH2), 14.0 (2C, 
CH3). 
8.11. Synthesis of N'-octanoyloctanehydrazine (15) 
Octanoyl chloride (5.2 mL, 30.3 mmol, 3.2 eq) was dissolved in Et2O (40 mL) 
and dist. H2O (4.0 mL) and NaHCO3 (2.52 g, 30.0 mmol, 3.0 eq) was added. 
The mixture was cooled to 0 °C, hydrazine monohydrate (0.5 mL, 10.0 mmol, 1.0 eq) was 
added slowly and the mixture was stirred at RT overnight. The resulting colorless solid was 
filtered, washed with dist. H2O and dried under high vacuum to obtain the desired hydrazine 
derivative 15 as colorless solid (2.85 g, quant.). 1H-NMR (SO(CD3)2, 400 MHz) d/ppm: 9.59 
(s, 2H, NH), 2.09 - 2.05 (m, 4H, OCCH2), 1.51 - 1.46 (m, 4H, CH2), 1.25 - 1.24 (m, 16H, CH2), 
0.88 - 0.83 (m, 6H, CH3). 13C-NMR (SO(CD3)2, 101 MHz) d/ppm: 171.0 (2C, CO), 33.1 (2C, 
OCCH2), 31.1 (2C, CH2), 28.5 (2C, CH2), 28.4 (2C, CH2), 25.0 (2C, CH2), 22.0 (2C, CH2), 13.9 
(2C, CH3). 1H-NMR (CDCl3, 400 MHz) d/ppm: 8.29 (s, 2H, NH), 2.25 (t, 3JHH = 7.6 Hz, 4H, 
OCCH2), 1.66, (q, 3JHH = 7.2 Hz, 4H, CH2), 1.32 - 1-25 (m, 16H, CH2), 0.88 (t, 3JHH = 6.6 Hz, 
6H CH3). 13C-NMR (CDCl3, 101 MHz) d/ppm: 169.8 (2C, CO), 34.4 (2C, OCCH2), 31.8 (2C, 
CH2), 29.3 (2C, CH2), 29.0 (2C, CH2), 25.5 (2C, CH2), 22.8 (2C, CH2), 14.2 (2C, CH3). 
8.12. Synthesis of 1,1'-(diazene-1,2-diyl)bis(hexan-1-one) (16) 
Hydrazine derivative 14 (688 mg, 3.02 mmol, 1.0 eq) was suspended in 
DCM (50 mL), cooled to 0 °C and a solution of Pb(OAc)4 (1.48 g, 3.32 mmol, 
1.1 eq) in DCM (20 mL) was added dropwise. The ice bath was removed and the reaction was 
stirred for 1 h at 30 °C. The resulting solid was filtered off and the organic layer was washed 
with brine (2 × 100 mL) and aq. sat. NaHCO3 (1 × 100 mL) and again with brine (1 × 100 mL). 
The organic layer was dried over MgSO4, filtered and dried under high vacuum to obtain the 
desired diazene 16 as an orange oil (682 mg, quant.). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 2.61 
(t, 3JHH = 7.3 Hz, 4H, OCCH2), 1.77 - 1.68 (m, 4H, CH2), 1.40 - 1.30 (m, 8H, CH2), 0.93 - 0.89 
(m, 6H, CH3). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 190.3 (2C, CO), 33.5 (2C, CH2), 31.3 (2C, 
CH2), 22.8 (2C, CH2), 22.4 (2C, CH2), 14.0 (2C, CH3). 
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8.13. Synthesis of 1,1'-(diazene-1,2-diyl)bis(octan-1-one) (17) 
The hydrazine derivative 15 (250 mg, 885 µmol, 1.0 eq) was dissolved in 
benzene (75 mL), heated to reflux at 80 °C and Pb(OAc)4 (393 mg, 879 µmol, 
1.0 eq) was added at once. The mixture was stirred at 80 °C for 15 s and filtered. The orange-
red solution was allowed to cool to RT and the solvent was removed under reduced pressure to 
yield an orange solid which decolored over time. The crude product was purified by 
recrystallization from DCM/n-hexane (2:1) at 40 °C to obtain the diazene 17 as a yellowish 
solid (249 mg, quant.). 1H-NMR (SO(CD3)2, 400 MHz) d/ppm: 4.18 - 4.10 (m, 4H, OCCH2),  
3.01 - 2.80 (m, 4H, CH2), 2.17 - 1.99 (m, 16H, CH2), 1.72 - 0.59 (m, 6H, CH3). 13C-NMR 
(SO(CD3)2, 101 MHz) d/ppm: 178.2 (2C, CO), 31.6 (2C, OCCH2), 28.9 (2C, CH2), 27.4 (6C, 
CH2) , 22.5 (2C, CH2), 14.4 (2C, CH3). 
8.14. Syntheses of 4-bromo-N-(2-(2-(2-hydroxyethoxy)ethoxy)ethyl)benzamide-(25a) 
PEG 2 (214 mg, 1.43 mmol, 1.05 eq) was dissolved in dist. H2O 
(2.0 mL) and acetone (1.0 mL) and NaHCO3 (123 mg, 1.46 mmol, 
1.07 eq) was added. The mixture was cooled to 0 °C and 4-
bromobenzoyl chloride (27) (299 mg, 1.36 mmol, 1.0 eq) dissolved in acetone (1.2 mL) was 
added slowly and the formation of a colorless solid was observed. Acetone was removed under 
reduced pressure, dist. H2O (15 mL) was added and the mixture was extracted with EtOAc (4 
× 15 mL). The combined organic layers were washed with aq. sat. NaHCO3 (1 × 20 mL) and 
dist. H2O (1 × 20 mL), dried over MgSO4, filtered and concentrated. The crude product was 
purified by flash column chromatography (SiO2, DCM/MeOH 95:5) to yield the desired 
bromobenzamide 25a as a yellow oil (341 mg, 75%). 1H-NMR (CDCl3, 400 MHz) d/ppm: 7.70 
(d, 3JHH  = 8.5 Hz, 2H, CH), 7.57 (d, 3JHH  = 8.5 Hz, 2H, CH), 6.86 (s, 1H, NH), 3.73 - 3.70 (m, 
2H, CH2), 3.68 - 3.63 (m, 10H, CH2), 3.60 - 3.58 (m, 2H, CH2). 13C-NMR (CDCl3, 101 MHz) 
d/ppm: 166.7 (1C, CO), 133.4 (1C, CC), 131.8 (2C, CH), 128.9 (2C, CH), 126.2 (1C, CBr), 
72.6 (1C, CH2), 70.5 (2C, CH2), 70.0 (1C, CH2), 61.8 (1C, CH2), 39.4 (1C, CH2). 
8.15. Synthesis of 3-Icosyl-1,2,4,5-tetramethoxybenzene (36) 
1,2,3,4-Tetramethoxybenzene (35) (430 mg, 2.20 mmol, 1.0 eq) was dissolved 
in THF (10 mL) and the solution was cooled to -10 °C and n-BuLi (2.5 M in 
hexane, 1 mL, 2.42 mmol, 1.1 eq) was slowly added. The mixture was stirred at -
10 °C for 30 min, and 1-bromoicosane (904 mg, 2.42 mmol, 1.1 eq) was slowly added. The 
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mixture was stirred at -10 °C for 10 min and then allowed to warm to room temperature 
overnight. After completion of the reaction, aqueous saturated NH4Cl (2 mL) was added to the 
solution, and the mixture was extracted with Et2O (3 × 50 mL), washed with brine (1 × 50 mL), 
dried over MgSO4, filtered, and concentrated under reduced pressure. The crude product was 
purified by flash column chromatography (SiO2, pentane/EtOAc 40:1) to yield the desired 
alkylated tetramethoxybenzene 36 as a colorless solid (710 mg, 68%). 1H-NMR (CDCl3, 400 
MHz) δ/ppm: 6.41 (s, 1H, CH), 3.84 (s, 6H, OCH), 3.76 (s, 6H, OCH), 2.62 - 2.59 (m, 2H, 
CH2), 1.56 - 1.49 (m, 2H, CH2), 1.37 - 1.35 (m, 2H, CH2), 1.25 (s, 32H, CH2), 0.88 (t, 3JHH = 
6.2 Hz, 3H, CH3). 13C-NMR (CDCl3, 101 MHz): δ/ppm: 149.0 (2C, CH3OC), 141.3 (2C, 
CH3OC), 131.3 (1C, CC20H41), 96.9 (1C, CH), 61.1 (2C, OCH3), 56.4 (2C, OCH3), 32.1 (1C, 
CH2), 30.9 (1C, CH2), 30.2 (1C, CH2), 29.9 (10C, CH2), 29.8 (1C, CH2), 29.7 (1C, CH2), 29.6 
(1C, CH2), 29.5 (1C, CH2), 24.8 (1C, CH2), 22.8 (1C, CH2), 14.3 (1C, CH3). IR (cm-1): 2957 
(w), 2916 (m), 2849 (m), 1594 (w), 1467 (m), 1408 (m), 1367 (w), 1343 (w), 1306 (w), 1244 
(w), 1203 (w), 1117 (m), 1066 (w), 1044 (m), 1024 (w), 954 (m), 899 (w), 868 (w), 854 (w), 
831 (W), 811 (w), 721 (w), 639 (w). ESI-MS+ Calcd for C30H54O4Na ([M + Na]+): m/z 501.4. 
Found: m/z 501.4. UV-VIS (1.0 × 10-4 M, CH2Cl2): λmax 229 nm (ε = 0.7 × 103 M-1 cm-1); λmax 
284 nm (ε = 1.7 × 103 M-1 cm-1). EA: Calcd for C30H54O4 (478.4): C, 75.26; H, 11.37. Found: 
C, 75.40; H, 11.39.  
8.16. Synthesis of 3-Icosyl-2,5-dimethoxycyclohexa-2,5-diene-1,4-dione (37) 
Alkylated tetramethoxybenzene 36 (177 mg, 370 µmol, 1.0 eq) was suspended 
in MeCN (3 mL), ceric ammonium nitrate (CAN) (510 mg, 930 µmol, 2.51 eq) 
was added, and the yellow suspension turned into an orange suspension. The mixture was stirred 
at RT for 2 h. After completion of the reaction, the mixture was extracted with EtOAc (3 × 15 
mL). The combined organic layers were washed with brine (1 × 20 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure. The crude product was purified by flash 
column chromatography (SiO2 and 20:1 pentane/EtOAc) to yield the desired benzoquinone 37 
as a colorless solid (80.2 mg, 48%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 5.72 (s, 1H, CH), 4.04 
(s, 3H, OCH3), 3.80 (s, 3H, OCH3), 2.42 (t, 3JHH = 7.5 Hz, 2H, CH2), 1.41 - 1.35 (m, 2H, CH2), 
1.25 (s, 34 H, CH2), 0.88 (t, 3JHH = 6.6 Hz, 3H, CH3). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 
183.7 (1C, CO), 182.6 (1C, CO), 158.9 (1C, CH3OC), 156.0 (1C, CH3OC), 130.9 (1C, 
CC20H41), 105.5 (1C, CH), 61.5 (1C, OCH3), 56.5 (1C, OCH3), 32.1 (1C, CH2), 29.81 (8C, 
CH2), 29.75 (4C, CH2), 29.7 (1C, CH2), 29.6 (1C, CH2), 29.5 (1C, CH2), 28.8 (1C, CH2), 23.2 
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(1C, CH2), 22.8 (1C, CH2), 14.3 (1C, CH3). IR (cm-1): 2916 (m), 2849 (m), 1649 (w), 1597 (w), 
1467 (w), 1324 (w), 1206 (w), 1154 (w), 1046 (w), 928 (w), 835 (w), 797 (w), 720 (w), 500 
(w), 483 (w), 469 (w), 401 (w), 453 (w), 433 (w), 429 (w). ESI-MS+ Calcd for C28H48O4Na 
([M + Na]+): m/z 471.4. Found: m/z 471.3. UV-VIS (1.0 × 10-4 M, CH2Cl2): λmax 286 nm (ε = 
5.6 × 103 M-1 cm-1). EA: Calcd for C28H48O4 (448.4): C, 74.95; H, 10.78. Found: C, 75.21; H, 
10.85.  
8.17. Synthesis of 2,5-dihydroxy-3-icosylcyclohexa-2,5-diene-1,4-dione (38) 
The benzoquinone derivative 37 (116 mg, 259 µmol, 1.0 eq) and EtOH (10 mL) 
were mixed to give an orange suspension. NaOH (2 M, 5 mL) was added, and the 
suspension turned into a violet solution. The solution was heated to 70 °C and stirred until thin-
layer chromatography showed full conversion of the starting material. The reaction was allowed 
to cool to RT, HCl (2 M, 25 mL) was added, and the solution turned into an orange suspension. 
The mixture was extracted with EtOAc (3 × 30 mL). The combined organic layers were dried 
over MgSO4, filtered, concentrated, and dried under high vacuum to yield the desired 
dihydroxybenzoquinone 38 as a light brown solid, which was used without further purification 
(73 mg, 72%). 1H-NMR (SO(CD3)2, 400 MHz) δ/ppm: 11.17 (s, 2H, OH), 5.77 (s, 1H, CH), 
2.27 (t, 3JHH = 7.5 Hz, 2H, CH2), 1.34 (m, 2H, CH2), 1.22 (m, 34H, CH2), 0.84 (t, 3JHH = 6.6 
Hz, 3H, CH3). IR (cm-1): 3304 (m), 2917 (m), 2847 (m), 1612 (m), 1462 (w), 1325 (m), 1187 
(m), 860 (w), 768 (w), 708 (w). ESI-MS- Calcd for C26H43O4 ([M - H]-): m/z 419.3. Found: m/z 
419.3. UV-VIS (1.0 × 10-4 M, CH2Cl2): λmax 282 nm (ε = 1.4 × 104 M-1 cm-1); λmax 290 nm (ε = 
1.4 × 104 M-1 cm-1). EA: Calcd for C26H44O4·EtOH·H2O (420.6 + 18.0 + 46.1): C, 69.38; H, 
10.81; N, 0.00. Found: C, 69.87; H, 10.57; N, 0.01. 
8.18. Syntheses of 1-(methylsulfonyl)triacontane (43) 
A two-necked flask under nitrogen atmosphere was charged with 1-triacontalol 
(42) (200 mg, 460 µmol, 1.0 eq) and suspended in dry DCM (20 mL) and NEt3 
(148 µL, 1.06 mmol, 2.3 eq). To solubilize the mixture was heated until it turned into a solution. 
The mixture was stirred at RT for 30 min and MsCl (84.4 mg, 736 µmol, 1.6 eq) was added and 
the mixture was stirred at RT for 24 h. The mixture was diluted with DCM (20 mL) and the 
organic phase was washed with dist. H2O, HCl (2M), aq. sat. NaHCO3 and dist. H2O, dried over 
MgSO4, filtered and concentrated to yield the desired sulfonyl 43 as a colorless solid. (229 mg, 
96%). 1H-NMR (CDCl3, 400 MHz) d/ppm: 4.22 (t, 3JHH = 6.6 Hz, 2H, OCH2), 3.00 (s, 3H, 
C20H41
HO
OH
O
O
S
O
O
H3C O C30H61
EXPERIMENTAL PART 
 106 
SCH3), 1.78 - 1.71 (m, 2H, CH2), 1.60 - 1.54 (m, 2H, CH2), 1.41 - 1.35 (m, 2H, CH2), 1.30 - 
1.25 (m, 50H, CH2), 0.88 (t, 3JHH = 6.7 Hz, 3H, CH3). 
8.19. Synthesis of Molecular Clip [(η6-p-Cymene)2Ru2(µ4- N1,N2-
dihexyloxalamide)Cl2] (50) 
N1,N2-Dihexyloxalamide (3) (200 mg, 780 µmol, 1.0 eq) was suspended 
in EtOH (15 mL), and DIPEA (0.3 mL, 1.73 mmol, 2.2 eq) was added 
dropwise at RT. The mixture was heated to 50 °C until the solid was 
dissolved, and the solution was stirred at that temperature for 30 min. The 
dinuclear complex [(η6-p-cymene)2Ru2(µ2-Cl)2Cl2] (49) (500 mg, 816 µmol, 1.05 eq) was 
added, and the mixture was stirred at 80 °C overnight. The mixture was allowed to cool to RT, 
filtered, washed with EtOH, acetone, H2O, Et2O, and pentane, and then dissolved in CH2Cl2, 
before being filtered over Celite and concentrated under reduced pressure to yield the desired 
dinuclear clip 50 as an orange solid (156 mg, 25%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 5.31 
- 5.26 (m, 6H, CH, p-cymene), 4.99 (d, 3JHH = 5.9 Hz, 2H, CH, p-cymene), 4.06 - 3.99 (m, 2H, 
CHH, hexylchain), 3.32 - 3.26 (m, 2H, CHH, hexylchain), 2.69 (sept, 3JHH = 6.9 Hz, 2H, CH, p-
cymene), 2.15 (s, 6H, CH3, p-cymene), 1.71 - 1.56 (m, 4H, CH2, hexylchain), 1.38 - 1.27 (m, 
12H, CH2, hexylchain), 1.22 (d, 3JHH = 6.9 Hz, 6H, CH3, p-cymene), 1.18 (d, 3JHH = 6.9 Hz, 6H, 
CH3, p-cymene), 0.92 - 0.87 (m, 6H, CH3, hexylchain). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 
170.2 (2C, CO, oxalamide), 100.7 (2C, CCH(CH3)2, p-cymene), 94.4 (2C, CCH3, p-cymene), 
82.6 (2C, CH, p-cymene), 81.2 (2C, CH, p-cymene), 79.8 (2C, CH, p-cymene), 79.6 (2C, CH, 
p-cymene), 51.7 (2C, NCH2, hexylchain), 31.9 (2C, CH2, hexylchain), 30.9 (2C, HC(CH3)2, p-
cymene), 29.4 (2C, CH2, hexylchain), 27.6 (2C, CH2, hexylchain), 22.9 (2C, CH2, hexylchain), 22.6 
(2C, HC(CH3)2, p-cymene), 22.2 (2C, HC(CH3)2, p-cymene), 18.6 (2C, CH3, p-cymene), 14.3 
(2C, CH3, hexylchain). IR (cm-1): 2923 (w), 1596 (s), 1458 (w), 1333 (m), 1051 (w), 872 (w), 
532 (w), 524 (w), 511 (w), 501 (w), 494 (w), 485 (w), 475 (w), 467 (w), 458 (w), 450 (w), 441 
(w), 433 (w). ESI-MS+ Calcd for C34H54ClN2O2Ru2 ([M - Cl]+): m/z 761.2. Found: m/z 761.1. 
UV-VIS (1.0 × 10-5 M, CH2Cl2): λmax, 228 nm (ε = 2.1 × 105 M-1 cm-1); λmax, 281 nm (ε = 1.1 × 
104 M-1 cm-1); λmax, 331 nm (ε = 1.1 × 104 M-1 cm-1). EA: Calcd for C34H54Cl2N2O2Ru2 (795.9): 
C, 51.31; H, 6.84; N, 3.52. Found: C, 51.32; H, 6.85; N, 3.72.  
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8.20. Synthesis of Molecular Clip [(η6-p-Cymene)2Ru2(µ4- N1,N2-
dioctyloxalamide)]Cl2 (51) 
N1,N2-Dioctyloxalamide (4) (500 mg, 1.60 mmol, 1.0 eq) was 
suspended in EtOH (30 mL), and DIPEA (0.6 mL, 3.44 mmol, 2.1 
eq) was added slowly and stirred at RT for 30 min. The dinuclear 
precursor 49 (1.03 g, 1.68 mmol, 1.05 eq) was added, and the 
mixture was stirred at 90 °C overnight. The reaction was allowed to cool to RT, the volume was 
reduced to half, and the mixture was stored in the refrigerator for 1 h. The orange residue was 
filtered and washed with EtOH, H2O, acetone, Et2O, and pentane. The residue was dissolved in 
CH2Cl2, filtered over Celite, and concentrated under reduced pressure to yield the desired 
dinuclear clip 51 as red crystals (280 mg, 21%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 5.30 - 
5.25 (m, 6H, CH, p-cymene), 4.97 (d, 3JHH = 5.8 Hz, 2H, CH, p-cymene), 4.04 - 3.97 (m, 2H, 
CHH, octylchain), 3.30 - 3.24 (m, 2H, CHH, octylchain), 2.68 (sept, 3JHH = 6.9 Hz, 2H, CH, p-
cymene), 2.12 (s, 6H, CH3, p-cymene), 1.70 - 1.52 (m, 4H, CH2, octylchain), 1.33 - 1.25 (m, 20H, 
CH2, octylchain), 1.20 (d, 3JHH = 6.8 Hz, 6H, CH3, p-cymene), 1.16 (d, 3JHH = 6.9 Hz, 6H, CH3, 
p-cymene), 0.89 - 0.86 (m, 6H, CH3, octylchain). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 170.1 
(2C, CO, oxalamide), 100.7 (2C, CCH(CH3)2, p-cymene), 94.4 (2C, CCH3, p-cymene), 82.5 
(2C, CH, p-cymene), 81.2 (2C, CH, p-cymene), 79.7 (2C, CH, p-cymene), 79.5 (2C, CH, p-
cymene), 51.7 (2C, NCH2, octylchain), 32.1 (2C, HC(CH3)2, p-cymene), 30.7 (2C, CH2), 29.7 
(2C, CH2), 29.5 (2C, CH2), 29.4 (2C, CH2), 27.9 (2C, CH2), 22.8 (2C, CH2), 22.6 (2C, 
HC(CH3)2, p-cymene) , 22.2 (2C, HC(CH3)2, p-cymene), 18.6 (2C, CH3, p-cymene), 14.3 (2C, 
CH3, octylchain). IR (cm-1): 2954 (m), 2914 (m), 2849 (m), 1645 (w), 1604 (s), 1531 (w), 1510 
(w), 1466 (w), 1373 (w), 1349 (w), 1324 (m), 1200 (w), 1153 (w), 1080 (w), 1055 (w), 1025 
(w), 996 (w), 857 (m), 800 (m), 724 (m), 594 (w), 496 (w), 463 (w), 445 (w), 429 (w). ESI-
MS+ Calcd for C38H62ClN2O2Ru2 ([M - Cl]+): m/z 817.3. Found: m/z 817.2. UV-VIS (1.0 × 10-
4 M, CH2Cl2): λmax 228 nm (ε = 2.3 × 104 M-1 cm-1); λmax 274 nm (ε = 1.3 × 104 M-1 cm-1); λmax 
313 nm (ε = 1.6 × 104 M-1 cm-1). EA: Calcd for C38H62N2O2Cl2Ru2 (852.2): C, 53.57; H, 7.33; 
N, 3.29. Found: C, 53.61; H, 7.48; N, 3.24.  
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8.21. Synthesis of Molecular Clip [(η6-p-Cymene)2Ru2(µ4-3-icosyl-
dihydroxybenzoquinone]Cl2 (59) 
2,5-dihydroxy-3-icosylcyclohexa-2,5-diene-1,4-dione (38) (158 mg, 375 µmol, 
1.0 eq) was suspended in EtOH (50 mL), and CH3COONa (64.7 mg, 789 µmol, 
2.1 eq) was added. The yellow suspension turned into a red solution. The mixture 
was allowed to stirr for 1 h at RT, then 49 (225 mg, 367 µmol, 0.98 eq) was 
added, and the reaction was stirred at 80 °C for 48 h. The reaction was allowed 
to cool to RT, the volume was reduced to half, and the mixture was stored in the refrigerator 
overnight. The violet precipitate was filtered and washed with cold dist. H2O to obtain the 
desired dinuclear clip 59 as a violet solid (267 mg, 77%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 
5.69 (s, 1H, CH, dhbq), 5.63 - 5.59 (m, 4H, CH, p-cymene), 5.36 (d, 3JHH = 5.8 Hz, 4H, CH, p-
cymene), 2.90 (sept, 3JHH = 6.9 Hz, 2H, CH, p-cymene), 2.36 - 2.32 (m, 2H, CH2, icosylchain), 
2.91 (s, 6H, CH3, p-cymene), 1.36 - 1.33 (m, 12H, (CH3)2, p-cymene), 1.27 - 1.26 (m, 36H, 
CH2, icosylchain), 0.88 (t, 3JHH = 6.6 Hz, 3H, CH3, icosylchain). 13C-NMR (CDCl3, 101 MHz) 
δ/ppm: 184.4 (2C, CO, dhbq), 181.8 (2C, CO, dhbq), 115.5 (1C, CC20H41, dhbq), 100.7 (1C, 
CH, dhbq), 100.6 (2C, CCH(CH3)2, p-cymene), 96.4 (2C, CCH3, p-cymene), 82.0 (1C, CH, p-
cymene), 81.4 (1C, CH, p-cymene), 79.7 (1C, CH, p-cymene), 79.1 (1C, CH, p-cymene), 32.1 
(1C, CH2, icosylchain), 31.5 (1C, C(CH3)2, p-cymene), 30.01 (1C, CH2, icosylchain), 29.95 (2C, 
CH2, icosylchain), 29.93 (2C, CH2, icosylchain), 29.91 (2C, CH2 icosylchain), 29.89 (2C, CH2, 
icosylchain), 29.86 (4C, CH2, icosylchain), 29.8 (2C, CH2, icosychain), 29.7 (1C, CH2, icosylchain), 
29.5 (1C, CH2, icosylchain), 28.3 (1C, CH2, icosylchain), 22.8 (1C, CH2, icosylchain), 22.7 (4C, 
(CH3)2, p-cymene), 18.7 (2C, CH3, p-cymene), 14.3 (1C, CH3, icosylchain). IR (cm-1): 2918 (m), 
2849 (m), 1509 (s), 1495 (s), 1469 (m), 1363 (s), 1315 (w), 1236 (w), 1225 (w), 1165 (w), 1086 
(w), 1030 (w), 874 (w), 834 (w), 805 (w), 788 (w), 722 (w), 502 (w), 487 (w), 464 (w), 453 
(w), 449 (w), 445 (w), 433 (w), 430 (w). ESI-MS+ Calcd for C46H70ClO4Ru2 ([M - Cl]+): m/z 
925.3. Found: m/z 925.3. UV-VIS (1.0 × 10-5 M, CH2Cl2): λmax 228 nm (ε = 3.7 × 104 M-1 cm-1); 
λmax 317 (1.5 × 104 M-1cm-1); λmax 500 nm (ε = 2.0 × 104 M-1 cm-1). EA: Calcd for 
C46H70O4Cl12Ru2 (960.3): C, 57.55; H, 7.35; N, 0.00. Found: C, 58.08; H, 7.56; N, 0.01.  
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8.22. Syntheses of Molecular Prism [(η6-p-cymene)6Ru6(µ4-N1,N2-
dihexyloxalamide)3(µ3-4-tpt)][CF3SO3]6 (63) 
Molecular clip [(h6-p-cymene)2Ru2(µ4-N1,N2-
dihexyloxalamide)Cl2] (50) (100 mg, 128 µmol, 1.0 eq) 
was dissolved in MeOH (20 mL), and AgCF3SO3 (64.0 
mg, 249 µmol, 1.95 eq) was added. The mixture was 
stirred at RT for 3 h. AgCl was filtered off, 4-tpt (44.0 
mg, 141 µmol, 1.1 eq) was added to the solution, and the 
mixture was stirred at 60 °C for 24 h. The reaction was 
allowed to cool to RT, and the solvent was removed under reduced pressure. CH2Cl2 (2 mL) 
and pentane (100 mL) were added to induce precipitation. The dark-green precipitate was 
filtered and washed with cold EtOH (3 × 20 mL) to yield the desired hexa-nuclear prism 63 as 
a dark-green solid. (152 mg, 96%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 8.99 - 8.20 (m, 24H, 
CH, 4-tpt), 5.83 - 5.69 (m, 12H, CH, p-cymene), 5.56 - 5.44 (m, 12H, CH, p-cymene), 4.20 - 
4.13 (m, 6H, NCH2, hexylchain), 3.62 - 3.55 (m, 6H, CH2, hexylchain), 2.86 - 2.75 (m, 6H, CH, p-
cymene), 2.14 - 2.07 (m, 6H, CH2, hexylchain), 1.96 (s, 18H, CH3, p-cymene), 1.82 - 1.66 (m, 
22H, CH2, hexylchain), 1.61 - 1.52 (m, 20H, CH2, hexylchain), 1.40 - 1.37 (m, 18H, (CH3)2, p-
cymene), 1.32 - 1.26 (m, 18H, (CH3)2, p-cymene), 1.07 - 1.03 (m, 18H, CH3, hexylchain). 13C-
NMR (CDCl3, 151 MHz, 45 °C) δ/ppm: 171.0 (NCquartN, 4-tpt), 170.7 (CO, oxalamide), 154.3 
(NCH, 4-tpt), 151.2 (NCH, 4-tpt), 143.9 (CCquartC, 4-tpt), 142.4 (CCquartC, 4-tpt), 122.4 (CCH, 
4-tpt), 120.2 (CCH, 4-tpt), 106.0 (CCH(CH3)2, p-cymene), 97.2 (CCH3, p-cymene), 84.6 (CH, 
p-cymene), 83.7 (CH, p-cymene), 82.3 (CH, p-cymene), 81.7 (CH, p-cymene), 53.5 (NCH2, 
hexylchain), 32.1 (CH2, hexylchain), 32.0 (CH2, hexylchain), 31.5 (C(CH3)2, p-cymene), 31.4 
(C(CH3)2, p-cymene), 30.3 (CH2, hexylchain), 29.9 (CH2, hexylchain), 29.5 (CH2, hexylchain), 27.4 
(CH2, hexylchain), 22.9 (CH2, hexylchain), 22.8 (CH2, hexylchain), 22.5 ((CH3)2, p-cymene), 22.3 
((CH3)2, p-cymene), 17.8 (CH3, p-cymene), 14.3 (CH3, hexylchain). IR (cm-1): 2928 (w), 1596 
(s), 1516 (s), 1371 (m), 1257 (s), 1222 (m), 1149 (m), 1056 (w), 1028 (s), 811 (m), 670 (w), 
636 (s), 496 (w), 480 (w), 445 (w). ESI-MS+ Calcd for C141H186F9N18O15Ru6S3 ([M - 
3CF3SO3]3+): m/z 1083.3. Found: m/z 1082.4. Calcd for C142H186F12N18O18Ru6S4 ([M - 
2CF3SO3]2+): m/z 1699.4. Found: m/z 1697.3. UV-VIS (1.0 × 10-5 M, CH2Cl2): λmax 249 nm (ε 
= 1.7 × 105 M-1 cm-1). EA: Calcd for C144H186F18N18O24Ru6S6 (3696.6): C, 46.82; H, 5.08; N, 
6.83. Found: C, 46.71; H, 5.12; N, 7.30. 
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8.23. Syntheses of Molecular Prism [(η6-p-cymene)6Ru6(µ4-N1,N2-
dioctyloxalamide)3(µ3-4-tpt)][CF3SO3]6 (64) 
Molecular clip [(h6-p-cymene)2Ru2(µ4- N1,N2-
dioctyloxalamide)Cl2] (51) (150 mg, 176 µmol, 1.0 eq) 
was dissolved in MeOH (20 mL), and AgCF3SO3 (88.1 
mg, 343 µmol, 1.95 eq) was added. The mixture was 
stirred at RT for 3 h. AgCl was filtered off, 4-tpt (60.4 
mg, 194 µmol, 1.1 eq) was added to the mixture, and the 
solution was stirred at 60 °C for 24 h. The reaction was 
allowed to cool to RT, and MeOH was removed under reduced pressure. CH2Cl2 (2 mL) was 
added, and pentane (100 mL) was added to induce precipitation. The dark-green-black 
precipitate was filtered and washed with EtOH (3 × 20 mL) to yield the desired hexa-nuclear 
prism 64 as a dark green solid (129 mg, 60%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 8.78 - 8.21 
(m, 24H, CH, 4-tpt), 5.77 - 5.65 (m, 12H, CH, p-cymene), 5.51 - 5.39 (m, 12H, CH, p-cymene), 
4.26 - 4.07 (m, 6H, NCHH, octylchain), 3.60 - 3.42 (m, 6H, NCHH, octylchain), 2.85 - 2.69 (m, 
6H, CH, p-cymene), 2.13 - 2.00 (m, 8H, CH2, octylchain), 1.96 - 1.86 (m, 18H, CH3, p-cymene), 
1.79 - 1.39 (m, CH2, 100H, octylchain), 1.34 - 1-31 (m, 18H, (CH3)2, p-cymene), 1.25 - 1.21 (m, 
18H, (CH3)2, p-cymene), 1.06 - 0.92 (m, 18H, CH3, octylchain). 13C-NMR (CDCl3, 151 MHz, 
45 °C) δ/ppm: 171.7 (NCquartN, 4-tpt), 170.9 (CO, oxalamide), 170.6 (CO, oxalamide), 154.3 
(NCH, 4-tpt), 151.2 (NCH, 4-tpt), 143.9 (CCquartC, 4-tpt), 143.7 (CCquartC, 4-tpt), 142.6 
(CCquartC, 4-tpt), 122.4 (CCH, 4-tpt), 122.3 (CCH, 4-tpt), 120.2 (CCH, 4-tpt), 118.1 (CCH, 4-
tpt), 105.9 (CCH(CH3)2, p-cymene), 97.2 (CCH3, p-cymene), 84.6 (CH, p-cymene), 83.7 (CH, 
p-cymene), 82.2 (CH, p-cymene), 81.7 (CH, p-cymene), 53.5 (NCH2, octylchain), 32.08 (CH2, 
octylchain), 32.06 (CH2, octylchain), 31.5 (CH, p-cymene), 31.5 (CH, p-cymene), 30.3 (CH2, 
octylchain), 29.9 (CH2, octylchain), 29.6 (CH2, octylchain), 27.7 (CH2, octylchain), 22.9 (CH2, 
octylchain), ((CH3)2, p-cymene), 22.3 ((CH3)2, p-cymene), 17.8 (CH3, p-cymene), 17.8 (CH2, 
octylchain), 14.3 (CH3, octylchain). IR (cm-1): 2926 (w), 1596 (s), 1517 (s), 1466 (w), 1371 (m), 
1332 (w), 1257 (s), 1222 (m), 1149 (m), 1056 (w), 1028 (s), 871 (w), 811 (m), 753 (w), 670 
(w), 658 (w), 635 (s), 572 (w), 487 (w), 467 (w), 439 (w). ESI-MS+ Calcd for 
C153H210F9N18O15Ru6S3 ([M - 3CF3SO3]3+): m/z 1139.3. Found: m/z 1138.4. Calcd for 
C154H210F12N18O18Ru6S4 ([M - 2CF3SO3]2+): m/z 1782.5. Found: m/z 1780.7. UV-VIS (1.0 × 
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10-5 M, CH2Cl2) λmax 251 nm (ε = 1.3 × 105 M-1 cm-1)]. EA: Calcd for C156H210F18F18O24Ru6S6 
(3864.8): C, 48.51; H, 5.48; N, 6.53. Found: C, 48.31; H, 5.42; N, 7.76.  
8.24. Synthesis of Molecular Prism [(η6-p-cymene)6Ru6(µ4-3-icosyl-
dihydroxybenzoquinone)3(µ3-4-tpt)][CF3SO3]6 (65) 
Molecular clip [(h6-p-cymene)2Ru2(µ4-3-icosyl-
dihydroxybenzoquinone]Cl2 (59) (50.0 mg, 52.0 µmol, 
1.0 eq) was suspended in MeOH (20 mL), and 
AgCF3SO3 (26.7 mg, 104 µmol, 2.0 eq) was added and 
the mixture was stirred at RT for 3 h. AgCl was filtered 
off and 4-tpt (10.7 mg, 34.3 µmol, 0.66 eq) was added, 
and the mixture heated to 60 °C. The reaction was 
stirred for 30 h until the 1H-NMR spectrum showed full 
conversion of the starting material. The reaction was allowed to cool to RT, the solvent was 
removed under reduced pressure, and the crude product was dried overnight. CH2Cl2 (1 mL) 
was added to dissolve the solid, and pentane (50 mL) was added to induce precipitation. The 
dark-red solid was filtered and dried under vacuum to obtain the desired hexa-nuclear prism 65 
as a red solid (56.7 mg, 60%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 8.75 (s, 12 H, CH, 4-tpt), 
8.49 (s, 12H, CH, 4-tpt), 5.88 - 5.68 (m, 27 H, CH, p-cymene, dhbq), 2.85 (m, 6H, CH, p-
cymene), 2.28 - 2.17 (m, 36H, CH2, icosylchain; CH3, p-cymene), 1.37 - 1.27 (132H, CH2, 
icosylchain; (CH3)2, p-cymene), 0.88 (m, 9H, CH3, icosylchain). 13C-NMR (CDCl3, 101 MHz) 
δ/ppm: 184.0 (OCCC20H41, dhbq), 181.7 (OCCH4, dhbq), 169.7 (NCquartN, 4-tpt), 154.2 (NCH, 
4-tpt), 144.3 (CCquartC, 4-tpt), 125.6 (CCH, 4-tpt), 122.4 (CC20H41, dhbq), 119.2 (CC20H41, 
dhbq), 104.4 (CCH(CH3)2, p-cymene), 101.4 (CH, dhbq), 99.1 (CCH3, p-cymene), 84.1 (CH, 
p-cymene), 83.5 (CH, p-cymene), 83.3 (CH, p-cymene), 82.4 (CH, p-cymene), 32.1 (CH2, 
icosylchain), 31.5 (CH, p-cymene), 30.2 (CH2, icosylchain), 30.1 (CH2, icosylchain), 30.1 (CH2, 
icosylchain), 30.0 (CH2, icosylchain), 30.0 (CH2, icosylchain), 29.9 (CH2, icosylchain), 29.8 (CH2, 
icosylchain), 29.5 (CH2, icosylchain), 22.8 (CH2, icosylchain), 22.5 (CH2, icosylchain), 22.4 ((CH3)2, 
p-cymene), 22.4 ((CH3)2, p-cymene), 18.2 (CH3, p-cymene), 14.3 (CH3, icosylchain). IR (cm-1): 
2924 (w), 2852 (w), 1575 (w), 1514 (m), 1367 (m), 1278 (m), 1243 (m), 1224 (m), 1156 (m), 
1058 (w), 1027 (m), 870 (w), 810 (w), 800 (w), 759 (w), 671 (w), 667 (w), 635 (w), 487 (w), 
472 (w), 464 (w), 453 (w). ESI-MS+ Calcd for C177H234F9N12O21Ru6S3 ([M - 3CF3SO3]3+): m/z 
1246.7. Found: m/z 1246.7. Calcd for C178H234F12N12O24Ru6S4 ([M - 2CF3SO3]2+): m/z 1944.5. 
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Found: m/z 1945.1. UV-VIS (1.0 × 10-5 M, CH2Cl2): λmax 245 nm (ε = 7.8 × 104 M-1 cm-1); λmax 
304 nm (ε = 4.3 × 104 M-1 cm-1); λmax 494 nm (ε = 2.8 × 104 M-1 cm-1).  EA: Calcd for 
C180H236F18N18O30Ru6S6·3CH2Cl2 (4191.0 + 254.8): C, 49.49; H, 5.45; N, 3.78. Found: C, 
49.50; H, 5.88; N, 3.39.  
8.25. Syntheses of Metalla-Cube [(η6-p-cymene)8Ru8(µ4-N1,N2-
dihexyloxalamide)3(µ4-tpp)][CF3SO3]8 (66) 
 Molecular clip [(h6-p-cymene)2Ru2(µ4-N1,N2-
dihexyloxalamide)Cl2] (50) (50.0 mg, 62.8 µmol, 1.0 
eq) was dissolved in MeCN (5 mL), AgCF3SO3 (32.3 
mg, 126 µmol, 2.0 eq) was added and the suspension 
was stirred at RT. After 3 h AgCl was filtered off, tpp 
(40.0 mg, 62.8 µmol, 1 eq) was added and the reaction 
was stirred at 80 °C for 3 days. The reaction was 
allowed to cool to RT and was then concentrated. 
DCM (2 mL) was added to the mixture and pentane was added to induce precipitation to afford 
the desired octa-nuclear cube 66 as a dark brown solid (59.9 mg, 73%). 1H-NMR (CD3NO2, 
600 MHz, 65°C) d/ppm: 9.33 - 8.31 (m, 52H, tpp), 6.23 - 5-70 (m, 32H, p-cymene), 4.17 - 4.06 
(m, 8H, CHH, hexylchain), 3.21 - 3.05 (m, 8H, CHH, hexylchain), 2.36 - 2.19 (CH, 8H, p-cymene; 
CH3, 24H, p-cymene), 2.19 - 1.60 (m, CH2, hexylchain), 1.59 - 1.56 (m, 24H, (CH3)2, p-cymene), 
1.53 - 1.48 (m, 24H, (CH3)2, p-cymene), 1.13 - 1.04 (m, CH3, hexylchain). 13C-NMR (CD3NO2, 
151 MHz, 65 °C) d/ppm: 167.8 (CO, oxalamide), 152.3 (tpp), 133.2 (tpp), 130.4 (tpp), 127.7 
(tpp), 126.0 (tpp), 123.9 (tpp), 121.8 (tpp), 119.7 (tpp), 116.5 (tpp), 86.3 (p-cymene), 84.7 (p-
cymene), 84.6 (p-cymene), 54.8 (NCH2, hexylchain), 33.3 (CH2, hexylchain), 33.2 (CH2, 
hexylchain), 33.0 (CH2, hexylchain), 31.7 (CH, p-cymene), 28.92 (CH2, hexylchain or (CH3)2, p-
cymene), 28.86 (CH2, hexylchain or (CH3)2, p-cymene), 24.1 (CH2, hexylchain or (CH3)2, p-
cymene), 24.0 (CH2, hexylchain or (CH3)2, p-cymene), 23.9 (CH2, hexylchain or (CH3)2, p-
cymene), 23.2 (CH2, hexylchain or (CH3)2, p-cymene), 18.6 (CH3, p-cymene), 14.80 (CH3, 
hexylchain), 14.75 (CH3, hexylchain). IR (cm-1): 2961 (w), 2931 (w), 2869 (w), 2359 (w), 1597 
(s), 1468 (w), 1418 (w), 1334 (w), 1258 (s), 1221 (m), 1152 (s), 1090 (w), 1062 (w), 1029 (s), 
999 (w), 981 (w), 969 (w), 883 (w), 803 (m), 754 (w), 746 (w), 721 (w), 684 (w), 636 (s), 573 
(w), 435 (m), 412 (s). ESI-MS+ Calcd for C220H268F12N24O20Ru8S4 ([M - 4CF3SO3]4+): m/z 
1184.3. Found m/z 1184.8. Calcd for C221H268F15N24O23Ru8S5 ([M - 3CF3SO3]3+): m/z 1628.7. 
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Found: m/z 1628.3. Calcd for C35H54F3N2O5Ru2S ([Clip - 2Cl + CF3SO3]+): m/z 875.2. Found: 
875.7.  UV-VIS (3.33 × 10-6 M, MeNO2): λmax 414 nm (ε = 3.27 × 105 M-1 cm-1). EA: Calcd for 
C224H268F24N24O32Ru8S8 (5329.8): C, 50.48; H, 5.07; N, 6.31. Found: C, 52.31; H, 4.87; N, 
8.23. 
8.26. Syntheses of Metalla-Cube [(η6-p-cymene)8Ru8(µ4-N1,N2-dioctyloxalamide)3(µ4-
tpp)][CF3SO3]8 (67) 
 Molecular clip [(h6-p-cymene)2Ru2(µ4- N1,N2-
dioctyloxalamide)Cl2] (51) (50.0 mg, 58.7 µmol, 1.0 
eq) was dissolved in MeCN (5 mL), AgCF3SO3 (30.2 
mg, 117 µmol, 2.0 eq) was added and the suspension 
was stirred at RT. After 3 h AgCl was filtered off, tpp 
(36.3 mg, 58.7 µmol, 1 eq) was added and the reaction 
was stirred at 80 °C for 3 days. The reaction was 
allowed to cool to RT and was then concentrated. 
DCM (2 mL) was added to the mixture and pentane was added to induce precipitation to afford 
the desired octa-nuclear cube 67 as a dark brown solid (58.0 mg, 71%). 1H-NMR (CD3NO2, 
600 MHz, 65 °C) d/ppm: 9.44 - 7.81 (m, 52H, tpp), 6.22 - 5.65 (m, 32H, p-cymene), 4.17 - 4.01 
(m, 8H, CHH, octylchain), 3.23 - 2.99 (m, 8H, CHH, octylchain), 2.35 - 2.19 (m, CH, 8H, p-
cymene; CH3, 24H, p-cymene), 2.00 - 1.27 (m, CH2, octylchain; (CH3)2, p-cymene), 1.02 - 0.85 
(m, CH3, octylchain). 13C-NMR (CD3NO2, 151 MHz, 65 °C) d/ppm: 130.4 (tpp), 127.7 (tpp), 
33.3 (CH2, octylchain or CH3, p-cymene or (CH3)2, p-cymene), 33.0 (CH2, octylchain or CH3, p-
cymene or (CH3)2, p-cymene), 31.7 (CH2, octylchain or CH3, p-cymene or (CH3)2, p-cymene), 
31.0 (CH2, octylchain or CH3, p-cymene or (CH3)2, p-cymene), 30.8 (CH2, octylchain or CH3, p-
cymene or (CH3)2, p-cymene), 29.3 (CH2, octylchain or CH3, p-cymene or (CH3)2, p-cymene), 
24.6 (CH2, octylchain or CH3, p-cymene or (CH3)2, p-cymene), 24.0 (CH2, octylchain or CH3, p-
cymene or (CH3)2, p-cymene), 24.0 (CH2, octylchain or CH3, p-cymene or (CH3)2, p-cymene), 
23.2 (CH2, octylchain or CH3, p-cymene or (CH3)2, p-cymene), 18.3 (CH3, p-cymene), 14.3 (CH3, 
octylchain). IR (cm-1): 2962 (w), 2931 (w), 2862 (w), 2360 (w), 1599 (s), 1468 (w), 1333 (w), 
1275 (s), 1257 (s), 1223 (s), 1156 (s), 1066 (w), 1029 (s), 970 (w), 882 (w), 856 (w), 799 (m), 
719 (m), 676 (w), 636 (s), 573 (w), 510 (w), 470 (w), 420 (s). ESI-MS+ Calcd for 
C236H300F12N24O20Ru8S4 ([M - 4CF3SO3]4+): m/z 1240.4. Found m/z 1240.5. Calcd for 
C237H300F15N24O23Ru8S5 ([M - 3CF3SO3]4+): m/z 1703.5. Found: 1702.7. Calcd for 
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C39H62F3N2O5Ru2S ([Clip - 2Cl + CF3SO3]+): m/z 931.2. Found: 931.1. UV-VIS (3.33 × 10-6 
M, MeNO2) λmax 422 nm (ε = 3.61 × 105 M-1 cm-1). EA: Calcd for C240H300F24N24O32Ru8S8 
(5554.2): C, 51.90; H, 5.44; N, 6.05. Found: C, 50.96; H, 4.88; N, 8.20. 
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ABSTRACT: The enhanced permeability and retention 
(EPR) effect is an attractive avenue to target tumors: 
The size of the drug being the key to accumulate 
predominantly in tumors. Therefore, to increase the 
molecular weight of arene ruthenium metalla-
assemblies, several strategies can be adopted, and we 
present here our first step in the design of larger and 
heavier discrete arene ruthenium metalla-assemblies to 
dfreach an EPR-size dimension. 
 
 
 
 
Introduction 
Most solid and metastatic tumors show unique 
characteristics which are not observed in healthy tissues 
and organs, such as increased production of vascular 
permeability mediators, defective vascular architecture, 
impaired lymphatic drainage and impaired recovery 
system, as well as an extensive angiogenesis leading to 
hypervasculature. All these features compose the 
enhanced permeability and retention effect (EPR-
effect).1,2 Currently, only a small number of drugs are 
effective against metastatic cancers, therefore the EPR-
effect offers great perspectives in nanomedicine therapy.  
The EPR-effect was first described in 1986 by Maeda 
and it remains a popular strategy for cancer-selective 
drug delivery,1,2 despite recent indication that the EPR-
effect might not be valid in humans.3 Nevertheless, 
rapid and chaotic angiogenesis coupled to excessive 
production of vascular mediators generate poorly 
defined blood vessels, showing gaps between 
endothelial cells.1-4 Tumor blood vessels do not have a 
fixed and compact structure like healthy tissues, but a 
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very dynamic system with large openings between 
endothelial cells, which make them leaky and 
permeable. The size of those gaps can vary from 100 nm 
to approximately 1 µm, whereas in normal tissues the 
gaps are < 6 nm (continuous endothelial cells in striated 
muscles), 10 - 100 nm in diameter (fenestrated 
endothelial cells in renal medulla, endocrine glands, 
renal glomerulus, choroid plexus in the brain, intestinal 
villus) and even larger (discontinuous endothelial cells 
in sinusoid vessels, liver, spleen, bone marrow, 
extraneous particles from the blood).5-7  
High molecular weight compounds such as 
nanoparticles, macromolecular drugs, polymeric drugs 
and lipid particles enter predominantly into tumor 
tissues rather than into normal tissues (enhanced 
permeability) and will remain in the tumor tissues for a 
prolonged period of time (retention). In Figure 1, the 
upper part shows healthy tissues where the cellular 
structure is well defined, and where small molecules are 
able to pass the endothelial cells to enter, and are 
subsequently removed by the lymphatic drainage. The 
lower part shows cancerous tissues with large gaps 
between cells, where not only small molecules but also 
macromolecules can enter. Furthermore, large 
molecules (drugs) will accumulate due to a defective 
lymphatic drainage. 
  
Figure1. Illustration of the EPR-effect (top = healthy 
tissue; bottom = tumor tissue). 
A key mechanism of the EPR-effect is the retention of 
high-molecular weight substances in the tumor 
environment, whereas low molecular weight substances 
are returned to the blood circulatory system by 
diffusion.1 Retention is caused by the impaired 
lymphatic drainage. An intact lymphatic drainage 
ensures that ectopic substances are removed from 
tissues. However, in a damaged lymphatic system, only 
low-molecular weight substances are removed and high-
molecular weight substances are retained. After 
administration of such high-molecular weight 
compounds it was shown that their concentration are 10 
- 200 times higher in tumors than in normal tissues,5 and 
this phenomenon can be used to our benefit. 
However, great diversities exist among tumors and the 
grade of EPR-effect observed can differ tremendously. 
Some tumors show a strong EPR-effect whereas others 
only a limited or even no effect, which can be 
demonstrated by arterial angiography using an X-ray 
lipid contrast agent.2 Vascular permeability and the 
grade of EPR-effect may also depend on tumor type and 
may increase with tumor size and growth rate, and it 
might be higher in the periphery than in the central 
region of tumors.8 Therefore, there is no uniform 
treatment of solid cancers exploiting the EPR-effect, 
which ensures sufficient drug delivery to all tumor 
regions.9  
The over production of vascular mediators such as 
bradykinin, nitric oxide (NO), vascular endothelial 
growth factor (VEGF) and carbon monoxide (CO), 
further enhance the permeability of tumors. This can be 
used for the augmentation of EPR-based tumor 
targeting, achieving more tumor accumulation of 
macromolecular drugs.5 NO production is inevitable 
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during tumor growth to maintain the supply of nutrients 
and oxygen. In the presence of NO-scavengers the 
extravasation is significantly inhibited. CO is involved 
in many biological functions including vascular 
regulation, anti-apoptosis, anti-inflammation and 
angiogenesis. CO is also found to increase vascular 
permeability, blood flow and augment the EPR-effect. 
Furthermore, the usage of CO donors can increase the 
grade of the EPR-effect.5 Another strategy to enhance 
the EPR-effect is the elevation of systolic blood pressure 
via slow angiotensin II infusion.10 Infusion of 
angiotensin II, a peptide hormone, leads to a tremendous 
increase of the blood flow in tumor tissue without 
increasing blood flow in normal tissue.11  
In this regard, many macromolecular compounds 
containing clinically approved small molecular drug 
linked to biologically relevant enzymes or proteins have 
been developed to exploit the EPR-effect. In addition, 
polymer-conjugates can increase the water solubility of 
those drugs and therefore the effectiveness can also be 
enhanced. Polymer conjugation alters the bio-
distribution of low molecular weight drugs, thus 
enabling tumor-specific targeting.12 Examples of EPR-
targeting compounds under clinical trials or being 
clinically approved are presented in Table 1. 
 
In the case of Oncaspar® (Pegaspargase) the active 
component is the already large enzyme L-asparaginase 
which causes an L-asparagine depletion that prevents 
protein synthesis and cell proliferation. The drug was 
further modified by PEGylation (Calaspargase Pegol) 
which is an important tool in the development of anti-
cancer conjugates. PEGylation has proven to be useful 
for a variety of reasons:12 
-increases protein solubility and stability and reduces 
protein immunogenicity 
-prevents the rapid clearance of small proteins 
-is non-toxic and non-immunogenic 
-increases plasma residence of the drug-conjugate 
-can increase the therapeutic index in order to elevate 
the dose without causing toxicity 
-its high degree of hydration provides a water shell to 
mask the active core 
Overall, these commercial examples confirm that 
designing large conjugates to treat cancers is a suitable 
strategy. 
Nevertheless, researchers disagree about the perfect 
size (20-200 nm)3 or weight (25-160 kDa) for an EPR-
effective drug. In the year 2000 Maeda stated that the 
EPR-effect was observed at a molecular weight of 60 
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kDa, whereas later he stated that accumulation was 
observed already at a weight of 40 kDa.1,2,10,20 In 2006 
Haag and Kratz observed an EPR-effect at a molecular 
weight of 20 kDa, but they also stated that the renal 
clearance occurs at a molecular weight of 30 - 50 kDa.21 
In 2014 Kobayashi estimated a desired size of over 6 nm 
in diameter, which is approximately the pore size of a 
glomerulus of the kidney, to avoid excretion.22 Caliceti 
and Veronese stated in 2003 that renal clearance can be 
avoided from a molecular weight of 70 kDa, but 
molecules that exceed this size can be eliminated from 
the body by other pathways, such as liver uptake, 
proteolytic digestion, and clearance by the immune 
system.23 However one thing is certain: As molecular 
size increases, systematic clearance decreases. 
To investigate the molecular size dependence of 
drugs, Jain and coworkers have examined compounds 
between 25 and 160 kDa in a mice transplanted human 
colon adenocarcinoma model using intravital 
fluorescence microscopy technique.8 The permeability 
increased by a factor of two from 25 to 160 kDa. The 
transport of macromolecular compounds appears to 
occur by diffusion through the porous structure. 
Experiments with liposomes performed by the same 
group suggest that the cutoff size of the pores lies 
between 400 and 600 nm in diameter.8 
According to these studies, arene ruthenium metalla-
assemblies, if they are big enough, could in principle 
exploit the EPR-effect. For many years, we24-27 as well 
as others28-30 have synthesized numerous tetranuclear, 
hexanuclear and octanuclear arene ruthenium metalla-
assemblies, and the first example of a biologically active 
system was published in 2008.31 The complex-in-a-
complex system [(acac)2PtÌRu6(p-
cymene)6(tpt)2(dhbq)3]6+ was able to carry platinum 
acetylacetonate to cancer cells. This supramolecular 
system possesses several components (Figure 2) and has 
a molecular weight of approximately 4 kDa. The 
components are: The arene ligands that can protect and 
stabilize the ruthenium atom in a 2+ oxidation state;32 
Multidentate anionic spacers that can modulate the size 
of the cavity;33 Multidentate N-donor panels that can 
dictate the shape and geometry of the assembly.34All 
components can therefore be used to increase upon 
functionalization the molecular weight and size of the 
arene ruthenium metalla-assemblies, including also the 
guest molecule. 
 
Figure 2. Components of a typical arene ruthenium 
metalla-assembly. 
 
Indeed, several pyrenyl-functionalized compounds 
have been used as guest molecules to increase the 
molecular weight of arene ruthenium metalla-
assemblies.35-36 The pyrenyl group fits perfectly in the 
cavity of the metalla-assemblies, while the remaining 
part sits outside (Figure 3). The hydrophobicity of 
pyrene coupled to the ideal shape of the cavity allows 
APPENDICES 
  153 
the formation of highly stable host-guest systems. As 
illustrated in Figure 3, when a large pyrenyl-
functionalized guest is used, the arene ruthenium 
metalla-assembly provides a cationic and hydrophilic 
head to the system. The largest host-guest system 
obtained so far has a combined (host-guest) molecular 
weight of 5.5 kDa.37 
  
Figure 3. Pyrenyl-functionalized dendrimer encapsulated 
in an arene ruthenium metalla-prism. 
 
Until now, our efforts to increase the molecular weight 
of arene ruthenium metalla-assemblies have mainly 
focused on the guest molecules. We want now to explore 
other possibilities such as the arenes, the panels and the 
spacers. Herein, as a proof of concept, we present our 
preliminary study dealing with functionalized spacers, 
in which alkyl chains of different lengths were attached. 
 
Results and Discussion 
To increase the molecular weight of arene ruthenium 
metalla-assemblies, we have first focused our attention 
to the insertion of alkyl chains to the spacer-
components. Two types of spacers were chosen, 
dialkyloxalamide and 2,5-dihydroxy-3-alkyl-2,5-diene-
1,4-dione (Figure 4). Synthetic strategies to prepare 
such compounds are already available in the literature. 
The dihexyloxalamide (H2La) and dioctyloxalamide 
(H2Lb) were obtained following the strategy developed 
by Lu and Facchetti,38 while the 2,5-dihydroxy-3-
icosyl-2,5-diene-1,4-dione (H2Lc) was prepared 
according to the method developed by Huang and Hu,39 
by replacing a C11H23 alkyl chain with a C20H41 chain 
(see exp. part). All compounds show the expected 
spectroscopic data, and were used without further 
purification to synthesize the corresponding dinuclear 
arene ruthenium clip. 
 
Figure 4. Spacers (H2L) used in this study. 
 
The dinuclear arene ruthenium metalla-clips 1a and 
1b are obtained in moderate yield by reacting first the 
alkyloxalamide (H2La, H2Lb) with two equivalents of 
N,N-diisopropylethylamine (DIPEA), followed by the 
addition of [(η6-p-cymene)2Ru2(µ2-Cl)2Cl2]. The 
metalla-clip 1c is prepared in good yield in a similar 
fashion, using NaCOOCH3 as the base. All dinuclear 
complexes show in their 1H NMR spectrum 
diastereotopic protons due to the coordination of the 
arene ruthenium units to the spacers; the ruthenium 
atoms being chiral-at-the-metal in these complexes. 
  
Scheme 1. Synthesis of the dinuclear arene ruthenium clips 
(1a-1c). 
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Once the dinuclear clips have been prepared and 
purified, the synthesis of the larger metalla-assemblies 
was performed. A series of metalla-prisms was obtained 
by reacting the dinuclear clips (1) with silver triflate, 
followed by addition of 2,4,6-tri(pyridin-4-yl)-1,3,5-
triazine (4-tpt). These metalla-prisms are isolated in 
good yields as dark green (2a and 2b) or dark red (2c) 
solids (Figure 5). They are non-hygroscopic and stable 
in solution (DMSO, CH2Cl2, CHCl3, CH3CN) for 
several days. 
  
Figure 5. Molecular structures of the hexanuclear arene 
ruthenium metalla-prisms (2a-2c). 
 
The molecular structure of the metalla-prisms was 
confirmed by a combination of NMR spectroscopy and 
mass spectrometry. Upon formation of the metalla-
prisms, the 1H NMR signals assigned to the metalla-
clips are slightly shifted and become broad, while new 
signals associated to the 4-tpt panels appear (Figure 6). 
These observations are consistent with the formation of 
the metalla-prisms 2a-2c, in which the alkyl chains are 
either pointing away or towards the cavity and the 
components of the assemblies, thus generating large and 
broad signals.40 Moreover, the nature of the metalla-
clips (1a-1c) generates two isomers for each metalla-
prism,41 in which the orientation of the µ4-L spacers are 
either all the same or mixed. 
Figure 6. 1H NMR spectra of 1b (top) and 2b (bottom). 
  
The ESI mass spectra of the metalla-prisms show 
characteristic dicationic ([2 – 2 CF3SO3-]2+) and 
tricationic ([2 – 3 CF3SO3-]3+) peaks, corresponding to 
the intact metalla-prism plus four triflate and three 
triflate anions respectively (Figure 7). Moreover, the 
dinuclear arene ruthenium clips show a single parent 
mass peak corresponding to [1 – Cl]+; a peak not 
observed in the mass spectra of the metalla-prims. 
However, fragments corresponding to 
[(p-cymene)2Ru2(µ4-L)]2+ and [(p-cymene)2Ru2(µ4-L) + 
CF3SO3]+ are observed in the mass spectra of 2 and 
confirmed the presence of the metalla-clips in the 
metalla-prisms. To illustrate this behavior, the mass 
spectra of 1b and 2b are presented in Figure 7. 
  
Figure 7. ESI-MS of 1b (top right) and 2b. 
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Thus far in this project three prisms were synthesized. 
The molecular weight of the prisms amounts 3692.6 
g·mol-1 (2a), 3864.8 g·mol-1 (2b) and 4191.0 g·mol-1 
(2c), still remaining relatively small to fully exploit the 
EPR-effect. However, by introducing octyl chains on 
the oxalamide spacer, an additional mass of 589 g·mol-1 
was added to the metalla-prism 2b, in comparison to a 
dimethyloxalamide analogue. Unfortunately, attempts 
to introduce longer alkyl chains to the oxalamide moiety 
were unsuccessful, generating only insoluble materials. 
Nevertheless, by simply adding one icosyl chain to a 
dihydroxy benzoquinone spacer, a mass of nearly 1 kDa 
was added to the metalla-prism, representing an increase 
of about 20% when compare to the non-functionalized 
dihydroxybenzoquinone metalla-prism (Figure 2). 
As demonstrated here, insertion of alkyl chains to 
organic spacers remains easy synthetically but reduces 
the solubility of the compounds. Therefore, to facilitate 
solubility whilst still increasing the molecular weight of 
the metalla-assemblies, we are now shifting our 
attention to pegylated chains, and instead of dealing 
with mono-functionalized hydroxybenzoquinone 
spacers, we are preparing bis-functionalized 
derivatives.42 
Conclusion 
The EPR-effect represents an important discovery 
which occurs in most solid cancers. This phenomenon is 
based on the cellular structure of solid cancers and on a 
defective lymphatic drainage. Macromolecular 
compounds can be administered in order to accumulate 
on tumor sites and to operate locally via the EPR-effect. 
However to date, no ruthenium containing drugs are 
known to operate via the EPR-effect, and studies have 
showed that the EPR-effect is questionable when 
dealing with humans.3 
Therefore, if reaching an EPR-effect is no more a 
goal, these functionalized arene ruthenium metalla-
assemblies can still found other applications, such as 
drug delivery vectors. Indeed, the use of metalla-cages 
as drug delivery vectors and as anticancer agents is 
becoming a new field of research, showing great 
promises.43-45 Then, like in arene ruthenium metalla-
assemblies, the introduction of tumor targeting agents at 
the periphery of the metalla-assembly can in principle 
increase the selectivity and efficacy of these abiological 
systems.46 
For these reasons, we want in the future to use similar 
synthetic strategies to functionalize as well the arenes 
and the panels, not only the spacers and the guest 
molecules. We also want to use other metals (iridium or 
osmium) and introduce specific functional-groups 
(targeting agents, hydrophilic or hydrophobic groups, 
peptidic chains, etc…) to fine tune the biological 
activity, and to ultimately, generate metalla-assemblies 
with higher and better therapeutic properties (Figure 8). 
  
Figure 8. Highly functionalized metalla-assemblies. 
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ASSOCIATED CONTENT  
Experimental Part 
Materials and Methods: All solvents were dried before 
use according to standard procedures, and all reactions 
were performed under an inert atmosphere. All other 
reagents were commercially available and used as 
received. NMR spectra were recorded with a Bruker 
Avance II 400 spectrometer. UV/VIS absorption spectra 
were recorded with a Perkin–Elmer UV/Vis 
spectrophotometer. Infrared spectra were recorded with 
a Nicolet iS5 from Thermo scientific spectrometer. 
Electrospray mass spectra were obtained in positive or 
negative mode with a LCQ Finnigan mass spectrometer. 
Microanalyses were carried out by the 
Mikroelementaranalytisches Laboratorium, ETH 
Zürich (Switzerland). The ruthenium precursor [(η6-p-
cymene)2Ru2(µ2-Cl)2Cl2],47 the spacers 
dihexyloxalamide (H2La)38 and dioctyloxalamide 
(H2Lb)38 and the panel ligand 2,4,6-tri(pyridin-4-yl)-
1,3,5-triazine48 were prepared according to published 
methods. 
 
Synthesis of 3-Icosyl-1,2,4,5-tetramethoxybenzene 
1,2,3,4-Tetramethoxybenzene, (430 mg, 2.20 mol, 1.0 
eq) was dissolved in THF (10 mL) and the solution was 
cooled to -10 °C. The flask was flushed with N2 and n-
BuLi (2.5 M in hexane, 1 mL, 2.42 mmol, 1.1 eq) was 
slowly added under a N2 atmosphere. The mixture was 
stirred at -10 °C for 30 min and 1-bromo-icosane (904 
mg, 2.42 mmol, 1.1 eq) was slowly added. The mixture 
was stirred at -10 °C for 10 min and then allowed to 
warm to RT overnight. After completion of the reaction 
aqueous saturated NH4Cl (2 mL) was added to the 
solution and the mixture was extracted with Et2O (3 x 
50 mL), washed with brine (1 x 50 mL), dried over 
MgSO4 and concentrated under reduced pressure. The 
crude product was purified by flash column 
chromatography (SiO2, pentane/EtOAc 40:1) to yield 
the desired product as a colorless solid. (710 mg, 68%). 
1H-NMR (CDCl3, 400 MHz) d/ppm: 6.41 (s, 1H, CH), 
3.84 (s, 6H, OCH3), 3.76 (s, 6H, OCH3), 2.62-2.59 (m, 
2H, CH2), 1.56-1.49 (m, 2H, CH2), 1.37-1.35 (m, 2H, 
CH2), 1.25 (s, 32H, CH2), 0.88 (t, 3JHH = 6.2 Hz, 3H, 
CH3). 13C-NMR (CDCl3, 101 MHz) d/ppm: 149.0 (2C, 
CH3OC), 141.3 (2C, CH3OC), 131.3 (1C, CC20H41), 
96.9 (1C, CH), 61.1 (2C, OCH3), 56.4 (2C, OCH3), 32.1 
(1C, CH2), 30.9 (1C, CH2), 30.2 (1C, CH2), 29.9 (10C, 
CH2), 29.8 (1C, CH2), 29.7 (1C, CH2), 29.6 (1C, CH2), 
29.5 (1C, CH2), 24.8 (1C, CH2), 22.8 (1C, CH2), 14.3 
(1C, CH3). IR (cm-1): 2957 (w), 2916 (m), 2849 (m), 
1594 (w), 1467 (m), 1408 (m), 1367 (w), 1343 (w), 1306 
(w), 1244 (w), 1203 (w), 1117 (m), 1066 (w), 1044 (m), 
1024 (w), 954 (m), 899 (w), 868 (w), 854 (w), 831 (W), 
811 (w), 721 (w), 639 (w). MS (ESI+, m/z): calculated 
for C30H54O4Na [M + Na]+ 501.4; found: 501.4 [M + 
Na]+.  UV-VIS (1.0 x 10-4, CH2Cl2): λmax 229 (ε = 0.7 x 
103 M-1cm-1), λmax 284 (ε = 1.7 x 103 M-1cm-1). EA: 
Anal. calc. for C30H54O4 (478.4) C 75.26; H 11.37; 
Found: C 75.40; H 11.39. 
Synthesis of 3-Icosyl-2,5-dimethoxycyclohexa-2,5-diene-
1,4-dione 
3-Icosyl-1,2,4,5-tetramethoxybenzene (177 mg, 370 
µmol, 1.0 eq) was suspended in MeCN (3 mL) and ceric 
ammonium nitrate (510 mg, 930 µmol, 2.51 eq) was 
added and the yellow suspension turned into an orange 
suspension. The mixture was stirred at RT for 2 h. After 
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completion of the reaction, the mixture was extracted 
with EtOAc (3 x 15 mL). The combined organic layers 
were washed with brine (1 x 20 mL), dried over MgSO4, 
filtered and concentrated. The crude product was 
purified by flash column chromatography (SiO2, 
pentane/EtOAc 20:1) to yield the desired product as a 
colorless solid (80.2 mg, 48%). 1H-NMR (CDCl3, 400 
MHz) d/ppm: 5.72 (s, 1H, CH), 4.04 (s, 3H, OCH3), 3.80 
(s, 3H, OCH3), 2.42 (t, 3JHH = 7.5 Hz, 2H, CH2), 1.41-
1.35 (m, 2H, CH2), 1.25 (s, 34 H, CH2), 0.88 (t, 3JHH = 
6.6 Hz, 3H, CH3). 13C-NMR (CDCl3, 101 MHz) d/ppm: 
183.7 (1C, CO), 182.6 (1C, CO), 158.9 (1C, CH3OC), 
156.0 (1C, CH3OC), 130.9 (1C, CC20H41), 105.5 (1C, 
CH), 61.5 (1C, OCH3), 56.5 (1C, OCH3), 32.1 (1C, 
CH2), 29.8 (8C, CH2), 29.75 (4C, CH2), 29.68 (1C, 
CH2), 29.55 (1C, CH2), 29.51 (1C, CH2), 28.82 (1C, 
CH2), 23.2 (1C, CH2), 22.8 (1C, CH2), 14.3 (1C, CH3). 
IR (cm-1): 2916 (m), 2849 (m), 1649 (w), 1597 (w), 
1467 (w), 1324 (w), 1206 (w), 1154 (w), 1046 (w), 928 
(w), 835 (w), 797 (w), 720 (w), 500 (w), 483 (w), 469 
(w), 401 (w), 453 (w), 433 (w), 429 (w). MS (ESI+, 
m/z): calculated for C28H48O4Na [M + Na]+ 471.4; 
found: 471.3 [M + Na]+.  UV-VIS (1.0 x 10-4, CH2Cl2): 
λmax 286 (ε = 8.2 x 103 M-1cm-1). EA: Anal. calc. for 
C28H48O4 (448.4) C 74.95; H 10.78; Found: C 75.21; H 
10.85. 
Synthesis of 2,5-dihydroxy-3-icosylcyclohexa-2,5-diene-1,4-
dione (H2Lc) 
3-Icosyl-2,5-dimethoxycyclohexa-2,5-diene-1,4-
dione (116 mg, 259 µmol, 1.0 eq) and EtOH (10 mL) 
was mixed to give an orange suspension. NaOH (2 M, 5 
mL) was added and the suspension turned into a violet 
solution. The solution was heated to 70 °C and stirred 
until TLC showed full conversion of the starting 
material. The reaction was allowed to cool to RT and 
HCl (2 M, 25 mL) was added, and the solution turned 
into an orange suspension. The mixture was extracted 
with EtOAc (3 x 30 mL). The combined organic layers 
were dried over MgSO4, filtered, concentrated and dried 
under high vacuum to yield the desired product as a 
brown solid which was used without further purification 
(73 mg, 72%). 1H-NMR (SO(CD3)2, 400 MHz) δ/ppm: 
11.17 (s, 2H, OH), 5.77 (s, 1H, CH), 2.27 (t, 3JHH = 7.5 
Hz, 2H, CH2), 1.34 (m, 2H, CH2), 1.22 (m, 34H, CH2), 
0.84 (t, 3JHH = 6.6 Hz, 3H, CH3). IR (cm-1): 3304 (m), 
2917 (m), 2847 (m), 1612 (m), 1462 (w), 1325 (m), 
1187 (m), 860 (w), 768 (w), 708 (w). MS (ESI-, m/z): 
calculated for C26H43O4 [M - H]- 419.3; found: 419.3 [M 
- H]-. UV-VIS (1.0 x 10-4, CH2Cl2): λmax 282 (ε = 1.4 x 
104 M-1cm-1), λmax 290 (ε = 1.4 x 104 M-1cm-1). 
 
Synthesis of Metalla-Clip [(h6-p-Cymene)2Ru2(µ4-La)Cl2] 
(1a) 
Dihexyloxalamide (H2La) (200 mg, 780 µmol, 1.0 eq) 
was suspended in EtOH (15 mL) and DIPEA (0.3 mL, 
1.73 mmol, 2.2 eq) was added dropwise at RT. The 
mixture was heated to 50 °C until the solid was 
dissolved, and the solution stirred at that temperature for 
30 min. The dinuclear complex [(η6-p-cymene)2Ru2(µ2-
Cl)2Cl2] (500 mg, 0.816 mmol, 1.05 eq) was added and 
the mixture was heated at 80 °C overnight. The mixture 
was allowed to cool to RT and was filtered and washed 
with EtOH, acetone, H2O, Et2O and pentane then 
dissolved in CH2Cl2, before being filtered over celite 
and concentrated to yield the desired product as an 
orange solid (156 mg, 25%). 1H-NMR (CDCl3, 400 
MHz) δ/ppm: 5.31-5.26 (m, 6H, CH), 4.99 (d, 3JHH = 5.9 
Hz, 2H, CH), 4.06-3.99 (m, 2H, CHH), 3.32-3.26 (m, 
2H, CHH), 2.69 (sept, 3JHH = 6.9 Hz, 2H, CH), 2.15 (s, 
6H, CH3), 1.71-1.56 (m, 4H, CH2), 1.38-1.27 (m, 12H, 
CH2), 1.22 (d, 3JHH = 6.9 Hz, 6H, CH3), 1.18 (d, 3JHH = 
6.9 Hz, 6H, CH3), 0.92-0.87 (m, 6H, CH3). 13C-NMR 
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(CDCl3, 101 MHz) δ/ppm: 170.2 (2C, CO), 100.7 (2C, 
CCH(CH3)2), 94.4 (2C, CCH3), 82.6 (2C, CH), 81.2 
(2C, CH), 79.8 (2C, CH), 79.6 (2C, CH), 51.7 (2C, 
HC(CH3)2), 31.9 (2C, CH2), 30.9 (2C, CH2), 29.4 (2C, 
CH2), 27.6 (2C, CH2), 22.9 (2C, CH2), 22.6 (2C, 
HC(CH3)2), 22.2 (2C, HC(CH3)2), 18.6 (2C, CH3), 14.3 
(2C, CH3). IR (cm-1): 2923 (w), 1596 (s), 1458 (w), 
1333 (m), 1051 (w), 872 (w), 532 (w), 524 (w), 511 (w), 
501 (w), 494 (w), 485 (w), 475 (w), 467 (w), 458 (w), 
450 (w), 441 (w), 433 (w). MS (ESI+, m/z): calculated 
for C34H54ClN2O2Ru2 [M - Cl]+ 761.2; found: 761.1 [M 
- Cl]+.  UV-VIS (1.0 x 10-5, CH2Cl2): λmax 231 (ε = 2.1 x 
105 M-1cm-1). EA: Anal. calc. for C34H54 Cl2N2O2Ru2 
(795.9) C 51.31; H 6.84; N 3.52; Found: C 51.32; H 
6.85; N 3.72. 
Synthesis of Metalla-Clip [(h6-p-Cymene)2Ru2(µ4-Lb)Cl2] 
(1b) 
Dioctyloxalamide (H2Lb) (500 mg, 1.60 mmol, 1.0 eq) 
was suspended in EtOH (30 mL) and DIPEA (0.6 mL, 
3.44 mmol, 2.1 eq) was added slowly and stirred at RT 
for 30 min. The dinuclear complex [(η6-p-
cymene)2Ru2(µ2-Cl)2Cl2] (1.03g, 1.68 mmol, 1.05 eq) 
was added and the mixture was heated at 90 °C 
overnight. The reaction was allowed to cool to RT and 
the volume was reduced to its half and the mixture was 
stored in the fridge for 1 h. The orange residue was 
filtered and washed with EtOH, H2O, acetone, Et2O and 
pentane. The residue was dissolved in CH2Cl2 and 
filtered over celite and concentrated to yield the desired 
product as an orange solid (280 mg, 21%). 1H-NMR 
(CDCl3, 400 MHz) δ/ppm: 5.30-5.25 (m, 6H, CH), 4.97 
(d, 3JHH = 5.8 Hz, 2H, CH), 4.04-3.97 (m, 2H, CHH), 
3.30-3.24 (m, 2H, CHH), 2.68 (sept, 3JHH = 6.9 Hz, 2H, 
CH), 2.12 (s, 6H, CH3), 1.70-1.52 (m, 4H, CH2), 1.33-
1.25 (m, 20H, CH2), 1.20 (d, 3JHH = 6.8 Hz, 6H, CH3), 
1.16 (d, 3JHH = 6.9 Hz, 6H, CH3) 0.89-0.86 (m, 6H, 
CH3). 13C-NMR (CDCl3, 101 MHz) δ/ppm: 170.1 (2C, 
CO), 100.7 (2C, CCH(CH3)2), 94.4 (2C, CCH3), 82.5 
(2C, CH), 81.2 (2C, CH), 79.7 (2C, CH), 79.5 (2C, CH), 
51.7 (2C, HC(CH3)2), 32.1 (2C, CH2), 30.7 (2C, CH2), 
29.7 (2C, CH2), 29.5 (2C, CH2), 29.4 (2C, CH2), 27.9 
(2C, CH2), 22.8 (2C, CH2), 22.6 (2C, HC(CH3)2, 22.2 
(2C, HC(CH3)2), 18.6 (2C, CH3), 14.3 (2C, CH3). IR 
(cm-1): 3302 (w), 2954 (m), 2914 (m), 2849 (m), 1645 
(w), 1604 (s), 1531 (w), 1510 (w), 1466 (w), 1373 (w), 
1349 (w), 1324 (m), 1200 (w), 1153 (w), 1080 (w), 1055 
(w), 1025 (w), 996 (w), 857 (m), 800 (m), 724 (m), 594 
(w), 496 (w), 463 (w), 445 (w), 429 (w). MS (ESI+, 
m/z): calculated for C38H62ClN2O2Ru2 [M - Cl]+ 817.3; 
found: 817.2 [M - Cl]+.  UV-VIS (1.0 x 10-4, CH2Cl2): 
λmax 228 (ε = 2.33 x 104 M-1cm-1), λmax 313 (ε = 1.6 x 104 
M-1cm-1). EA: Anal. calc. for C38H62N2O2Cl2Ru2 
(852.2) C 53.57; H 7.33; N 3.29; Found: C 53.61; H 
7.48; N 3.24.  
 
Synthesis of Metalla-Clip [(h6-p-Cymene)2Ru2(µ4-Lc]Cl2 
(1c) 
2,5-Dihydroxy-3-icosylcyclohexa-2,5-diene-1,4-
dione (H2Lc) (158 mg, 375 µmol, 1.0 eq) was suspended 
in EtOH (50 mL) and NaCOOCH3 (64.7 mg, 789 µmol, 
2.1 eq) was added. The yellow suspension turned into a 
red solution. The mixture was allowed to stir for 1 hour 
at RT and then [(η6-p-cymene)2Ru2(µ2-Cl)2Cl2] (225 
mg, 367 µmol, 0.98 eq) was added and the reaction was 
heated to 80 °C for 48 h. The reaction was allowed to 
cool to RT and the volume was reduced to its half and 
the mixture was stored in the fridge overnight. The 
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violet precipitate was filtered and washed with cold H2O 
to obtain the desired product as a violet solid (267 mg, 
77%). 1H-NMR (CDCl3, 400 MHz) d/ppm: 5.69 (s, 1H, 
CH), 5.63-5.59 (m, 4H, CH), 5.36 (d, 3JHH = 5.8 Hz, 4H, 
CH), 2.90 (sept, 3JHH = 6.9 Hz, 2H, CH), 2.36-2.32 (m, 
2H, CH2), 2.91 (s, 6H, CH3), 1.36-1.33 (m, 12H, 
(CH3)2), 1.27-1.26 (m, 36H, CH2) 0.89-0.86 (m, 3H, 
CH3). 13C-NMR (CDCl3, 101 MHz) d/ppm: 184.4 (2C, 
CO), 181.8 (2C, CO), 115.5 (1C, CC20H41), 100.7 (1C, 
CH), 100.6 (2C, CCH(CH3)2), 96.4 (2C, CCH3), 82.0 
(1C, CH), 81.4 (1C, CH), 79.7 (1C, CH), 79.1 (1C, CH), 
32.1 (1C, CH2), 31.5 (1C, CH2), 30.0 (1C, CH2), 30.0 
(2C, CH2), 29.9 (2C, CH), 29.9 (2C, CH2), 29.9 (2C, 
CH2), 29.9 (4C, CH2), 29.8 (1C, CH2), 29.7 (1C, CH2), 
29.5 (1C, CH2), 28.3 (1C, CH2), 22.8 (1C, CH2), 22.7 
(2C, (CH3)2), 18.7 (1C, CH3), 14.3 (1C, CH3). IR (cm-
1): 2918 (m), 2849 (m), 1509 (s), 1495 (s), 1469 (m), 
1363 (s), 1315 (w), 1236 (w), 1225 (w), 1165 (w), 1086 
(w), 1030 (w), 874 (w), 834 (w), 805 (w), 788 (w), 722 
(w), 502 (w), 487 (w), 464 (w), 453 (w), 449 (w), 445 
(w), 433 (w), 430 (w). MS (ESI+, m/z): calculated for 
C46H70ClO4Ru2 [M - Cl]+ 925.3; found: 925.3 [M - Cl]+.  
UV-VIS (1.0 x 10-5, CH2Cl2): λmax 228 (ε = 3.7 x 104 M-
1cm-1), λmax 317 (ε = 1.5 x 104 M-1cm-1), λmax 500 (ε = 
2.0 x 104 M-1cm-1). EA: Anal. calc. for C46H70O4Cl12Ru2 
(960.3) C 57.55; H 7.35; N 0.00: Found: C 58.08; H 
7.56; N 0.01. 
 
Syntheses of Metalla-Prism [(η6-p-cymene)6Ru6(µ4-La)3(µ3-
4-tpt)2][CF3SO3]6 (2a) 
Metalla-clip [(h6-p-cymene)2Ru2(µ4-La)Cl2] (1a) (100 
mg, 128 µmol, 1.0 eq) was dissolved  in MeOH (20 mL) 
and AgCF3SO3 (64.0 mg, 249 µmol, 1.95 eq) was added. 
The mixture was stirred at RT for 3 h. AgCl was filtered 
off and 4-tpt (44.0 mg, 141 µmol, 1.1 eq) was added to 
the solution and the mixture was heated at 60 °C for 24 
h. The reaction was allowed to cool to RT and the 
solvent was removed under reduced pressure. CH2Cl2 (2 
mL) and pentane (100 mL) was added to induce 
precipitation. The dark green precipitate was filtered 
and washed with cold EtOH (3 x 20 mL) to yield the 
desired product as a dark green solid. (152 mg, 96%). 
1H-NMR (CDCl3, 400 MHz) δ/ppm: 8.99-8.20 (m, 
24H, CH), 5.83-5.69 (m, 12H, CH), 5.56-5.44 (m, 12H, 
CH), 4.20-4.13 (m, 6H, CH2), 3.62-3.55 (m, 6H, CH2), 
2.86-2.75 (m, 6H, CH2), 2.14-2.07 (m, 6H, CH2), 1.96 
(s, 18H, CH3), 1.82-1.66 (m, 22H, CH2), 1.61-1.52 (m, 
20H, CH2), 1.40-1.37 (m, 18H, CH3), 1.32-1.26 (m, 
18H, CH3), 1.07-1.03 (m, 18H, CH3). IR (cm-1): 2928 
(w), 1596 (s), 1516 (s), 1371 (m), 1257 (s), 1222 (m), 
1149 (m), 1056 (w), 1028 (s), 811 (m), 670 (w), 636 (s), 
496 (w), 480 (w), 445 (w). MS (ESI+, m/z): calculated 
for C141H186F9N18O15Ru6S3 [M - 3 CF3SO3]3+ 1083.3; 
found: 1082.4 [M - 3 CF3SO3]3+; calculated for 
C142H186F12N18O18Ru6S4 [M - 2 CF3SO3]2+ 1699.4; 
found: 1697.3 [M - 2 CF3SO3]2+.  UV-VIS (1.0 x 10-5, 
CH2Cl2): λmax 249 (ε = 1.73 x 105 M-1cm-1). EA: Anal. 
calc. for C144H186F18N18O24Ru6S6 (3692.6) C 46.82; H 
5.08; N 6.83; Found: C 46.71; H 5.12; N 7.30. 
 
Syntheses of Metalla-Prism [(η6-p-cymene)6Ru6(µ4-Lb)3(µ3-
4-tpt)2][CF3SO3]6 (2b) 
Metalla-clip [(p-cymene)2Ru2(µ4-Lb)Cl2] (1b) (150 
mg, 176 µmol, 1.0 eq) was dissolved in MeOH (20 mL) 
and AgCF3SO3 (88.1 mg, 343 µmol, 1.95 eq) was added. 
The mixture was stirred at RT for 3 h. The AgCl was 
filtered off and 4-tpt (60.4 mg, 194 µmol, 1.1 eq) was 
added to the mixture and the solution heated at 60 °C for 
24 h. The reaction was allowed to cool to RT and MeOH 
was removed. CH2Cl2 (2 mL) was added and pentane 
(100 mL) was added to induce precipitation. The dark 
green-black precipitation was filtered and washed with 
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EtOH (3 x 20 mL) to yield the desired product (129 mg, 
60%). 1H-NMR (CDCl3, 400 MHz) δ/ppm: 8.78-8.21 
(m, 24H, CH), 5.77-5.65 (m, 12H, CH), 5.51-5.39 (m, 
12H, CH), 4.26-4.07 (m, 6H, CH2), 3.60-3.42 (m, 6H, 
CH2), 2.85-2.69 (m, 6H, CH2), 2.13-2.00 (m, 8H, CH2), 
1.96-1.86 (m, 18H, CH3), 1.79-1.74 (m, 4H, CH2), 1.70-
1.60 (m, 30H, CH2), 1.48-1.34 (m, 44H, CH2; CH3), 
1.30-1.19 (m, 22H, CH2; CH3), 1.06-0.92 (m, 18H, 
CH3). IR (cm-1): 2926 (w), 1596 (s), 1517 (s), 1466 (w), 
1371 (m), 1332 (w), 1257 (s), 1222 (m), 1149 (m), 1056 
(w), 1028 (s), 871 (w), 811 (m), 753 (w), 670 (w), 658 
(w), 635 (s), 572 (w), 487 (w), 467 (w), 439 (w). MS 
(ESI+, m/z): calculated for C153H210F9N18O15Ru6S3 [M - 
3 CF3SO3]3+ 1139.3; found: 1138.4 [M - 3 CF3SO3]3+; 
calculated for C154H210F12N18O18Ru6S4 [M - 2 
CF3SO3]2+ 1782.5; found: 1780.7 [M - 2 CF3SO3]2+.  
UV-VIS (1.0 x 10-5, CH2Cl2): λmax 251 (ε = 1.33 x 105 
M-1cm-1). EA: Anal. calc. for C156H210F18F18O24Ru6S6 
(3864.8) C 48.51; H 5.48; N 6.53; Found: C 48.31; H 
5.42; N 7.76. 
 
Synthesis of Metalla-Prism [(η6-p-cymene)6Ru6(µ4-Lc)3(µ3-
4-tpt)2][CF3SO3]6 (2c) 
Metalla-clip [(h6-p-cymene)2Ru2(µ4-Lc]Cl2 (1c) (50.0 
mg, 52.0 µmol, 1.0 eq) was suspended in MeOH (20 
mL), and AgCF3SO3 (26.7 mg, 104 µmol, 2.0 eq) was 
added. The solution turned red, and a white suspension 
was observed after 1 h. The reaction was stirred for an 
additional 3 hours at RT before filtering the suspension 
(AgCl). Then, to the red solution, 4-tpt (10.7 mg, 34.3 
µmol, 0.66 eq) was added and the mixture was heated to 
60 °C. The reaction was stirred for 30 h until the 1H-
NMR showed full conversion of the starting material. 
The reaction was allowed to cool to RT and the solvent 
was removed under reduced pressure and the crude 
product was dried overnight. CH2Cl2 (1 mL) was added 
to dissolve the solid and pentane (50 mL) was added to 
induce precipitation. The dark red solid was filtered and 
dried under vacuum (56.7 mg, 60%).1H-NMR (CDCl3, 
400 MHz) d/ppm: 8.75 (s, 12 H, CH), 8.49 (s, 12H, CH), 
5.88-5.68 (m, 35 H, CH), 2.85 (m, 6H, CH), 2.28-2.17 
(m, 36H, CH3)2), 1.37-1.27 (132H, CH2; CH3), 0.88 (m, 
9H, CH3). 13C-NMR (CDCl3, 101 MHz) d/ppm: 184.1 
(6C, CO), 181.7 (6C, CO), 169.7, (6C, NCN), 154.2 
(6C, CCC), 144.3 (12C, NCC), 125.6 (12C, CCC), 
122.4 (3C, CC20H41), 119.2 (3C, CH), 104.4 (12C, CH), 
99.1 (12C, CH), 84.1 (6C, CCH(CH3)2), 82.4 (6C, 
CCH3), 32.1 (1C, CH2), 31.5 (1C, CH2), 30.2 (1C, CH2), 
30.1 (1C, CH), 30.1 (1C, CH2), 30.0 (1C, CH2), 30.0 
(2C, CH2), 29.9 (2C, CH2), 29.8 (4C, CH2), 29.5 (2C, 
CH2), 22.8 (2C, (CH3)2), 22.9 (1C, CH2), 22.5 (1C, 
CH2), 22.4 (1C, CH2), 18.2 (1C, CH3), 14.3 (1C, CH3). 
IR (cm-1): 2924 (w), 2852 (w), 1575 (w), 1514 (m), 
1367 (m), 1278 (m), 1243 (m), 1224 (m), 1156 (m), 
1058 (w), 1027 (m), 870 (w), 810 (w), 800 (w), 759 (w), 
671 (w), 667 (w), 635 (w), 487 (w), 472 (w), 464 (w), 
453 (w). UV-VIS (1.0 x 10-5, CH2Cl2): λmax 245 (ε = 7.8 
x 104 M-1cm-1), λmax 304 (ε = 4.3 x 104 M-1cm-1), λmax 
494 (ε = 2.8 x 104 M-1cm-1). MS (ESI+, m/z): calculated 
for C177H234F9N12O21Ru6S3 [M - 3 CF3SO3]3+ 1246.7; 
found: 1246.7 [M - 3 CF3SO3]3+; calculated for 
C178H234F12N12O24Ru6S4 [M - 2 CF3SO3]2+ 1944.5; 
found: 1945.1 [M - 2 CF3SO3]2+.  EA: Anal. calc. for 
C180H236F18N18O30Ru6S6·[3 CH2Cl2] (4191.0 + 254.78) 
C 49.49; H 5.45; N 3.78; Found: C 49.50; H 5.88; N 
3.39. 
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ABBREVIATIONS 
EPR-effect = enhanced permeability and retention 
effect, 4-tpt = 2,4,6-tri(pyridin-4-yl)-1,3,5-triazine, 
MeCN = acetonitrile, DCM = dichloromethane, THF = 
tetrahydrofuran, MeOH = methanol, EtOH = ethanol, 
DIPEA = diisopropylethylamine, RT = room 
temperature. 
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